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Bone modeling and remodeling during development and bone integrity throughout life are 
normally regulated via complex coupled actions of bone-resorbing osteoclasts and bone-
forming osteoblasts. Loss of coupling between bone formation and bone resorption leads 
to pathogenesis of bone metabolic diseases including osteoporosis or osteopetrosis. Defects 
in osteoclast activity, whether increased activity or deficiency is responsible for bone 
destruction in many bone diseases such as osteoporosis, osteopetrosis and rheumatoid 
arthritis rather than impaired osteoblastic bone formation. Despite our growing knowledge 
in the mechanisms involved in the regulation of osteoclast differentiation and function, 
there is still a lot unknown. For this reason, it is important to understand the molecular 
mechanisms underlying how the activity of these bone-resorbing cells are regulated in 
order to develop effective therapies for bone disorders. Histone deacetylation is one such 
potential mechanism. It has been reported that class IIa histone deacetylase (HDAC), which 
include HDAC4, 5, 7 and 9 are regulators of osteoclastogenesis. Evidence from our lab and 
other labs using in vitro cell culture and in vivo mouse model systems indicated that 
HDAC7 and 9 are negative regulators of osteoclast differentiation and activity. However, 
whether the other class IIa members are functionally significant in osteoclasts is largely 
unknown. The aim of this research was to use in vitro osteoclast cell culture assays in 
conjunction with an in vivo mouse model to investigate the role(s) of HDAC4 in 
osteoclasts. HDAC4 conditional knockout (4cKO) mice exhibited increased bone mass 
phenotype (osteopetrosis) cause by decreased bone-resorbing activity of osteoclasts. 
HDAC4-deficient osteoclasts show reduced resorptive activity resulting from impaired 
signaling downstream of the M-CSF and avb3 integrin and diminished M-CSF mediated 
adhesion and migration. Moreover, I demonstrated that c-Src activation in osteoclasts is 
regulated by HDAC4. The results of this thesis have identified HDAC4 as an essential 
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Chapter 1. Introduction, Statement of Purpose and Specific Aims 
1.1. Introduction: Normal bone remodeling 
Bone is a highly complex specialized connective tissue that undergoes remodeling 
(replacement of old bone) throughout life so as to maintain skeletal integrity and bone 
mass. Human skeleton has two type of bones, cortical and trabecular, that gets remodeled.  
The trabecular bone is more actively remodeled than cortical bone because of the much 
larger surface area to volume ratio. Bone  tissue is made up of organic and inorganic 
(mineralized) components (1). The organic component  includes bone cells, type I collagen, 
proteoglycans and numerous noncollagenous proteins, while the inorganic component is 
comprise of calcium hydroxyapatite providing rigidity and strength (2). It is estimated that 
10% of human skeleton is completely remodeled every year (3, 4). 
 
During bone remodeling, a balance exists between bone formation by osteoblasts and 
resorption by osteoclasts. This balance between these two processes is essential for 
maintaining bone mass and mineral homeostasis in adult life (5). The overall process of 
bone remodeling is a tightly controlled and coordinated, and regulated by various local and 
systemic factors (1). Hormones such as calcitonin (CT), parathyroid hormone (PTH), 
estrogen, growth factors including bone morphogenetic proteins (BMPs), wingless 
integrated 1(Wnts) and transforming growth factor b (TGF-b) and cytokines such as 
macrophage colony-stimulating factor (M-CSF, also called CSF-1), receptor activator of 
nuclear factor kb (RANKL), interleukins (IL) and tumor necrosis factor a (TNF-a), play 
a critical role in bone remodeling process by regulating bone cells, osteoblasts and 
osteoclasts.   
 
In normal physiological bone remodeling, the tight coupling of bone formation by 
osteoblast and resorption by osteoclasts requires communication between different bone 
cells. Cells of the osteoblast lineage (osteoblasts, osteocyte and bone-lining cells) and 
bone-resorbing cells (osteoclasts) are arranged in a systematic unit called bone 
multicellular units (BMU) (6). Osteoblasts arise from mesenchymal stem cells and are 
responsible for bone matrix synthesis and its mineralization (7). Osteocytes play an 
important role in regulating bone remodeling process (8). Osteoclasts are multinucleated  
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giant cells that develop from hematopoietic stem cells of the monocyte/macrophage 
lineage, and are responsible for removing the organic and inorganic components of bone 
matrix using acid secretion and cysteine proteinases (9). The purpose of BMU is to promote 
normal bone resorption by supplying connective tissues and blood vessels. 
 
The remodeling cycle consists of activation, resorption, reversal, formation and 
quiescence phases, as shown in figure 1 (3) (4). During the activation phase, pre-osteoclasts 
are attracted by activation signals to the remodeling site, where they fuse to form 
multinucleated osteoclasts. The resorption phase begins with mature osteoclasts digging 
out a cavity termed a resorption pit whereas the name implies resorption occurs. The bone 
resorption ends with apoptosis of osteoclasts. During the reversal phase, mesenchymal 
stem cells, pre-cursors to osteoblasts, appear along the resorption pit, where they proliferate 
and differentiate into pre-osteoblasts. At the formation phase, pre-osteoblasts mature into 
osteoblasts at the surface of the resorption pit, and release osteoid at the site, forming a new 
soft nonmineralized matrix. The new bone matrix is then mineralized with calcium and 
phosphorous (hydroxyapatite) (3, 4). During quiescence phase, the new bone surface is 
covered with lining bone cells and the cells remain dormant until a new remodeling cycle 
is initiated. Resorption phase is short ( 2 to 4 weeks), while formation phase can continue 
for 3 to 6 months (3). Imbalance between bone formation and resorption leads to severe 
bone diseases, and most clinical bone diseases are associated with osteoclast dysregulation 
in the remodeling process. Thus, understanding how osteoclasts are regulated is necessary.  
 
Figure 1. The process of bone remodeling in healthy bone.  Cartoon illustration of 
bone remodeling cycles (image obtained from https://basicmedicalkey.com/structure-and-
function-of-the-musculoskeletal-system/). 





1.1.2 Osteoclastic Bone Resorption 
 
Osteoclasts are large multinuclear cells formed by fusion of mononuclear precursors. 
These cells are highly mobile and alternate between migratory and bone-resorbing stages 
(10, 11). The bone resorption process begins with osteoclasts attaching firmly to bone 
surface using integrins such as avb3 (12). Following attachment to bone surface, 
osteoclasts polarize to create a tight sealing zone in close proximity to the bone surface and 
a ruffled border, a highly convoluted membrane that faces the resorbing surface. The 
formation of sealing zone is important for osteoclast polarization since it forms a diffusion 
barrier and allows the directional secretion of hydrochloric acid and lysosomal enzymes 
into the ruffled border (10).The mineral component of bone is degraded through 
acidification by electrogenic vacuolar H+ ATPases proton pump (V-type ATPase), Cl- 
channel, and a basolateral chloride-bicarbonate exchanger (13). The production of 
bicarbonate ions by carbonic anhydrase and release of  H+ regulates osteoclast intracellular 
pH (14). The organic component of the bone matrix is degraded by secretion of acidic 
lysosomal proteinases such as cathepsin K, TRAP and MMP9. Cathepsin K is a major  a 
major proteinase in the degradation of bone matrix in the resorption pit (15). The products 
of matrix degradation are endocytosed by osteoclasts and transported in vesicles to and 
released at cell’s extracellular environment (16). In order to arrange these highly polarized 
structures, osteoclast must migrate, adhere to the bone surface, detach and move to new 
resorption site. In this sense, crosstalk between signaling pathways in osteoclasts is an 








Figure 2. Osteoclastic bone resorption. Image modified from (17) 
 
1.1.3 Osteoclasts 
Osteoclasts are multinucleated giant cells originated from hemopoietic stem cells of the 
monocyte/macrophage lineage that are responsible for bone resorption under both normal 
conditions during development and remodeling, and pathological conditions (9). 
Osteoclast differentiation is a multi-step process that includes cell proliferation, 
commitment and fusion. Osteoclast differentiation is dependent on two important 
cytokines: macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear kappa B ligand (RANKL) (9, 10). These cytokines are produced by osteoblasts and 
stromal cells in the proximity of osteoclasts and are required for differentiation, survival 
and bone-resorption (18). The differentiation process begins with the hematopoietic stem 
cell becoming multipotent progenitor cell then committing to be a cell of 
monocyte/macrophage lineage. Under the presence of M-CSF and RANKL, the cells 
proliferate, exit the cell cycle to become committed osteoclast precursor and then 
differentiate into mononuclear prefusion osteoclasts. Eventually, mononuclear osteoclast 
will fuse into multinuclear osteoclasts, become polarized, activated and resorb bone (see 
Figure 3). 
 




Figure 3. Osteoclast differentiation. Cartoon illustrating the process of osteoclast 
differentiation. 
 
1.1.4 RANK Signaling 
In osteoclast precursors and mature osteoclasts, binding of RANKL to its receptor 
RANK supply the critical signal to drive osteoclast differentiation from hematopoietic stem 
cells as well as activate mature osteoclasts (19). The essential role of RANKL and RANK 
in osteoclasts was identified by genetic experiments which demonstrated that mice lacking 
either Rank or Rankl had severe osteopetrosis due to lack of osteoclasts (20, 21). RANKL 
is membrane bound protein that may also be released by osteoblasts or stromal cells to 
activate osteoclast differentiation. RANK is a member of tumor necrosis factor receptor 
(TNFR) superfamily, which lacks intrinsic enzymatic activity and is required to activate 
downstream signaling cascades. Therefore, RANK transduces intracellular signals by 
recruiting adaptor molecules such as TNF receptor-associated factor 6 (TRAF6), which 
then activates NF-kB, PI3K/Akt, and MAP kinases (ERK, p38, and JNK) pathways to 
regulate osteoclastogenesis (22). This interaction also triggers signaling cascades that 
activate transcription factors NF-kB and NFATc1. These transcription factors activate 
genes such as c-Fos, dc-stamp, and cathepsin K that have been associated with osteoclast 
differentiation, survival , and activity (19).  
 
1.1.5 M-CSF Signaling 
M-CSF is critical for both osteoclast development and function. The role of M-CSF in 
osteoclast formation was first observed in op/op mice, which demonstrated that deletion of 
M-CSF results in osteopetrotic mice due to lack osteoclasts (23). Additionally, it was 
reported that deletion of M-CSF receptor, c-Fms, also results in osteopetrotic mice (24).  c-
Fms, a platelet-derived growth factor (PDGF) receptor family member, is a sole cell surface 
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receptor of M-CSF (25, 26).  Binding of M-CSF to its cell surface receptor c-Fms results 
in receptor dimerization, and hence activation of its intrinsic receptor tyrosine kinase 
activity, leading to autophoshorylation of c-Fms domains. Each phosphorylated residue 
then acts as a docking site for phosphotyrosine-binding (PTB) or Src homology region 2 
(SH2) containing proteins, which amplify and activate signaling that promotes osteoclast 
differentiation, survival and activity. Activation of PI3K/Akt and ERK1/2 pathways 
regulate proliferation of osteoclast precursors and osteoclast survival (27). c-Src activation 
is important for osteoclast proliferation as well as cytoskeletal reorganization for osteoclast 
bone resorption (28). It has also been reported that crosstalk between αvβ3 integrin and M-
CSF regulates cytoskeleton rearrangement, as both signals regulate osteoclast bone 
resorption (29, 30). 
 
1.1.6 Histone Deacetylases (HDACs) 
Acetylation of core histones, as well as non-histone proteins, is becoming more evident 
as a widespread reversible posttranslational modification in regulating gene expression and 
various cellular processes. The opposing activities of two type of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), control the reversible 
acetylation process (31, 32). HATs promote transcription activation, whereas HDACs 
favors transcriptional repression as shown in Figure 4. Association of HATs and HDACs 
with sequence specific DNA-binding proteins permit gene-specific activation and 
repression, respectively (31). 
 
Figure 4. Histone acetyltransferases (HATs) and Histone deacetylases (HDACs). 
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1.1.6.1 Mammalian HDACs 
Based on their similarities to yeast deacetylase domain, 18 mammalian HDACs have 
been identified and classified into four classes based on their catalytic mechanisms as 
shown in Figure 5 (31). Class I, II and IV are zinc-dependent enzymes, whereas class III 
enzymatic activity is dependent on NAD+. Class I HDACs consist of HDAC1, 2, 3 and 8, 
which are ubiquitously expressed and located in nuclei, with the exception of HDAC3, 
which is both nuclear and cytoplasmic. Class II HDAC4, 5, 6,7, 9 and 10, exhibit tissue-
specific expression patterns, with highest expression in brain and skeletal muscle, and can 
shuttle between nucleus and cytoplasm in response to intracellular signaling. Class III 
HDACs consists of sirtuins (SIRT 1-7), which require NAD+ for activity (33). Class IV 
HDAC 11, is the sole member of this class and has homology to both class I and II (34). 
HDACs have been shown to regulate many biological processes such as cell cycle 
progression, differentiation and development. Several HDACs inhibitors have been 
developed to help with treatments of human diseases; however, these inhibitors were 
reported to not be specific, as they target both class I and II HDACs (35). Therefore, the 
effects of individual HDACs, such as class IIa HDACs on osteoclasts and bone in health 
and disease state is pivotal.  
 
Figure 5. The four classes of HDACs in mammals - class I, class IIa, class IIb, class 
II, class III and class IV. Image obtained from (36). 
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1.1.6.2 Class II HDACs 
Based on their domain organization, class II HDACs are further divided into class IIa 
(HDAC4, 5, 7 and 9) and class IIb (HDAC6 and 10). In recent years, class IIa HDACs have 
been accepted as critical regulators of a multitude of biological processes (37), with 
aberrant expression or activity being linked with wide range of human diseases such as 
cancer (38). It has been reported that HDAC4, 5, and 7 regulate chondrocyte and osteoblast 
differentiation and activity, suggesting that these HDACs are critical regulators of 
endochondral ossification (36). Recently, HDAC7 and 9 have been reported both in vivo 
and in vitro as negative regulators of osteoclast differentiation and function (39-41). 
HDAC4 was shown to regulate osteoclast differentiation in vitro (42), however HDAC4 in 
vivo role in osteoclastogenesis has not been examined. 
 
1.1.6.3 Histone deacetylase 4 (HDAC4)   
HDAC4, a key member of the class IIa HDACs, is expressed in various tissues and 
plays a central role in the formation of the skeleton (43, 44) (45).  HDAC4 has been shown 
to regulate chondrocyte hypertrophy in part by regulating the activity of transcription factor 
RUNX2, a master gene of skeletogenesis, in proliferating chondrocytes (43). Given that 
RUNX2 expression in osteoblasts regulates endochondral  bone formation, this suggest 
that HDAC4 also regulates bone formation (7). Mice lacking HDAC4 die perinatally stage 
due to ectopic ossification of endochondral cartilage (43). In osteoclasts, HDAC4 is 
expressed during early stages of osteoclastogenesis (42). The Mansky lab has previously 
demonstrated that knockdown of HDAC4 using shRNA causes an increase in osteoclast 
number, size and resorption (42). However, the in vivo significance of HDAC4 expression 
in osteoclast differentiation and function has not been studied. 
 
1.2 Statement of Purpose 
1.2.1 Significance of Research 
To develop novel pharmacologic agents that arrest the progression of skeletal disorders 
such as osteoporosis, we need to know how osteoclasts differentiation and function is 
regulated. Incomplete understanding of the molecular mechanisms which regulate 
osteoclast function limit this process. A novel approach for the treatment of skeletal 
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disorders is via HDAC regulation of bone resorption. Given the core biological functions 
of HDACs, it is not surprising that they are involved in many pathological processes, and 
their inhibition could provide clinical benefits. Recently, HDAC inhibitors (HDIs) 
vorinostat and romidepsin, were approved by the US FDA for the treatment of T cell 
lymphoma and ovarian/cervical cancers (35). The first generation of HDIs promoted the 
acetylation of histone and non-histone proteins to increase or decrease expression of 
multiple genes. Moreover, long-term use to these drugs leads to detrimental side effects 
such as loss of bone density.  
 
The next generation of HDIs is predicted to target specific HDACs. However, there is 
a compelling need to first understand the role of individual HDACs in regulating 
osteoclasts and more generally in bone in physiological and pathological disorders. 
Conditional knockout animals can provide valuable information on suitable targets, 
potential therapeutic benefits and define the role of specific HDACs on osteoclasts and 
bone.  
 
The in vivo role of HDAC4 in osteoclast function, and the mechanism(s) by which 
HDAC4 regulates osteoclast function have not been examined. These gaps in our 
knowledge limit the development of HDAC member-specific HDIs that maintain 
therapeutic benefits but minimize detrimental side effects. The data outlined in this thesis 
will address these important questions and are vital towards the development of new 
clinical therapeutics based on each HDACs in osteoclasts. 
 
1.2.2 Hypothesis 
I hypothesize that HDAC4 regulates osteoclast function through its interactions with key 
osteoclast proteins.  
 
1.3 Specific Aims 
1.3.1 Specific Aim 1: Characterize the in vivo phenotype and cellular effects of 
conditional knockout of HDAC4 (4cKO) in osteoclasts progenitors.  
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To understand the role of HDAC4 in osteoclast, I have generated a conditional knockout 
mice model for HDAC4 expression in osteoclasts by mating Hdac4fl/fl mice to c-Fms-Cre 
mice.  
 
1.3.2 Specific Aim 2: Characterize the molecular mechanisms by which HDAC4 
regulates osteoclast differentiation and function 
 
Change in gene expression is required for sufficient osteoclast differentiation. To 
determine global changes in gene expression in HDAC4 conditional knockout (4cKO) 
osteoclasts, I performed RNA-SEQ on HDAC4 WT (4WT) and 4cKO osteoclasts. 
 
The results of this thesis will address the role of HDAC4 on osteoclasts. It will further 
our knowledge in the effects of individual HDACs in osteoclasts and bone. This 
knowledge is vital towards the development of new clinical therapeutics for the treatment 
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Chapter 2. Regulation of Osteoclast Differentiation and 
Skeletal Maintenance by Histone Deacetylases 
 
Chapter 2 incorporates review paper: Regulation of Osteoclast Differentiation and 
Skeletal Maintenance by Histone Deacetylases. Faulkner B, Astleford K, and Mansky 
KC. Molecules 2019; 24(7): 1355  
 
Author contribution 




The roles of HDACs in osteoclasts differentiation and function have not been widely 
studied as they have been in osteoblast, nevertheless this is a developing area of scientific 
interest. The aim of this review was therefore to summarize the general properties of 
HDACs and the research that have revealed their important functions in osteoclasts. 
Understanding the biological significance of HDACs will not only provide new insights 
into the mechanisms of HDACs involved in mediating biological response, but also form 
a platform to develop pharmacologic agents to achieve clinical implications. 
 
2.1 Introduction 
A common misconception about the skeleton is that it is static, however, bone is an 
ever-changing organ that is remodeled through tight coupling of bone resorption followed 
by formation of new bone (as reviewed (46-48)). These processes are performed by bone 
resorbing osteoclasts and bone forming osteoblasts. Skeletal homeostasis depends on strict 
control over the number of active osteoclasts at any site (19). Since osteoclasts are a 
perpetrator of many skeletal diseases, understanding the mechanisms that regulate their 
activity during the bone remodeling process is necessary (as reviewed in (49-51)).  
The dynamic and responsive nature of bone during the remodeling process requires 
temporal changes in gene expression within the osteoclast lineage (as reviewed in (52)). 
Combination of transcription factors and co-factors binding to DNA sequences plays an 
important role in chromatin remodeling and cellular signaling events in regulating 
osteoclasts, thus impacting bone remodeling. Additionally, regulation of gene expression 
is controlled, in part, by histone deacetylases (HDACs) (31), which are intracellular 
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enzymes that directly affect chromatin structure, transcription factor activity (53), signaling 
events, and thus affect the activities required for bone remodeling. Understanding how 
these molecular and cellular switches work has become an important mechanism(s) to 
consider in regards to developing targeted bone therapies. HDACs are clinically relevant 
because many molecules that inhibit their activities are used alone or in combination with 
other drugs to treat diseases such as osteoporosis and cancer (54). 
To develop therapies that halt progression of skeletal diseases, we need to understand 
how osteoclasts operate including the mechanisms that regulate their generation, regulation 
and bone resorbing activity. Therefore, transcription factors, co-factors, transcriptional 
regulators and co-regulators must be studied to determine their effects on 
osteoclastogenesis. Recently, a great deal of progress has been made in investigating these 
mechanisms, and the bone degradation process using experimental mouse models and 
patients with abnormal bone phenotypes (9, 49, 55, 56).  
In this review, we focus on regulation of osteoclasts by transcriptional factors and 
introduce important findings on how osteoclasts are regulated by HDACs to exert bone-
resorbing activity. We have organized this review according to the different categories of 
regulation. We will begin by discussing osteoclasts and their transcriptional factors 
followed by the influence of HDACs on osteoclast differentiation and activity. 
 
2.2 Osteoclast Biology  
     Bone is comprised of multiple cell types, including osteoblasts, which are 
mesenchymal-derived cells responsible for synthesizing new bone, osteocytes which are 
terminally differentiated osteoblasts and bone degrading osteoclasts, which are 
hematopoietic in origin (10). Bone homeostasis and normal function result from the tightly 
regulated interactions between osteoblasts, osteocytes and osteoclasts. To maintain this 
balance in the adult skeleton, osteoblasts and/or osteocytes produce two necessary 
cytokines, macrophage colony stimulating factor (M-CSF) and receptor activator of NF-
κB ligand (RANKL) to promote osteoclast differentiation (57).  
    Osteoclasts are giant multinucleated cells of hematopoietic origin that degrade the bone 
matrix. They are formed by fusion of mononuclear precursors of the monocyte/macrophage 
lineage, and are the primary resorptive cells of the skeleton (19, 58). One of the most 
remarkable features of the osteoclast is its ruffled membrane, which is the resorptive 
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organelle of the cell. When this membrane comes into contact with bone, skeletal matrix 
degradation follows (13). Most skeletal disorders manifest when osteoclast activity is 
dysfunctional (50, 51).  Increased bone mass phenotype (osteopetrosis) is associated with 
low osteoclast activity while decrease bone mass phenotype (osteoporosis) is associated 
with increased osteoclast activity.  
Progression from multipotent progenitors into specialized, terminally differentiated 
cells involves carefully regulated patterns of gene expression to control lineage 
specification and emergence of the cellular phenotype.  This process requires coordinated 
action of transcription factors with co-activators and co-repressors to bring about proper 
activation and inhibition of gene expression. In the following section, we will describe 
what is known about transcription factors that regulate osteoclast differentiation (Figure 
6). 
 
2.3 Transcriptional Regulators of Osteoclast Gene Expression  
  
2.3.1 PU.1 
PU.1 is a member of the ETS-domain transcription factor family (59). It has been 
shown that mice lacking PU.1 have a deficiency in both macrophage and osteoclast 
differentiation, and this established PU.1 as one of the earliest markers of the osteoclast 
lineage (60). During osteoclast differentiation, the expression level of PU.1 is unchanged 
or modestly increased (60, 61). In the early stages of commitment to the 
monocyte/macrophage lineage, PU.1 upregulates expression of Csf1r the receptor for M-
CSF one of the essential ligands for osteoclast differentiation (62). Along with other 
osteoclast transcription factors, PU.1 regulates expression of Tnfrsf11a the gene for 
RANK, the receptor for RANKL, the other essential cytokine for osteoclast differentiation 
(63). Lastly PU.1 along with other osteoclast transcription factors, c-FOS, MITF and 
NFATc1, regulates multiple genes necessary for osteoclast differentiation including 
cathepsin K (Ctsk), Acp5, the gene for TRAP, dendritic cell seven transmembrane protein 
(Dc-stamp), and Oscar  (61, 64, 65).   
 
2.3.2 MITF 
Microphthalmia transcription factor (MITF) is a basic helix-loop-helix-leucine zipper 
transcription factor (66-68). It has been established that MITF plays an essential role in 
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regulating gene expression during osteoclast differentiation. This observation was based 
on a bone marrow transplantation experiment which showed that osteopetrotic condition 
in mi/mi mutant mouse could be cured using bone marrow from a wild type littermate (69). 
Additionally, mononuclear osteoclasts from these mi/mi mice were unable to fuse, form a 
ruffled border and resorb bone (70). These results not only confirmed osteoclasts 
hematopoietic origin but also established MITF as a necessary transcription factor during 
osteoclast differentiation. MITF along with PU.1 was shown to upregulate the expression 
of Tnfrsf11a (71). Studies on MITF in osteoclasts have also revealed that it can 




The CCAAT/enhancer binding protein-α (C/EBPα) is a member of C/EBPα family of 
transcription factors which act as master regulators of various cellular processes (74). 
C/EBPα has been shown to be important for differentiation of myeloid progenitors (75). 
Recently, C/EBPα was shown to be highly expressed in osteoclasts (76). Overexpression 
studies revealed that PU.1 upregulates expression of C/EBPα while C/EBPα upregulates 
expression of c-FOS and NFATc1 (76, 77). Forced expression studies revealed that 
C/EBPα can specify mouse bone marrow cells to become osteoclasts, suggesting that 
C/EBPα can induce osteoclast lineage priming and plays a role in regulating gene 
expression during the early stages of osteoclast differentiation (76). In addition, C/EBPα 
deficient mice were shown to have severe osteopetrosis due to impaired osteoclast 
development (78, 79). In a subsequent study, overexpression of C/EBPα was shown to 
promote osteoclast differentiation and induce expression of osteoclast genes Nfatc1, Ctsk, 
and Acp5  (80). Besides its role in regulating osteoclast differentiation, functional 
experiments revealed that C/EBPα plays a role in bone resorption (80). Together all these 
studies suggest that C/EBPα is essential for osteoclast differentiation and activity. 
 
2.3.4 MEF2 
The myocyte enhancer factor 2 (MEF2) family of transcription factors play an 
important role in many cellular processes including cell differentiation and apoptosis (81-
83). These proteins can affect the expression of many genes by binding with other 
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transcription factors (81-83). One of these binding partners is HDACs. Each individual 
HDAC contains a MEF2-interacting transcriptional repressor homology domain 
suggesting that they have the ability to regulate the MEF2 family (81-83). MEF2 family 
consists of 4 members, MEF2A, B, C and D (81-83). Osteoclasts primarily express MEF2A 
and D (Mansky,unpublished observation). Osteoclasts null for MEF2A and D express 
reduced levels of c-FOS and NFATc1 suggesting that MEF2 may regulate expression of 
these transcription factors in osteoclasts (Mansky, unpublished observation).     
 
2.3.5 c-FOS 
c-FOS is a member of activator protein -1 (AP-1) family of transcription factors, and 
its expression is induced early during osteoclast differentiation (84, 85). c-FOS acts as an 
important switch between osteoclast and macrophages differentiation, and in its absence 
osteoclasts do not form (84). This observation was made in c-Fos knockout mice which 
develop osteopetrosis due to the inability of cells to commit to osteoclast lineage (84, 86). 
c-FOS and NF-κB both target and upregulate Nfatc1 expression in osteoclasts and at least 
in part explain why c-Fos knockout mice do not develop osteoclasts (85). 
   
2.3.6 NF-κB 
Nuclear factor kappa-light-chain-enhancer of activated B cells or NF-κB is a 
pleiotropic transcription factor part of the Rel subfamily of proteins (87). In osteoclasts, 
NF-κB regulates formation, function and survival (87-89). NF-κB is activated downstream 
of RANK signaling that ultimately results in the activation of NFATc1 to induce 
osteoclastogenesis (87, 90). The inhibitory protein IκB localizes NF-κB in the cytoplasm 
until it is activated by dimerizing with Rel family proteins promoting nuclear translocation 
to activate transcription (87-89). Loss of the p50 and p52 subunits of NF-κB results in an 
osteoporotic bone phenotype in mice most likely due to the inability to activate Nfatc1 
expression (90).  
 
2.3.7 NFATc1 
NFAT is a family of transcription factors that regulate the expression of cytokines and 
other immunoregulatory genes (91). NFATc1 mediates RANKL-induced osteoclast 
formation, and its overexpression in c-Fos deficient cells rescues osteoclastogenesis (85, 
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92). At early stages of osteoclast differentiation, RANKL  increases the stability of 
NFATc1 protein by stimulating calcineurin-mediated dephosphorylation of NAFTc1 in the 
cytosol, causing it to translocate to the nucleus (93). However, during late stage 
osteoclastogenesis, M-CSF downregulates NFATc1 protein levels, and eventually 
NFATc1 is degraded through ubiquitin-proteosome pathway in the cytoplasm (94). This 
degradation is mediated by Cbl-b and c-Cbl ubiquitin ligases in a Src-dependent manner 
(94). While NFATc1 is termed the “master regulator” and is sufficient for osteoclast 
differentiation, ChIP experiments demonstrated that NFATc1 regulates osteoclast gene 
expression in a complex with PU.1, MITF and c-FOS (95). There are no studies yet to 
demonstrate how or if MEF2 and C/EBPα interact with this complex to regulate osteoclast 






Figure 6. Expression of transcription factors and HDACs during osteoclast 
differentiation.  Cartoon illustrates expression of transcription factors and HDACs during 
osteoclast differentiation based on studies presented in this review.  HDACs in red inhibit 
osteoclast differentiation, HDACs in green promote osteoclast differentiation and the 
function of HDACs in orange are not known due to lack of animal studies (96).    
 
2.4 Histone Deacetylases (HDACs) 
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Histones are major regulators of gene expression and transcription, and their state of 
activeness and inactiveness controls this process (44). Acetylation is an important 
modification to histone tails that allow for genes to be transcribed by releasing DNA so it 
can unwind and become accessible for transcription (44).  There are two enzymes that play 
an important role in this process; histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (44). HATs are enzymes that will acetylate histone tails resulting 
in the relaxation of the chromatin and allowing for transcription factors to bind to their 
promoters (44). For transcription to be repressed, HDACs are recruited to remove acetyl 
groups on the tails, allowing chromatin to rewind around histones (44). Additionally, some 
HDAC members have the ability to directly interact with transcription factors to repress 
transcription (31). Understanding transcriptional regulation by HATs and HDACs in bone 
is vital in the study of differentiation and disease in which these two enzymes play a role. 
 
2.4.1 HDAC Classes 
There are 18 HDACs within the human genome, each of which are distributed into 4 
different classes: class I HDACs (HDACs 1,2,3,8), class II HDACs (HDACs 4,5,6,7,9,10), 
class III HDACs (Sirtuins 1-7) and class IV HDACs (HDAC11) (31). They are divided 
based on their enzymatic activity, location within the cell and their sequence homology to 
yeast (31). The structure and function of HDACs are similar to one another and are also 
closely related to that of budding yeast, however; each class has their own unique catalytic 
domain (31).  Class I HDACs are homologs to yeast RPD3 and are primary localized in 
the nucleus (31). They contain a catalytic domain unique to the class I HDACs and 
predominantly target histone substrates (31). Class II HDACs are homologs to yeast HDA1 
(97, 98). These HDACs are separated into two subclasses; class IIA and class IIB (44).  
Class IIA HDACs are transcriptional repressors that are shuttled between the nucleus and 
the cytoplasm by the chaperone protein 14-3-3 (44, 98). Class IIB HDACs differ from IIA, 
in that they contain two catalytic domains and they are primarily found in the cytoplasm 
(97). Class III HDACs, or sirtuins, are homologs to yeast Sir1 (99).  These HDACs are 
dissimilar to the class I and class II HDACs in that they are NAD+ dependent and contain 
an NAD+ binding site (99). Class III HDACs are known to deacetylate histones and 
regulate transcription factors (99). They can regulate transcription factors by altering their 
binding to DNA, modifying their location within the cell or changing their interaction with 
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other proteins (99). HDAC11 is the sole member of the class IV HDACs (100). It shares a 
similar structure to that of the class I HDACs, however little is known about the mechanism 
by which HDAC11 regulates transcription (100). 
 
2.4.2 HDACs in bone development 
Bone development occurs throughout life. The three bone cells that are involved in 
development, growth and remodeling are osteoblasts, osteocytes and osteoclasts. The two 
main types of bone formation/ossification are intramembranous and endochondral. 
Endochondral ossification is the process by which long bones and vertebrae form while 
intramembranous ossification results in formation of flat bones of skull, mandible and 
clavicle. It has been reported that some HDACs have roles in the ossification process. 
Intramembranous bone defects in mouse models associated with altered class I HDAC 
expression have been described (36, 101, 102). HDACs have also been shown to contribute 
to different steps of endochondral bone ossification. Germline deletion of HDAC1, 3 and 
7 are embryonic lethal and die before endochondral ossification begins (103-105). Deletion 
of HDAC2, 4, 5, 6, 8 and 9 are not embryonic lethal and do not appear to disrupt early 
endochondral ossification (43, 106, 107). HDAC3 and HDAC4 have been shown to play a 
role in chondrocyte maturation (43, 104, 108). There are currently no published studies 
demonstrating that HDACs play a role in regulating osteoclast activity during bone 
development. For a more complete review of HDAC mediated control of endochondral and 
intramembranous ossification see (109). 
 
2.4.3 HDACs and skeletal maintenance 
Skeletal maintenance requires a tightly coordinated activity of bone cells osteoclast, 
osteoblasts and osteocytes (48). Some of the 18 human HDACs have been shown to play 
a part in skeletal bone maintenance. Multiple HDACs (1, 3, 4, 5, 6 and 7) are expressed in 
osteoblasts and have been shown to regulate osteoblast differentiation and gene expression 
(110-116) as well as osteocyte activity (117, 118). More complete reviews on regulation 
of osteoblasts and osteocyte activity by HDACs are (6, 36, 109, 119). In section 5 of this 
review, we will discuss what is known concerning the role of regulating osteoclasts during 
maintenance or remodeling phase of the skeleton.   
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2.4.4 HDACs and skeletal diseases 
Currently in humans, mutations in HDAC2, 4,5,6 and 8 have been shown to affect the 
skeleton (120-128). These HDACs mutations results in either loss-of-function, deletion or 
gain of function in patients. Some of the defects in bone caused by these mutations are low 
bone mineral density, brachydactyly, and skeletal abnormalities in the craniofacial region, 
the spine and the growth plates (as reviewed in (36)). Further investigations are needed in 
order to understand the altered HDACs functions. It has also been reported that many 
HDACs are expressed in human articular cartilage and expression of some of the HDACs 
was even higher in joints from osteoarthritic patients (129-133). The causative role for the 
altered HDACs function needs to be investigated. Usually, the amount of bone resorbed by 
osteoclasts is balanced by the amount of bone formed by osteoblasts. Nevertheless, in 
increased bone resorption conditions such as osteoporosis and Paget’s disease, bone 
resorption surpass bone deposition which results in bone loss. The roles of HDACs in 
regulating osteoclasts in these bone resorption conditions is not understood and is an 
emerging area of scientific interest.    
 
2.5 Role of HDACs in Osteoclasts 
 
2.5.1 Class I HDACs  
Class I HDACs are thought to be expressed in most cell types (31). HDAC1 and 2 
expression is almost exclusively nuclear as both proteins lack a nuclear export signal (31). 
However, HDAC3 has both a nuclear import and export signal but is almost always found 
in the nucleus perhaps due to the fact that it recruited to the nucleus via its interactions with 
HDAC4, 5 and 7 when they are bound to DNA (134-136). There are currently no published 
animal model studies analyzing the role of HDAC1, 2, 3 or 8 in osteoclasts using 
conditional mouse models.  These studies are critical to understanding the role of class I 
HDACs in osteoclast differentiation as well as skeletal maintenance. Chemical inhibitors 
and siRNA studies are informative as they can be used to distinguish between effects of 
HDACs regulating osteoclast differentiation versus activity but they can have off target 
effects making the results difficult to interpret. Animal models are critical to understanding 
the role of class I HDACs in regulating osteoclasts and skeleton maintenance.   
   
2.5.1.1 HDAC1  
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HDAC1 is a transcriptional repressor that is present early during osteoclast 
differentiation (41). It is expressed in osteoclast precursors and then drops significantly 
after RANKL stimulation (41). The main role of HDAC1 in osteoclasts is to act as a co-
repressor (137). It does this by being recruited to the promotors of osteoclast genes such 
as Nfatc1 and Oscar to prevent their expression (137). By ChIP analysis, MITF and PU.1 
have been shown to be recruited to Ctsk and Acp5 promoters with M-CSF stimulation 
along with co-repressors CtBP, Sin3A and HDAC1 (138).   
 
2.5.1.2 HDAC2 
In contrast to HDAC1, HDAC2 expression increases during osteoclast differentiation 
(139). Studies have shown that knock down of HDAC2 in osteoclasts not only inhibits 
osteoclast differentiation, but also hinders actin ring formation, fusion, and osteoclast 
activity (139). HDAC2 was shown to activate Akt, which removed an inhibitor, FoxO1, 
and demonstrated that HDAC2 is not an inhibitor of osteoclast differentiation.     
 
2.5.1.3 HDAC3  
HDAC3 is expressed in osteoclast precursors, and its expression remains low during 
osteoclast differentiation (41). Knock down of HDAC3 results in inhibition of 
osteoclastogenesis resulting from the down regulation of osteoclast genes Nfatc1, Ctsk 
and Dc-stamp (140). Loss of HDAC3 expression is similar to the phenotype seen with 
osteoclasts treated with broad spectrum HDAC inhibitors (HDIs) such as trichostatin A 
(TSA) and sodium butyrate (NaB) (141, 142).    
 
2.5.1.4 HDAC8 
HDAC8 expression is low during early osteoclast differentiation, and its expression 
increase during late osteoclast differentiation (41). Not much is known about HDAC8 in 
osteoclasts, and as stated above further animal model studies will need to be done to 
understand its role in regulating differentiation and activity. 
 
2.5.2 Class II HDACs 
Based on cellular signals, class II HDACs are able to shuttle between the cytoplasm 
and the nucleus. At least in muscle cells HDAC4, 5 and 7 have a very regulated process of 
shuttling between the nucleus and cytoplasm (31, 143, 144); however, the subcellular 
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localization of class II HDACs has not been well studied in osteoclasts. HDAC4, 5, 7 and 
9 all have a binding site in their amino terminus for C-terminal binding protein (CtBP), 
MEF2 and 14-3-3 (31, 135, 145). One interesting question that has emerged pertaining to 
HDACs 4, 5, 7 and 9 given their similarity is why are they not functionally redundant in 
osteoclasts.  To answer this question, studies need to be performed to identify targets and 
partners of class II HDACs so as to understand the mechanisms by which class II HDACs 
regulate osteoclast differentiation and activity.  
  
2.5.2.1 HDAC4 
HDAC4 is expressed in osteoclast precursors, and its expression begins to decrease as 
osteoclasts become mature (41, 42). Knock down of HDAC4 by shRNA increases 
osteoclasts in size and number (42). With the increase in osteoclast differentiation there 
was also an up regulation of osteoclast genes (c-fos, Nfatc1, Dc-stamp, and Ctsk) and  
increases in osteoclast activity (42).  To further study the role of HDAC4 in regulating 
osteoclast differentiation, conditional deletion of Hdac4 using Cfms-Cre was created and 
demonstrated to have no gross phenotypic changes in bone structure. More focused 
analysis surprisingly revealed an increase in bone volume in trabecular bone at 3 months 
of age suggesting an increase in bone mass phenotype (Mansky,unpublished observation). 
Moreover, bone resorption was reduced in HDAC4cKO mice (Mansky, unpublished 
observation ). The mechanism(s) by which HDAC4 regulates osteoclast differentiation i.e. 
targets and partners is currently unknown and is being evaluated using an osteoclast 
specific HDAC4 mouse model (Mansky, unpublished observation).  
 
2.5.2.2 HDAC5 
HDAC5 is expressed later in osteoclast differentiation, having the highest expression 
around the time of osteoclast fusion (41, 42). Similar to HDAC4, HDAC5 knock down by 
shRNA results in an increase in osteoclast differentiation, an upregulation of osteoclast 
genes and an increase in resorption (42). Global deletion of HDAC5 in mice demonstrated 
no gross defect at birth, and mice are of normal size (107). In two other separate studies, 
HDAC5 knockout mice were reported to have reduced trabecular bone density at 2-3 month 
of age (114, 117). One study suggested loss of HDAC5 expression leads to an increase in 
RANKL expression by osteoblasts, which stimulated greater bone resorption by the 
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osteoclasts (114). However, since multiple types of bone cells are being affected in the 
global HDAC5 null mouse, and the mechanism(s) for bone loss is not clear more focused 
tissue specific studies need to be conducted. These mechanisms will be explored using an 
osteoclast specific HDAC5 mouse model (Mansky, unpublished observation). 
Mechanistically HDAC5 has been shown to deacetylate NFATc1 leading to NFATc1’s 




During osteoclast differentiation, HDAC6, a class IIb HDAC protein, expression was 
shown to peak around osteoclast fusion and to be expressed predominately in cytoplasm 
(41, 42). By using shRNA, knockdown of HDAC6 expression in mouse bone marrow 
macrophages (BMMs) did not display any phenotype nor did it seem to affect expression 
of major osteoclast genes (42). HDAC6 plays an important role in destabilizing the 
osteoclast cytoskeleton and inhibiting osteoclast migration and podosome formation (147, 
148). This observation revealed a molecular mechanism in which RhoA-mDia2-HDAC6 
forms a complex and regulate podosome patterning (147). It was demonstrated using 
microinjection experiments that injecting either activated RhoA or mDia2 caused 
microtubule deacetylation together with podosome belt disruptions (147). 
 
2.5.2.4 HDAC7 
HDAC7 is expressed early in osteoclast differentiation and continues at a low level of 
expression throughout differentiation (41, 42). HDAC7 has been shown to have a role in 
regulating osteoclast differentiation (39, 40, 140). Osteoclasts with reduced HDAC7 
expression resulted in accelerated osteoclast differentiation and increased size of TRAP 
positive multinucleated osteoclasts (39, 40, 140). This discovery was ascribed to the 
capacity of HDAC7 to suppress MITF transcriptional activity (39). It was reported that the 
N-terminus tail of HDAC7 was sufficient to bind and suppress MITF activity, suggesting 
that the deacetylase domain of HDAC7 is not required for its repression function (39). 
Conditional knockdown of HDAC7 using LysM-Cre, that targets monocytes and myeloid 
lineage cells which includes osteoclasts, was found to enhance osteoclast differentiation 
and resulted in an osteopenic skeletal phenotype (39, 40). Besides MITF, HDAC7 was 
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shown to inhibit b-catenin activity and cyclin D1 expression in the presence of RANKL 
(40). These studies suggest that HDAC7 is a negative regulator of osteoclastogenesis. 
 
2.5.2.5 HDAC9 
HDAC9 is expressed immediately after RANKL stimulation and then expression 
reduces to undetectable levels (41, 42). Osteoclast differentiation and bone resorption were 
highly elevated in HDAC9 KO mice (41). Bone marrow transplantation experiments 
revealed that the osteoclasts defects in HDAC9 KO are intrinsic primarily to the 
hematopoietic cell lineage, since when HDAC9 KO bone marrow was transplanted to wild-
type mice, it resulted in osteopenia, and when wild-type bone marrow was transplanted to 
HDAC9 KO mice, a rescue occurred (41). HDAC9 was found to take part in a negative 
regulatory circuit with PPARγ and RANKL signaling. Both PPARγ and RANKL can 
inhibit Hdac9 mRNA expression levels while HDAC9 forms a complex with NCoR and 
SMART to inhibit PPARγ activity (41). In conclusion, these studies demonstrate that 
HDAC9 expression inhibits osteoclastogenesis. Similar to HDAC5, creating a conditional 
mouse model of HDAC9 would allow for studies to be performed that analyze the role of 
HDAC9 in osteoclasts without the confusion of HDAC9’s role in regulating the other cells 
of the skeleton.   
 
2.5.2.6 HDAC10 
Like HDAC6, HDAC10 is a part of the class IIb HDAC family (149). The biological 
role of HDAC10 in osteoclasts is largely unknown however, what is known is that 
HDAC10 expression increases during differentiation and peaks around fusion (41, 42). 
Additionally, suppression of HDAC10 by shRNAs result in increased osteoclastogenesis, 
expression of osteoclast genes (c-fos, Nfatc1, Dc-stamp, and Ctsk), and osteoclast activity 
(42). This suggests that HDAC10 acts as an inhibitor of osteoclast differentiation; however, 
studies should be done in an animal model to confirm cell culture studies as well as identify 
osteoclast targets and partners of HDAC10.  
 
2.5.3 Class III HDACs  
Class III HDACs are a family of NAD+ dependent deacetylases known as sirtuins 
(150). These proteins are involved with many physiological processes such as cellular 
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metabolism, DNA repair, cell growth and autophagy (150). There are seven known sirtuins; 
however, only three have been studied in osteoclasts. There is not much known about 
sirtuins 2,4,5 and 7 in osteoclasts, and further studies will need to be performed to 
characterize their roles in regulating osteoclast differentiation and activity. 
 
2.5.3.1 Sirtuin 1   
Sirtuin 1 (SIRT1) is a repressor of osteoclast differentiation and activity by inhibiting 
RANKL signaling (151). SIRT1 is able to do this by deacetylating and activating a group 
of inhibitors of osteoclastogenesis known as forkhead box proteins (FOX) (151). Loss of 
SIRT1 expression results in an increase in osteoclast formation and activity due to the 
increase of acetylated FOX proteins (151). 
 
2.5.3.2 Sirtuin 3 
In osteoclasts, Sirtuin 3 (SIRT3) expression is induced by RANKL stimulation (152). 
Loss of SIRT3 in osteoclasts results in osteopenia in mice due to an increase in osteoclast 
number (152). This indicates that SIRT3 is a negative regulator of osteoclast differentiation 
(152). Additionally, the loss of SIRT3 results in an increase in osteoclast specific genes 
such as Oscar, Nfatc1 and Atp6v0d2 (152). Interestingly, SIRT3 does not regulate 
osteoclast activity meaning its ability to resorb mineral is unaffected by loss of the gene 
(152). Lastly, it is suggested that SIRT3 can negatively regulate osteoclast differentiation 
by controlling AMPK activity (152). 
 
2.5.3.3 Sirtuin 6 
Sirtuin 6 (SIRT6) is expressed in osteoclasts once monocytes are stimulated with M-
CSF and RANKL (153). SIRT6 acts as a transcriptional repressor through inhibiting NF-
κB transcription (153). This inhibition activity results from the deacetylation of H3K9 on 
the promotors of target genes for NF-κB (153). Therefore, overexpression of SIRT6 results 
in inhibition of osteoclastogenesis and enhanced osteoclast differentiation is measured 
when SIRT6 is lost (153).   
 
2.5.4 Class IV HDACs 
HDAC11, the sole member of class IV HDAC, is expressed late in osteoclast 
differentiation where it is most highly expressed after three days of RANKL stimulation 
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(41, 42).  HDAC11 appears to be most closely related to HDAC3 and 8; however, its 
classification has not been determined since its sequence identity with other HDACs is 
limited (100, 154). Loss of HDAC11 expression in osteoclasts results in an increase in 
osteoclast differentiation as well as osteoclast activity. Interestingly, HDAC11 does not 
affect c-fos or Nfatc1, but increases the expression of both Dc-stamp and Ctsk, suggesting 
that it plays a role on osteoclast fusion as well as activity but independent of regulating 
Nfatc1 expression or activity (42). These results suggest HDAC11 acts as a repressor, 
however, further animal model studies will need to be performed to characterize its role in 
regulating osteoclast differentiation and activity.  
 
 
2.6 Effects of HDAC Inhibitors (HDIs) on the Skeleton 
To date the majority of studies have analyzed the effects of HDACs and HDIs on the 
effect of individual bone cells (as reviewed in (6, 155). It has become apparent that 
maintaining a healthy skeleton requires continued crosstalk between osteoclasts, 
osteoblasts and osteocytes (Figure 7). Studies assessing the crosstalk between the various 
cells will need to be done to assess the efficacy of using broad or specific HDIs in treating 




Figure 7.  Coupling of bone formation and bone resorption.  Cartoon illustrates that 
osteoblasts express M-CSF and RANKL to stimulate osteoclast differentiation and bone 
resorption. Osteoclasts also express and release factors that regulate osteoblast 
differentiation and activity (96).    
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Since the 1960s, valproate an HDI has been used as treatment for epilepsy, bipolar and 
other mood disorders. In several patient groups, prolonged exposure to valproate leads to 
a decrease in bone mineral density and an increase in fracture risk (156-159). In the 
valproate studies the mechanism(s) resulting in the bone loss are not clear as changes in 
bone biomarkers was not conclusive (160-164). Additionally, valproate has other activities 
besides inhibiting HDACs (165, 166). In animal studies of periodontitis, a broad acting 
HDI resulted in bone loss and reduced the number of osteoclasts in the gingiva and alveolar 
bone (167). In animal models of rheumatoid arthritis, topical treatment with either broad 
spectrum HDI, phenyl butyrate or TSA, suppressed joint swelling, levels of TNF-α with 
no evidence of joint destruction (168). Class and isozyme specific HDI, NW-21 (targets 
HDACs1 and 2), MS-275 (targets HDAC1) and BML-275 (targets HDAC6) have been 
shown to have anti-arthritic activities in rodent models (169, 170). A number of broad 
acting and a HDAC6 specific HDI are currently being used in the clinic to treat multiple 
myeloma (171-174). While HDIs may help patients that suffer from skeletal diseases such 
as osteopetrosis, they may have off-target effects that cause bone loss in other patients. 
Additionally, these HDIs are broad acting and do not target specific HDACs. Producing 
new HDIs in the future that target specific HDACs may be more beneficial since HDACs 
have differing role in osteoclasts.   
2.6.1 HDAC Inhibitors (HDIs) and Fracture healing 
After initial trauma, bone heals by direct intramembranous or indirect fracture healing 
involving intramembranous and endochondral bone formation (as reviewed in (175)). Bone 
healing process involves an acute inflammatory response and the recruitment of 
mesenchymal stem cells so as to initiate formation of primary cartilaginous callus. The 
callus is then subjected to revascularization and calcification and eventually remodeled by 
osteoblasts and osteoclasts (175). It has been reported that HDIs can increase bone healing 
process. Lee et al reported that they saw greater bone formation in rabbit calvarial bone 
fracture model when cyclic depsipeptide largazole was added to a macroporous biphasic 
calcium phosphate scaffold compared to scaffold control. The activity of the largazole was 
attributed to increase expression of Runx2 and BMPs (176). This finding requires further 
investigation because as reported in the previous section, HDI administration in humans 
has been shown to have negative effects on bone mass.  






Over the years we have learned a great deal about the mechanisms by which the 
osteoclast is formed and resorbs bone. Most of this progress has come about as a result of 
rapid advances in cell and molecular biology studies. We now know more about the 
enzymes, signaling pathways, and cytokines which are important for osteoclast formation. 
While treatments such as HDIs may be beneficial for some skeletal diseases, this new level 
of understanding will result in the generation of new therapies that specifically target 
osteoclast generation and/or activity. Despite these advances, several key questions 
remained unanswered, one which relates to the detailed mechanism of osteoclast regulation 
by HDACs a process that seems to affect its function. More importantly, however, is the 
issue of roles of different HDACs at molecular and cellular levels in bone biology since, 
much remains unknown. A better understanding of the roles of HDACs in regulating 
osteoclasts, especially during bone resorption, will also provide insights into the cellular 
and molecular mechanisms that regulate skeletal development and homeostasis. 
 
Chapter 3.  Class II and IV HDACs function as inhibitors of 
osteoclast differentiation 
 
Chapter 3 incorporate paper: Class II and IV HDACs function as inhibitors of 
osteoclast differentiation. Blixt NC*, Faulkner BK*, Astleford K, Lelich R, Schering J, 
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Previous research studies using in vitro and in vivo models have demonstrated the roles 
for several HDACs in regulating chondrocyte and osteoblast differentiation and activity.  
By comparison, there is very little data on the roles of individual HDACs in osteoclast 
formation and function.  For this reason, the aim of this study was therefore to investigate 
the gene expression patterns and the effects of suppressing individual class II (Hdac4, 5, 
6, 9, and 10) and class IV (Hdac11) HDACs during osteoclast differentiation in vitro. It 
was hypothesized that that loss of any one HDAC would be compensated for by the 
remaining proteins in vitro. 
 
3.1 Introduction 
Bone is a dynamic tissue that is constantly remodeled through degradation by 
osteoclasts and renewal by osteoblasts (19).  Proper coordination between these cell types 
is essential for maintaining structural integrity of the skeleton throughout development.  
Osteoclasts are large, multinucleated cells derived from hematopoietic stem 
cells/monocyte precursors (19). Osteoclast differentiation is governed mainly by two 
important cytokines: macrophage colony stimulating factor (M-CSF) and receptor 
activator of nuclear factor kappa B ligand (RANKL) (9, 10, 177, 178).  RANKL stimulates 
the expression of key transcription factors such as NF-kB, c-Fos, MITF, and NFATc1 (68, 
178-180) that are necessary for osteoclast differentiation and maturation.  Osteoclasts are 
needed for normal bone functions such as bone remodeling and fracture repair.  However, 
uncontrolled osteoclast activity can lead to skeletal disorders such as osteoporosis.  
Therefore, it is important to determine mechanisms that regulate transcription of osteoclast 
genes.  This knowledge may reveal key modulators of bone resorption that can be 
considered as therapeutic targets.  
The existence of tissue-specific transcription factors alone is inadequate to control 
temporal gene expression; co-factors are needed for chromatin remodeling and recruitment 
of RNA polymerase II. Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) control gene expression markings by being drafted to target genes through 
interactions with specific transcription factors (181). Gene activation is linked to the 
recruitment of HATs by transcription factors.  Conversely, HDACs bind to the same 
transcription factors and promote transcriptional repression.  Thus, HATs and HDACs act 
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as molecular switches for the functions of transcription factors.  These processes have 
become essential mechanisms to examine regarding our understanding of bone physiology 
and diseases.  
  HDACs are negative regulators of transcription, and have been shown to induce 
specific changes to gene expression in various biological processes by deacetylating both 
histone and non-histone proteins (44, 182, 183).  Rooted in structural and functional 
similarities to yeast deacetylases, the 18 HDACs in the human genome are categorized into 
four classes: class I HDACs (HDAC1, 2, 3 and 8), class II HDACs (HDAC4, 5, 6, 7, 9 and 
10), class III HDACs (Sirtuins1-7) and class IV HDACs (HDAC11) (6, 31, 184-188).  
HDACs are emerging as important regulators of skeletal homeostasis (6).  Various in vitro 
studies have reported that HDAC inhibitors can repress osteoclast differentiation (141, 189, 
190).  These inhibitors are broad-spectrum compounds that target multiple HDACs.  
However, the specific effects of individual HDACs on osteoclasts are largely unknown.  
Previous work from our lab demonstrated that suppression of Hdac7 and Hdac3 have 
opposite effects on osteoclast differentiation in vitro (140).  Hdac7 suppression enhances 
differentiation, whereas suppression of Hdac3 inhibits osteoclast differentiation.  Our lab 
(39) as well as Jin et al (40) demonstrated that HDAC7 inhibits osteoclastogenesis and 
bone resorption in vivo.  We found that HDAC7 represses osteoclast differentiation through 
interacting with the transcription factor MITF (39), while Jin et al. showed that HDAC7 
regulates NFATc1 activity (40).  Additionally, Jin et al (41) demonstrated that HDAC9 
suppresses osteoclastogenesis through negatively regulating PPARg. These findings 
suggest that each HDAC member can induce suppression of osteoclast differentiation 
through distinct and possibly multiple mechanisms.  However, it is still unclear whether 
other HDAC members play separate and pivotal roles in osteoclastogenesis.  
The goal of this study was to investigate the functions of class II and IV HDACs during 
osteoclastogenesis and to determine whether any redundant roles exist for the class II and 
IV HDACs.  Our results revealed that suppression of individual HDACs enhance osteoclast 
differentiation, potentially through repression of different proteins within the same cellular 
pathways.  We anticipate that characterization of changes in gene expression patterns due 
to specific suppression of each HDAC in osteoclasts will further our understanding of how 
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class II and IV HDACs regulate osteoclastogenesis.  This knowledge will lead to potential 
new therapies in treating resorption-mediated bone diseases. 
 
3.2 Experimental Procedures 
3.2.1 Ethics. The use and care of the mice was reviewed and approved by the University 
of Minnesota Institutional Animal Care and Use Committee, IACUC protocol number 
150732820A. Euthanasia was performed by CO2 inhalation. Isolation and culture of 
osteoclasts from mouse bone marrow cells, as well as virus generation and viral 
transduction of osteoclasts were performed under approval of the University of Minnesota 
Institutional Biosafety Committee, permit number 1506-32712H. 
 
3.2.2 Primary Osteoclast Cell Culture.  Primary bone marrow macrophages (BMMs) 
were isolated from the femora and tibiae of C57BL/6 mice.  The femora and tibiae were 
dissected out and adherent tissue was removed.  The epiphyses of these long bones were 
removed, and the bone marrow was flushed from the diaphysis.  Red blood cells were lysed 
from the flushed marrow using red blood cell lysis buffer (150 mM NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA, pH 7.4), and the resulting cells were plated and cultured overnight 
in 100 mm tissue culture dishes (MidSci) in osteoclast media (phenol red-free alpha-MEM 
[Gibco] with 5% fetal bovine serum [Hyclone], 25 units/mL penicillin/streptomycin 
[Invitrogen], 400 mM L-Glutamine [Invitrogen], and supplemented with 1% CMG 14-12 
culture supernatant containing M-CSF).  CMG 14-12 cell line was obtained from Dr. Sunao 
Takeshita (Nagoya City University, Nagoya, Japan)(191).  The non-adherent cell 
population was then re-plated in 12-well plates (MidSci) at 2 x 105 cells/well in osteoclast 
media supplemented with 1% CMG 14-12 culture supernatant for 48 hours.  Cells were 
then fed every two days with osteoclast media containing 1% CMG culture supernatant 
plus 10 ng/mL RANKL (R&D Systems) to stimulate osteoclastogenesis. 
 
3.2.3 Tartrate resistant Acid Phosphatase (TRAP) Staining.  After five days of culture 
with 1% CMG 14-12 culture supernatant and 10 ng/ml RANKL, primary osteoclasts were 
rinsed in PBS and fixed with 4% paraformaldehyde for 20 minutes.  Cells expressing TRAP 
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were stained with Naphthol AS-MX phosphate and Fast Violet LB salt protocol as 
previously described (39).  The stained cells were then imaged and photographed with light 
microscopy and analyzed using NIH ImageJ to measure the number and size of TRAP-
positive multinuclear cells. 
 
3.2.4 Demineralization Assay. BMMs were plated on calcium phosphate-coated plates 
(Corning) and cultured as above.  After five days of stimulation with 1% CMG 14-12 
culture supernatant and 10 ng/ml RANKL, plates were processed according to the 
manufacturer’s instructions, the demineralized area was photographed by dark field 
microscopy and analyzed using NIH ImageJ. 
 
3.2.5 Lentiviral Infection of Osteoclasts.  Lentiviral vectors (Open Biosystems) encoding 
shRNAs against Hdac4 (TRCN0000039249 and TRCN0000039252), Hdac5 (V2LMM 
72835 and V3LMM 432047), Hdac6 (V2LMM 61798 and V2LMM 79557), Hdac9 
(V3LMM 481592 and V3LMM 481594), Hdac10 (V3LMM 425386 and V3LMM 
425387), Hdac11 (V2LMM 24029 and TRCN0000039224), or a control shRNA were used 
to produce replication-defective lentivirus according to the manufacturer’s protocols.  Viral 
stocks were titrated by infection in HeLa cells.  BMMs were isolated and cultured as 
described above.  48 hours after seeding the non-adherent population, lentiviruses were 
added at 10 MOI and incubated for 18 hours at 37°C in the presence of 1% CMG 14-12 
culture supernatant.  The following day cultures were stimulated with 1% CMG 14-12 
culture supernatant and 10 ng/ml RANKL.  Cells were used for either RNA extraction after 
48 hours with 1% CMG 14-12 culture supernatant and RANKL treatment, or TRAP 
staining or demineralization assays after 5 days with 1% CMG 14-12 culture supernatant 
and RANKL. 
 
3.2.6 RNA Isolation and Real-time PCR. RNA was harvested from cells plated in 
triplicate using TRIZOL Reagent (Ambion, Life Technologies) and quantified using UV 
spectroscopy.  cDNA was then prepared from 1 µg of purified RNA using iScript cDNA 
Synthesis Kit (Bio-Rad) per the manufacture’s protocol.  Quantitative real-time PCR (qRT-
PCR) was performed in duplicate using CFX Connect Real-Time PCR system (Bio-Rad).  
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Each 20 µl reaction mixture contained 1 µl cDNA, 10 µL iTaq Universal Sybr Green 
Supermix, and 500 nM forward and reverse primers.  The PCR conditions were as follows: 
95°C for 3 minute, and 40 cycles of 94°C for 15 seconds, 56°C for 30 seconds, and 72°C 
for 30 seconds, followed by melt curve analysis (95°C for 5 seconds, 65°C for 5 seconds, 
and then 65°C to 95°C with 0.5°C increase for 5 seconds).  Experimental genes were 
normalized to Hprt.  Primers amplified with equal efficiencies.  Their sequences used are 
listed in Table 1.  All measurements were analyzed using the DDCT method. 
 
Gene Primers  
(Forward and Reverse) 
Sequence  
5’®3’ 
Cathepsin K (Ctsk) Forward AGGGAAGCAAGCACTGGATA 
 Reverse GCTGGCTGGAATCACATCTT 
C-Fos Forward CCAAGCGGAGACAGATCAACTT 
 Reverse TCCAGTTTTTCCTTCTCTTTCAGCAG
A 
DC-STAMP Forward CAGACTCCCAAATGCTGGAT 
 Reverse CTTGTGGAGGAACCTAAGCG 
NFATC-1 Forward TCATCCTGTCCAACACCAAA 
 Reverse TCACCCTGGTGTTCTTCCTC 
HDAC4 Forward CAT GGG TAC TGC TGT AGG GG 
 Reverse ATG AGC TCC CAA AGC CAT C  
HDAC5 Forward CTGTCCCGTCCGTCTGTCTG 
 Reverse ATGCCATCTGCCGACTCGTT 
HDAC6 Forward GGA GAC AAC CCA GTA CAT GAA 
TGA A 
 Reverse CGG AGG ACA GAG CCT GTA G 
HDAC9 Forward CCAAGTCACTGGGGCATCTT 
 Reverse TGTTCCTCTCCCAGGGTTCT 
HDAC10 Forward GGCATCGCTGAATGAGTACA 
 Reverse GGATGAGGATCTTGCCACAC 
HDAC11 Forward GGGGGATCTCAGTGATGGTA 
 Reverse AAGAGAAGCTGCTGTCCGAT 
HPRT Forward GAGGAGTCCTGTTGATGTTGCCAG 
 Reverse GGCTGGCCTATAGGCTCATAGTGC 
 
Table 1.  Sequence of primers used for qRT-PCR 
 
 
 3.2.7 Immunoblot Analysis.  Protein cell lysates were harvested from primary osteoclasts 
in modified RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% IGEPAL, 0.25% sodium 
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deoxycholate, 1 mM EDTA) supplemented with Halt Protease & Phosphatase Inhibitor 
Cocktail (Thermo Scientific).  Lysates were cleared by centrifugation.  Proteins were 
resolved by SDS-PAGE, transferred to PVDF membrane (Millipore), blocked, and blotted 
in primary antibody overnight at 4°C.  The next day, blots were incubated with horseradish 
peroxidase conjugated secondary antibody (G.E. Healthcare) for 1 hour at room 
temperature.  Antibody binding was detected using western blotting detection kit (Western 
Bright Quantum, Advansta).  The following primary antibodies were all used at 1:1000 
dilution: polyclonal HDAC4 produced using peptide corresponding to amino acids 14-28 
of human HDAC4 – Sigma Aldrich (H9536, Antibody ID# AB477079); monoclonal 
HDAC5 produced using peptide corresponding to amino acids 371-443 of human HDAC5 
- Santa Cruz Biotechnology (SC-133225, Antibody ID# 2116791); polyclonal HDAC9 
produced using peptide corresponding to amino acids 112-129 of HDAC9 – Thermo 
Scientific (PA5-23346, Antibody ID# AB2540870); polyclonal MITR produced from 
peptide against human HDAC9 - Sigma Aldrich (SAB4503694, Antibody ID# 
AB10751345); polyclonal HDAC10 produced using peptide corresponding to amino acids 
2-16 of human HDAC10 –Sigma Aldrich (H3413, Antibody ID# AB261940); polyclonal 
HDAC11 produced using peptide corresponding to amino acids 2-16 of human HDAC11 
– Sigma Aldrich (H4539, Antibody ID# AB532246) and polyclonal ACTIN-Santa Cruz 
Biotechnology produced using carboxy terminus of human actin (SC-1616, Antibody ID# 
AB630836).  The secondary antibodies used were all used at 1:10,000 dilution: anti-rabbit 
(NA-934, Antibody ID# AB772206) and anti-goat (SC-2020, Antibody ID# AB631728).  
All densitometry data was generated using the Image Lab Software (Bio Rad) following 
the manufacturer’s instructions for normalizing data to a housekeeping protein.  The 
calculated volume intensity for HDAC expression was normalized to its corresponding 
actin from the same membrane.  
 
3.2.8 Statistical Analysis:  All experiments were run in triplicate, performed three times, 
and results are expressed as mean ± standard deviation.  Student’s t-test or one-way 
ANOVA analysis followed by a Tukey’s multiple comparison test were used to compare 
data using Graph-Pad Prism version 7. 
 




3.3.1 Expression of class II and IV HDACs during Osteoclastogenesis 
To investigate the roles of class II and IV HDACs during osteoclastogenesis we first 
examined their expression through the process of osteoclast differentiation.  Non-adherent 
cells from C57BL/6 (wild-type) mouse bone marrow cells were cultured with 1% CMG 
for two days to promote bone marrow macrophages (BMMs) proliferation, and then treated 
with M-CSF plus RANKL for four more days to stimulate osteoclast differentiation.  All 
Hdac members in class IIa, IIb and IV were expressed in both proliferating BMMs (day 
zero with M-CSF treatment) and differentiating osteoclasts (day one-day four with M-CSF 
plus RANKL treatment) (Figure 8A).  Among these HDACs, the expression of Hdac4, 
Hdac7, Hdac9 and Histone deacetylase related protein (Hdrp/Mitr) were significantly 
down-regulated upon RANKL stimulation (day zero vs day two) and expression remained 
low during osteoclast differentiation (day one-day four).  Conversely, Hdac5, Hdac6, 
Hdac10 and Hdac11 expression increased with RANKL expression (Figure 8A, day zero 
vs day two).  Jin et al (41) reported similar trends in HDAC mRNA expression.  Hdac11, 
Hdac5 and Hdac7 were the most highly expressed Hdac RNAs during osteoclast 
differentiation.  As expected, the expression of the osteoclast marker gene Cathepsin K 
(Ctsk) was significantly increased upon RANKL stimulation and served as a positive 
control for osteoclast differentiation (Figure 8A, bottom right panel).  HDAC protein 
expression as measured by western blot demonstrated similar expression patterns to the 
mRNAs (Figure 8B).  These results show that HDAC class II and IV members are 
differentially expressed during osteoclast differentiation. 
 




Figure 8. Class II and IV Hdac expression during osteoclast differentiation.  BMM 
cells from C57BL/6 mice were cultured in M-CSF only (day zero) or in M-CSF plus 
RANKL (day two and day four) to stimulate osteoclast differentiation. Class II and IV 
Hdac RNA expression (A) on day zero, day two and day four of osteoclast differentiation.  
qRT-PCR data shown are the mean of three independent experiments. * p <0.05 comparing 
vs. day zero, ns = not significant.  Representative protein expression (B) of class II and IV 
HDACs on each day of osteoclast differentiation.  Displayed relative expression values are 
HDAC expression relative to the normalized expression on day zero as calculated by Image 
Lab Software (BioRad).  In the case of HDAC9 no band was identified for day zero so data 
is expressed relative to day one.  The same lysates were analyzed for HDAC9 and MITR 
expression and therefore, have the same actin loading control.     
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3.3.2 Effect of shRNA Suppression of Hdacs on Osteoclast Differentiation 
Since we detected expression of all the examined Hdacs in osteoclast cultures, we next 
asked how suppression of each individual Hdac would affect osteoclast formation or 
function.  To this end, we used lentiviral vectors encoding shRNAs against these Hdacs.  
Prior to beginning RANKL stimulation, BMMs from wild-type mice were infected with 
one of two lentiviral vectors encoding an shRNA against an Hdac or a control shRNA.  For 
each Hdac, we obtained similar results with both shRNAs indicating that the outcomes 
were not due to off-target effects.  Following infection with shRNAs, we confirmed target 
gene knockdown by qRT-PCR and examined changes in the expression of c-Fos, Nfatc1, 
Dc-stamp and Ctsk genes important for osteoclast formation or function. Because our 
experiments produced similar results in our analysis of osteoclast differentiation and 
activity assays using the two different Hdac shRNA, we grouped our PCR data together 
from the Hdac shRNA experiments for qRT-PCR. We employed TRAP staining and 
demineralization assays to measure osteoclast differentiation, fusion and activity. 
 
3.3.2.1 Suppression of Hdac4 Increases Osteoclastogenesis  
First, we investigated the effects of silencing Hdac4 on osteoclastogenesis (Figure 9).  
Cells infected with Hdac4 shRNA #1 or #2 showed enhanced osteoclast differentiation 
compared to control shRNA (Figure 10A).  The observed TRAP-positive multinuclear cells 
(MNCs) from both Hdac4-shRNA cultures were more numerous, and their size 
significantly increased (3-fold) relative to the control (Figure 10B-C).  Demineralization 
assays on calcium phosphate-coated plates demonstrated cells infected with Hdac4 shRNA 
#2 produced significantly increased total number of pits, average pit size, and total percent 
demineralized area compared to control shRNA infected cells.  Hdac4 shRNA #1 infected 
cells showed similar trends (Figure 10D-E).  Moreover, BMMs infected with either Hdac4 
shRNA showed Hdac4 RNA expression levels reduced by approximately 50% (Figure 9), 
and Hdac4 protein expression levels reduced between 30-65% (Fig 10F).  Hdac4 shRNA 
increased expression of c-Fos, Nfatc1, Dc-stamp and Ctsk compared to control shRNA 
(Figure 10G-J).  Taken together these results reveal that Hdac4 suppression increased 
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osteoclast differentiation by producing larger and more numerous osteoclasts, suggesting 
HDAC4 inhibits osteoclastogenesis. 
 
 
Figure 9. mRNA expression of Hdac4 shRNA. qPCR of control and Hdac4 expressing 
cells. *** p <0.001 
 




Figure 10. Accelerated osteoclast differentiation in Hdac4-suppressed osteoclasts. 
Representative images of TRAP staining (A) of osteoclast cultures infected with control or 
Hdac4 shRNA-expressing lentivirus. Hdac4#1 represents Hdac4 shRNA #1and Hdac4#2 
represents Hdac4 shRNA #2. Number (B) and size (C) of TRAP-positive MNCs.  
Representative images (D) and quantification (E) of demineralization activity of control 
and Hdac4 shRNA-expressing osteoclast cultures grown on calcium phosphate-coated 
plates.  Scale bar represents 200 μm. Western blot (F) of control and Hdac4 shRNA-
expressing cells with relative expression of shRNA expressing cells relative to control 
expressing cells indicated under the blots.  Expression profile (G-J) of osteoclast genes c-
Fos, Nfatc1, Dc-stamp and Ctsk.  Data presented are the mean of three independent 
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experiments.   * p <0.05; ** p <0.01; *** p <0.001; ns = not significant compared to control 
infected cells.   
 
3.3.2.2 Hdac5 is a Negative Regulator of Osteoclastogenesis 
We investigated the effects of suppressing expression of the Class IIa deacetylase 
Hdac5 (Figure 11).  Osteoclast differentiation in either Hdac5-shRNA culture was 
enhanced compared to control shRNA (Figure 12A).  The average size of TRAP-positive 
MNCs in Hdac5-shRNA cells was significantly increased (Figure 12B).  However, the 
number of TRAP-positive MNCs per well in Hdac5-shRNA cells did not significantly 
change compared to control shRNA (Figure 12C).  When osteoclast activity was 
determined, cells infected with each Hdac5-shRNA had significantly increased total 
number of pits, average pit size, and total percent demineralized area (Figure 12D-E).  The 
cultured osteoclasts also showed reduced Hdac5 mRNA expression levels (Figure 11), and 
approximately 70-80% reduction in HDAC5 expression as measured by western blot 
(Figure 12F).  Hdac5-suppressed osteoclasts showed an upward but not significant change 
in expression of c-Fos (Figure 12G); while expression of genes important for osteoclast 
formation or function including Nfatc1, Dc-stamp, and Ctsk (Figure 12H-J) were 
significantly increased.  These findings indicate that Hdac5 suppression enhances 
osteoclast differentiation through increased expression of genes such as Nfatc1, Dc-stamp, 
and Ctsk but independent of changes to c-Fos. 
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Figure 11. mRNA expression of Hdac5 shRNA. qPCR of control and Hdac5 expressing 




Figure 12. Suppression of Hdac5 enhances osteoclast differentiation.  Representative 
images of TRAP staining (A) of osteoclast cultures.  Hdac5#1 represents Hdac5 shRNA 
#1and Hdac5#2 represents Hdac5 shRNA #2. Quantification of the number (B) and 
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average size of TRAP-stained multinucleated osteoclasts (C).  Representative photographs 
(D) and quantification (E) of demineralization activity of control and Hdac5 shRNA-
expressing osteoclast cultures grown on calcium phosphate-coated plates.  Scale bar 
represents 200 μm. Western blot (F) of control and Hdac5 shRNA-expressing cells with 
relative expression of shRNA expressing cells relative to control expressing cells indicated 
under the blots.  Expression profile (G-J) of osteoclast genes c-Fos, Nfatc1, Dc-stamp and 
Ctsk.  Data presented are the mean of three independent experiments. * p <0.05; ** p <0.01; 
*** p < 0.001; ns = not significant compared to control infected cells. 
 
3.3.2.3 Hdac6 Suppression Does Not Affect Osteoclast Differentiation  
HDAC6, a member of class IIb HDAC family and tubulin deacetylase, has been shown 
to regulate tubulin dynamics and stability of the podosome belt in mature osteoclasts (192, 
193).  However, the role of HDAC6 in early stages of osteoclast differentiation is unknown.  
There was no significant change in the number or size of TRAP-positive MNCs with 
Hdac6 suppression (Figure 13A-C).  Moreover, Hdac6-shRNA #1 showed no significant 
changes in the demineralization assay (Figure 13D-E). Commercially verifiable antibodies 
to HDAC6 are not available; therefore, we verified both Hdac6 shRNAs significantly 
repressed Hdac6 expression by qPCR (Figure 13F).  However, c-Fos, Nfatc1, Dc-stamp, 
and Ctsk were not significantly changed by Hdac6 suppression (Figure 13 G-J).  These 
data show that knockdown of HDAC6 does not have any impact on osteoclast 
differentiation, at least within the parameters and genes analyzed. 
 




Figure 13. Hdac6 suppression does not affect osteoclast differentiation.  Representative 
images of TRAP staining (A) of osteoclast cultures. Hdac6#1 represents Hdac6 shRNA 
#1and Hdac6#2 represents Hdac6 shRNA #2.   Quantification of (B) number and (C) size 
of TRAP-positive MNCs.  Representative photographs (D) and quantification (E) of 
demineralization activity of control and Hdac6 shRNA-expressing osteoclast cultures 
grown on calcium phosphate-coated plates.  Scale bar represents 200 μm.  qRT-PCR (F) 
of control and Hdac6 shRNA-expressing cells.  Expression profile (G-J) of c-Fos, Nfatc1, 
Dc-stamp, and Ctsk.  Data presented are the mean of three independent experiments. *** 
p < 0.001; ns = not significant compared to control infected cells.  
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3.3.2.4 Suppression of Hdac9 Inhibits Osteoclastogenesis 
We next used shRNAs to characterize the role of Hdac9 and Mitr in osteoclasts.  
Although our gene expression data (Figure 8) indicate that MITR is the predominant form 
of HDAC9 in osteoclasts, we were unable to identify shRNAs that distinguish between 
Mitr and full-length Hdac9.  Consequently, both shRNAs used are predicted to target 
Hdac9 and Mitr (Figure 14).  Suppression of Hdac9 increased the size of TRAP-positive 
MNCs, but had little effect on the number of osteoclasts formed (Figure 15A-C).  
Demineralization assays showed that in Hdac9-shRNA infected cells, average pit size and 
demineralized area were significantly increased (Figure 15D).  As expected, in Hdac9-
suppressed cells there was a reduction in Hdac9 protein expression (Figure 15F) as well as 
Hdac9 RNA (Figure 14).  Hdac9-suppressed cells revealed a slight but not significant 
reduction in c-Fos expression (Figure 15G), while expression of Nfatc1, Dc-stamp, and 
Ctsk was increased compared with control (Figure 15H-J).  These observations indicate 
that HDAC9/MITR inhibits osteoclastogenesis.  
 
 
Figure 14. mRNA expression of Hdac9. qPCR of control and Hdac9 expressing  
cells. * p <0.05 
 

















Figure 15. Suppression of Hdac9 Inhibits Osteoclast Differentiation.  Representative 
images of TRAP staining (A) of osteoclast cultures infected with control or Hdac9 shRNA-
expressing lentiviruses. Hdac9#1 represents Hdac9 shRNA #1and Hdac9#2 represents 
Hdac9 shRNA #2.   Number (B) and size (C) of TRAP-positive MNCs.  Representative 
photographs (D) and quantification (E) of demineralization activity of control and Hdac9 
shRNA-expressing osteoclast cultures grown on calcium phosphate-coated plates.  Scale 
bar represents 200 μm.  Western blot (F) of control and Hdac9 shRNA-expressing cells 
with relative expression of shRNA expressing cells relative to control expressing cells 
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indicated under the blots.  Expression profile (G-J) of c-Fos, Nfatc1, Dc-stamp and Ctsk.  
Data presented are the mean of three independent experiments.   * p <0.05; ** p <0.01; ns 
= not significant compared to control infected cells.  
 
3.3.2.5 HDAC10 Activity Inhibits Osteoclastogenesis  
HDAC6 and HDAC10 are members of class IIb HDAC family.  HDAC6 functions as 
a tubulin deacetylase, and its role as a disrupter of the actin belt in mature osteoclasts has 
been well established (147, 194), whereas the biological function(s) of HDAC10 remain 
largely unknown (195, 196). To explore HDAC10’s role in osteoclast differentiation, we 
examined the effects of suppressing its expression (Figure 16A), finding that in Hdac10-
suppressed cells showed a decrease in the mean number of TRAP-positive MNCs per well 
(Figure 16B). The average size of TRAP-positive MNCs in Hdac10-suppressed cells was 
significantly increased (Figure 16C). Demineralization assays show total number of pits, 
average pit size and percent demineralized area was increased with knockdown of Hdac10 
(Figure 16D-E).  As expected, Hdac10-suppressed osteoclasts showed a reduction in 
Hdac10 mRNA expression compared to control shRNA (Figure 16F).  We were unable to 
obtain a reliable western blot verifying HDAC10 protein reduction in shRNA expressing 
cells due to technical issues. Expression of c-Fos, Nfatc1, Dc-stamp, and Ctsk was 
significantly increased (Figure 16G-J).  These data indicate that reduction of Hdac10 
expression enhanced osteoclast formation, suggesting that HDAC10, unlike HDAC6, may 
negatively regulate osteoclast differentiation.   




Figure 16. Hdac10 suppression accelerates osteoclast differentiation.  Representative 
images of TRAP staining (A) of osteoclast cultures.  Hdac10#1 represents Hdac10 shRNA 
#1and Hdac10#2 represents Hdac10 shRNA #2. Quantification of number (B) and size (C) 
of TRAP-positive MNCs.  Representative images (D) and quantification (E) of 
demineralization activity of control and Hdac10 shRNA-expressing osteoclast cultures 
grow on calcium phosphate-coated plates. Scale bar represents 200 μm.  qRT-PCR (F) of 
control and Hdac10 shRNA-expressing cells. Expression profile (G, H, I and J) of c-Fos, 
Nfatc1, Dc-stamp, and Ctsk. Data presented are the mean of three independent 
experiments. * p < 0.05; *** p <0.001; ns = not significant compared to control infected 
cells. 
3.3.2.6 HDAC11 Inhibits Osteoclastogenesis  
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 We examined the effects of suppressing Hdac11 on osteoclast differentiation (Figure 
17). Cells infected with either Hdac11 shRNA had enhanced osteoclast differentiation 
(Figure 18A).  Quantitative analysis of these cultures indicated that there was no significant 
difference in the average number of TRAP-positive MNCs formed in either Hdac11 
shRNA cultures compared with control shRNA (Figure 18B).  However, the average size 
of TRAP-positive MNCs was increased in both Hdac11 shRNA cultures (Figure 18C).  
Hdac11 shRNA #2 in demineralization assays increased the total number of pits, average 
pit size and total percent demineralized area significantly (Figure 18D-E).  Hdac11 shRNA 
#1 infected cells did not show a significant difference in average pit size but did show a 
difference in the total number of pits and total percent demineralized area (Figure 18D-E). 
The Hdac11 shRNAs moderately reduced Hdac11 RNA (Figure17) and protein expression 
(Figure 18F), which led to increased Dc-stamp and Ctsk expression (Figure 18I-J) but no 
change in c-Fos (Figure 18G) and Nfatc1 expression (Figure 18H).  These results reveal 
that Hdac11 suppression enhanced osteoclast formation, thus suggesting Hdac11 acts as 
an inhibitor of osteoclast differentiation.   
 
 
Figure 17. mRNA expression of Hdac11. qPCR of control and Hdac5 expressing cells. 
*** p <0.001 
 
 




Figure 18. Suppression of Hdac11 inhibits osteoclast differentiation.  Representative 
images of TRAP staining (A) of osteoclast cultures. Hdac11#1 represents Hdac11 shRNA 
#1and Hdac11#2 represents Hdac11 shRNA #2.   Histomorphometric analysis of TRAP-
stained osteoclasts (B-C).  Representative photographs (D) and quantification (E) of 
demineralization activity of control and Hdac11 shRNA-expressing osteoclast cultures 
grown on calcium phosphate-coated plates.  Scale bar represents 200 μm.  Western blot (F) 
of control and Hdac11 shRNA-expressing cells with relative expression of shRNA 
expressing cells relative to control expressing cells indicated under the blots.  Expression 
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profile (G, H, I and J) of c-Fos, Nfatc1, Dc-stamp, and Ctsk.  Data presented are the mean 
of three independent experiments.  * p < 0.05; ** p <0.01; *** p <0.001; ns = not significant 




To better understand how osteoclast differentiation and activity are regulated, it is 
necessary to investigate classes of transcriptional activators and repressors that function in 
osteoclasts.  HDACs are a well-known class of transcriptional repressors that have been 
shown to be active in osteoclasts.  Due to their high sequence homology and interactions 
with the same proteins in other cell types (184, 197), some HDACs may perform redundant 
roles in regulating osteoclast differentiation.  However, recent studies demonstrated two 
class II HDACs, HDAC7 and HDAC9, repressed osteoclast differentiation using unique 
mechanisms.  Deletion of either Hdac7 or Hdac9 in BMMs resulted in enhanced osteoclast 
differentiation in vitro, and increased bone resorption and osteopenia in mice in vivo (39, 
41).  Our lab concluded HDAC7 interacted with and repressed the activity of MITF (39), 
another group demonstrated via reporter assays that HDAC7 might repress NFATc1 
activity (40), and HDAC9 repressed PPAR-γ (41).  Though these mechanisms are different, 
it was still possible that the remaining Class II HDACs performed redundant roles in 
osteoclasts, in which case we hypothesized that loss of any one HDAC would be 
compensated for by the remaining proteins.  To address this issue, we analyzed mRNA and 
protein expression, and the effects of shRNA-mediated knockdown of most class II 
(HDAC4, 5, 6, 9, and 10) and class IV (HDAC11) HDACs during osteoclast 
differentiation.  To help identify how each HDAC was affecting osteoclasts, we used TRAP 
staining, demineralization assays, and qRT-PCR to evaluate changes in differentiation, 
activity, or gene expression due to Hdac knockdown.  Individual knockdown of Hdac4, 5, 
9, 10, and 11 produced similar phenotypes, which was observed as increased size of 
multinuclear TRAP-positive MNCs and percent demineralization of a calcium phosphate 
matrix, but little to no change in multinuclear TRAP-positive osteoclast number (Figures 
9, 10, and 12-14).  Additionally, temporal expression patterns of these HDACs were also 
different from each other, which is in agreement with a previous study (41).  The presence 
of similar osteoclast phenotypes when different HDACs are knocked down and their 
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distinct expression profiles suggests that most HDACs have at least some unique targets 
rather than fully redundant roles. 
Inhibiting differentiation in early stages of osteoclast differentiation.  Hdac9 and 
the related Mitr are highly expressed in BMMs but drastically decrease in expression after 
RANKL stimulation.  Hdac4 follows a similar trend but maintains a low level of expression 
throughout differentiation (Figure 8A and 8B).  The initially high levels of HDAC9 and 
HDAC4 in BMMs which begin decreasing with the onset of RANKL stimulation could 
indicate that the presence of these HDACs is associated with maintaining proliferation 
rather than differentiation.  Knockdown of Hdac4 showed a small but significant increase 
in osteoclast number (Figure 10B) and a trend towards increased c-Fos expression (Figure 
10G).  Supporting this, osteoclasts from Hdac4-KO mice showed increased c-Fos 
expression (data not shown, manuscript in preparation).  Knockdown of Hdac9 
demonstrated increased differentiation marker expression and osteoclast size but not 
increased osteoclast number or c-Fos expression, indicating HDAC9 may not be involved 
in proliferation through regulating c-Fos expression (Figure 15, (41).  Previous research on 
HDAC9 in osteoclasts showed both increased cell number and size of osteoclasts from 
global Hdac9-KO mice (41).  These contrasting results could be explained by the global 
deletion of Hdac9 affecting the BMM population at a stage before our transient shRNA 
studies began.  Considering this, both previous and our work show upregulated expression 
of genes important for differentiation, implying knockdown of Hdac9 promotes a switch 
from proliferation to differentiation earlier than normal (Figure 15). 
 MITR is a truncated splice variant of HDAC9 that displays co-repressor activity 
despite lacking the C-terminal deacetylase catalytic domain.  Specific suppression of Mitr 
but not of Hdac9 expression in neurons leads to cell death, demonstrating a necessary role 
for MITR separate from HDAC9 (198, 199). It remains unknown whether MITR plays a 
distinct role in osteoclasts.  The commercially available Hdac9 shRNAs we used are 
predicted to target both the full-length Hdac9 and Mitr transcripts (BLAST alignment and 
data not shown), and the global Hdac9-KO mice have reduced HDAC9 and MITR protein 
levels (200).  Future work should examine potential roles that are specific to MITR but 
separate from those of HDAC9. 
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Repressors of differentiation, fusion, and activity: Contrary to Hdac4, Hdac9, and 
Mitr’s early expression, Hdac5, Hdac10, and Hdac11 have expression levels that increase 
after RANKL treatment (Figure 8).  Knockdown of any of these three HDACs results in 
increased osteoclast size and percent demineralization with little to no change in the 
number of osteoclasts (Figures 12, 16, and 18).  Supporting this, knockdown of each 
HDAC increased Dc-stamp expression, which would lead to more fusion and, 
consequently, larger cells.  However, knockdown did not affect c-Fos expression or cell 
number, indicating these HDACs mostly affect genes regulating differentiation, fusion, and 
possibly activity instead of proliferation (Figures 12, 16, and 18).  Knockdown of either 
Hdac5 or Hdac10 showed a trend of increased Nfatc1 expression (Figure 12H and 16H).  
NFATc1 regulates expression of genes important for cell fusion (Dc-stamp) and resorption 
activity (Ctsk), as well as its own autoamplification after it is stably induced during 
differentiation (94, 201, 202).  Therefore, HDAC-mediated inhibition of Nfatc1 expression 
could reduce NFATc1 activity, concomitantly decreasing expression of genes that promote 
differentiation, fusion, and activity of osteoclasts.  Indeed, Hdac5 shRNA treatment 
showed trends of increased Nfatc1 and Dc-stamp expression with significantly increased 
Ctsk expression (Figure 12).  Supporting this, HDAC5 activity promotes deacetylation and, 
consequently, destabilization of NFATc1 (146).  Generally, class IIa HDACs rely on 
recruitment of class I HDACs, typically HDAC3, for deacetylation of targets (185).  
Interestingly, HDAC10 interacts with all class I and IIa HDACs and could potentially act 
as an HDAC recruiter for the repression of targets (31).  Future HDAC5 and HDAC10 
studies should concentrate on a potential role for their repression of NFATc1 either 
cooperatively or separately. 
Suppression of Hdac11 resulted in a milder phenotype than either Hdac5- or Hdac10-
shRNA treatment (Figure 18).  This is a surprising result to us considering HDAC11 is 
more closely related to class I than II HDACs (31), and we have previously shown that loss 
of expression of Hdac3, a class I HDAC, inhibits osteoclast differentiation (140).  Distinct 
from Hdac5 and Hdac10, Hdac11 knockdown only increased Dc-stamp expression (Figure 
18I).  This potentially means HDAC11 specifically targets the Dc-stamp promoter or fusion 
genes without affecting the transcription of proteins such as NFATc1, which regulate both 
differentiation and fusion of osteoclasts.  HDAC11 may interact with NFATc1 in a protein-
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protein interaction to regulate NFATc1’s ability to activate targets such as Dc-stamp.  The 
mechanism(s) by which HDAC11 inhibits osteoclast differentiation will be explored in 
future work.  HDAC11 has previously been shown to associate with and deacetylate the 
IL-10 promoter in bone marrow-derived antigen-presenting cells ((203).  Surprisingly, 
HDAC6 and HDAC11 physically interact and oppose each other in regarding to Il-10 
expression; both HDAC6 and HDAC11 associate with the Il-10 promoter, but HDAC6 
promotes expression while HDAC11 represses expression (204).With the varied 
expression of different HDACs throughout differentiation, a similar mechanism may exist 
in osteoclasts.  However, as explained in detail below, HDAC6 most likely is not exerting 
an opposing action on HDAC11 activity in osteoclasts.   
The role of HDAC6:  HDAC6 can be recruited to gene promoters to modulate gene 
expression (204, 205).  Though we successfully reduced Hdac6 expression, no observable 
effects on gene expression were seen (Figure 13).  Since our four examined genes are far 
from an exhaustive characterization of altered gene expression by HDAC suppression, it is 
possible that HDAC6 does have some role in regulating osteoclast-specific gene expression 
that is outside of our examination or it does so in a redundant manner with another HDAC.  
Classically, HDAC6 is known to deacetylate α-tubulin, leading to changes in microtubule 
stabilization and dynamics (206, 207).  It may be that HDAC6’s role in regulating 
osteoclast differentiation is limited to effecting changes to microtubules but not gene 
expression.  Further characterizing potential gene targets of HDAC6 in osteoclasts is 
beyond the scope of this work and may be further examined in the future.   In vivo 
knockdown of HDAC6 in embryonic stem cells displayed hyperacetylated tubulin (208).  
Supporting this, studies in osteoclasts demonstrated that inhibition of HDAC6 activity with 
chemical inhibitors led to hyperacetylated tubulin and stabilized podosomes (147, 209).  
Microtubules are important in helping form and stabilize the podosome belt, which 
facilitates cell adhesion and matrix resorption by osteoclasts (210).  Knowing this, we 
predicted knockdown of Hdac6 to produce a significant effect in the demineralization 
assay; however, we did not observe any phenotype in terms of osteoclast size, number, or 
activity after Hdac6 depletion by shRNA (Figure 13).  Though these results are surprising, 
they are not completely unexpected considering the conflicting results between HDAC6 
knockdown and inhibition of activity in other cell types.  Importantly, chemical inhibition 
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of HDAC6 led to hyperacetylated tubulin and reduced microtubule dynamics, while 
siRNA-mediated knockdown of Hdac6 also showed hyperacetylated tubulin but did not 
affect microtubule dynamics (148, 211).  In this way, we would not expect Hdac6 
knockdown to impact osteoclast size, number, or activity.  Future HDAC6 research should 
concentrate on additional transcriptional regulatory roles or potential redundancy with 
Sirtuin 2, a class III HDAC known to also deacetylate α-tubulin (212). 
 Overall, we have demonstrated for the first time the results of specifically knocking 
down Hdac4, 5, 6, 10, and 11 in osteoclasts.  We found that HDACs differ in their temporal 
expression pattern during osteoclast differentiation (Figure 19).  Except for HDAC6, our 
studies indicate that class II and IV HDACs have non-redundant roles during osteoclast 
differentiation.  This study serves as an important starting block from which future work 
examining individual HDACs in osteoclasts should benefit.  
 
 
Figure 19. Expression pattern of class II and IV HDACs during osteoclast 
differentiation. Illustration of the stages of osteoclast differentiation with HDAC 
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Chapter 4. Histone Deacetylase 4 (HDAC4) Regulates 
Osteoclast Bone Resorption and Bone Mass 
 
Faulkner BK, Blixt  NC, Jensen ED, and Mansky KC 
(Manuscript in preparation) 
 
Short Title: HDAC4 Regulates Osteoclast Bone Resorption 
 
Chapter Summary 
The results of chapter 3 suggested that in vitro, members of class II and IV HDACs are 
differentially expressed during osteoclast differentiation and suppress osteoclast 
differentiation and function. Suggesting that HDACs are functionally significant in 
osteoclasts. Previous studies have shown that class IIa HDACs members, HDAC7 and 
HDAC9 can regulate osteoclast differentiation and bone resorption both in vivo and in 
vitro. No studies have assessed the in vivo role of the other class IIa HDAC members during 
osteoclastogenesis. HDAC4 is a class IIa HDAC whose importance during osteoclast 
development is not understood. In vitro, suppression of HDAC4 enhances osteoclast 
differentiation (Chapter 3). However, in vivo HDAC4’s role in osteoclast differentiation 
and function is unknown. For this reason, the aim of this study was to determine the role 
of HDAC4 in osteoclast formation and function by using in vitro osteoclast culture and in 
vivo HDAC4 conditional knockout mice model. It was hypothesized that mice null for 
HDAC4 expression in osteoclasts will be osteopenic due to enhanced osteoclast formation. 
 
4.1 Introduction 
Normally bone remodeling during development and bone integrity throughout life are 
regulated by bone-forming osteoblasts and bone resorbing-osteoclasts (213, 214) . The 
balance between bone formation and resorption is what maintains bone mass. When an 
imbalance occurs, bone metabolic diseases appear such as osteoporosis (213, 214). 
Osteoclasts are giant multinucleated cells that are responsible for bone resorption (9, 10). 
They differentiate from monocyte/macrophage lineage in response to two critical cytokines 
receptor activator of NF-kb ligand (RANKL) and macrophage colony-stimulating factor 
(M-CSF) (179, 215, 216). Jointly, RANKL and M-CSF promote proliferation and survival 
of osteoclast precursors and their differentiation into mature bone-resorbing osteoclasts 
(179).  While bone resorption is tightly regulated in the skeleton, the molecular 
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mechanisms underlying it are not fully understood. Hence, it is important to understand 
how osteoclast activity is being regulated in order to develop targeted therapies for bone 
disorders. 
Acetylation of lysine residues in histones, and/or transcription factors, is emerging as 
a widespread posttranslational mechanism involved in the regulation of several cellular 
functions (182, 217, 218). Histone deacetylases (HDACs) are enzymes that catalyze the 
removal of acetyl groups from histone and non-histone proteins, and in general act to 
repress transcription (31, 32, 44, 183). Eighteen mammalian HDACs have been identified 
thus far, and they are divided into four classes based on their homology to yeast 
deacetylases domain. They are class I HDACs (HDAC1, -2, -3, and -8), class II (HDAC4, 
-5, -6, -7, -9 and -10), class III (Sirtuins 1–7) and class IV (HDAC11) (6, 31, 42, 96). The 
class II HDACs can be further subdivided  into class IIa (HDAC4, -5, -7,  and -9)  and class 
IIb (HDAC6 and -10) based on the presence in class IIa members of an extended N-
terminal domain, and a C-terminal deacetylase domain, that are important in regulating 
their functions (188). HDACs have not only emerged as critical regulators of biological 
processes such as cell growth, differentiation, survival, proliferation and apoptotic 
programs, but also are a key regulator of skeletal homeostasis (6, 31, 44) (219). Several in 
vitro studies have demonstrated that osteoclast differentiation can be suppressed by using 
broad-spectrum HDAC inhibitors (141, 189, 220) that target different HDAC family 
members. However, there is a gap in the knowledge concerning the specific roles individual 
HDACs play in bone, particularly in osteoclasts. This is a critical question to answer since 
several HDACs inhibitors currently in clinical trials for the treatment of diseases such as 
cancer, diabetes, cognitive disorders and neurodegeneration are class specific (221, 222).  
   Recently, data demonstrating that class IIa HDACs act as regulators of osteoclast 
differentiation and activity has started to emerge. Overexpression of HDAC7 in mouse 
bone marrow macrophage (BMMs) inhibits fusion of osteoclast precursors through 
regulating MITF transcriptional activity (140). In a subsequent study, overexpression of 
HDAC7 in BMMs inhibited both number and size of TRAP positive multinuclear cells 
(39). Conversely, it has been shown that loss of HDAC7 expression enhances osteoclast 
differentiation. In this study, HDAC7 was found to reduce NFATc1 suppression of b-
catenin in the presence of RANKL (40). Lastly, osteoclast differentiation and bone 
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resorption was significantly elevated in HDAC9-null mice suggesting that HDAC9 similar 
to HDAC7 act as an inhibitor of osteoclast differentiation (41). 
   HDAC4 is a class IIa HDAC that has been associated with muscle and bone 
development (43, 145, 223-226).  In vitro studies have shown that HDAC4 can mediate 
these effects by repressing MEF2C and RUNX2 using its N-terminal binding domain (43, 
145, 223, 225, 226). In-vivo, HDAC4 together with RUNX2 have been shown to be 
important for bone development. HDAC4 knockout mice displayed premature ossification 
of endochondral bone because of early onset of chondrocyte hypertrophy resulting in 
postnatal lethality; however, the role of HDAC4 in regulating osteoclast differentiation has 
not been well studied (43). An in vitro study using shRNA against HDAC4 in osteoclasts 
suggested that HDAC4 similar to HDAC7 and HDAC9 acts as an inhibitor of 
osteoclastogenesis (42). However, whether HDAC4 is a physiological relevant regulator 
of osteoclast differentiation and bone resorption is still an unanswered question, and the 
mechanisms underlying potential HDAC4 regulation of osteoclasts is unclear. 
In this current study, we investigated the consequences of HDAC4 disruption during 
osteoclast differentiation, migration and bone resorptive activity in vivo and in vitro. We 
demonstrated that HDAC4 positively regulates the bone-resorbing activity of osteoclasts 
and that mice with HDAC4 null osteoclasts exhibit increase bone mass. Bone marrow 
macrophages (BMMs) derived from HDAC4 conditional knockout (4cKO) mice 
differentiated normally into multinuclear TRAP positive cells but had decreased bone 
resorption activity both in vivo and in vitro. We found that ERK1/2 and AKT signaling was 
reduced in 4cKO osteoclasts. Lastly, we demonstrate that 4cKO osteoclasts have impaired 
signaling downstream of M-CSF and αvβ3 integrin. Thus, our study suggests that HDAC4 
regulates osteoclast function by impairing activation of c-Src and ERK1/2 through a 
mechanism involving αvβ3-integrin and M-CSF mediated signaling.  
 
4.2 Experimental Procedures 
 
4.2.1 Mice 
Hdac4 floxed mice (43) were obtained from Dr. Eric Olson (UT Southwestern Medical 
Center) in a C57BL/6 background. c-fms-Cre mice, which expresses Cre recombinase in 
the cells of myeloid lineage that includes osteoclasts and their monocyte/macrophage 
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progenitors were purchased from the Jackson Laboratory. To obtain mice with Hdac4-
deficient osteoclasts (4cKO), Hdac4flox/flox mice were bred with c-fms-Cre mice. The  mice 
were of same age and same gender (male). In all experiments, Hdac4flox/flox Cre- mice 
(4WT) served as control. The presence of the floxed Hdac4 gene was determined using the 
primer 5’-ATCTGCCCACCAGAGTATGTG-3’ (forward) and primer 5’-
CTTGTTGAGAACA-AACTCCTGCAGCT-3’ (reverse).  
 
4.2.2 Ethics 
All mice were housed in the animal care unit of the University of Minnesota and 
maintained according to the guidelines set by the Institutional Animal Care (IACUC) and 
the Committee of the Office for the Protection of Research Subjects. All experimental 
protocols were approved by IACUC (protocol 180636053A) at the University of 
Minnesota. Euthanasia was performed by CO2 inhalation. 
 
4.2.3 Primary Osteoclast culture 
Cultures of murine osteoclast differentiation was performed as previously described 
(42). Bone marrow cells were flushed from the femora and tibiae of 4WT or 4cKO 4-week-
old male mice. Harvested cells were incubated in culture dishes overnight in phenol red-
free alpha-MEM (Gibco) containing 5% fetal bone serum (Atlanta Biologicals), 25 
units/mL penicillin/streptomycin (Invitrogen), 400 mM L-Glutamine (Invitrogen) in the 
presence of 1% CMG 14-12 culture supernatant containing M-CSF.  CMG14-12 cells were 
obtained from Dr. Sunao Takeshita (Nagoya City University, Nagoya, Japan). Non-
adherent cells were counted, plated in tissue culture plates, and cultured for 2 days with 
1% CMG culture supernatant containing M-CSF. After 2 days of culture, the cells are 
considered to be bone marrow-derived macrophages (BMMs). The BMMs were cultured 
for additional 4-5 days in phenol red-free alpha-MEM containing 5% fetal bone serum, 25 
units/mL penicillin/streptomycin, 1% CMG 14-12 culture supernatant containing M-CSF 
and 10 ng/mL RANKL (R&D Systems) to obtain osteoclasts.   
 
4.2.4 Enzyme-linked immunosorbent assays (ELISA)  
The in vivo bone resorption and formation levels were measured from serum of 3 and 
6-month-old male mice following ELISA kits manufacturer’s instructions. Blood samples 
were collected from 3 and 6-month-old male mice by cardiac puncture, and separated into 
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three phases by centrifugation for 10 minutes at 13000 rpm at 4°C. After centrifugation, 
serum was collected from the top of the microfuge tube and transferred into clean 
microfuge tube, leaving behind red blood cells. Serum CTX was measured using RatLaps 
ELISA kit; serum TRAP was measured using Mouse TRAP (TRAcP 5b) ELISA kit; and 
serum PINP was measured using Rat/Mouse PINP EIA ELISA kit. All the ELISA kits were 
purchased from Immunodiagnostic Systems (IDS) Inc (Gaithersburg, MD, USA). 
 
4.2.5 Real-time PCR  
Total RNA was harvested using TRIZOL Reagent (Ambion, Life Technologies) and 
quantified using UV spectroscopy. Single stranded cDNA was prepared from 1 µg of 
purified RNA using iScript cDNA Synthesis Kit (BIO-RAD) as per manufacturer’s 
protocol. Quantitative real-time PCR was performed on CFX Connect Real-Time PCR 
system (Bio-Rad) using iTaq Universal Sybr Green Supermix (BIO-RAD) according to 
manufacturer’s instructions. All reactions were performed in triplicate. Experimental 
genes were normalized to Hprt. Primer sequences were as follows: Hprt (Forward) 5’- 
GAGGAGTCCTGTTGATGTTGCCAG- 3’;(Reverse) 5’- 
GGCTGGCCTATAGGCTCATAGTGC -3’; Dc-stamp (Forward) 5’- 
CAGACTCCCAAATGCTGGAT -3’; (Reverse) 5’ CTTGTGGAGGAACCTAAGCG -
3’; c-Fos (Forward) 5’- CCAAGCGGAGACAGATCAACTT- 3’; (Reverse) 5’- 
TCCAGTTTTTCCTTCTCTTTCAGCAGA -3’; Nfatc-1 (Forward) 5’- 
TCATCCTGTCCAACACCAAA -3’; (Reverse) 5’- TCACCCTGGTGTTCTTCCTC- 3’; 
Ctsk (Forward) 5’- AGGGAAGCAAGCACTGGATA- 3’; (Reverse) 5’- 
GCTGGCTGGAATCACATCTT-3’; Mmp9 (Forward) 5’-
GTTTTTGATGCTATTGCTGAGATCCA -3’; (Reverse) 5’-
CCCACATTTGACGTCCAGAGAAGAA-3’. b3 integrin (Forward) 5’- 
TTACCCCGTGGACATCTACTA -3’ ;(Reverse) 5’-AGTCTTCCATCCAGGGCAATA 
-3’; av integrin (Forward) 5’- CCTCAGAGAGGGAGATGTTCACAC – 3’; (Reverse) 
5’- AACTGCCAAGATGATCACCCACAC- 3’; Rank receptor (Forward) 5’- 
CCAGGACAGGGCTGATGAGAA- 3’; (Reverse) 5’-
TGGCTGACATACACCACGATGA- 3’; c-Fms (CSF1R) 5’ -
TCGGAGAAAGTTGAGATGGTGT-3’; (Reevrse) 5’- 
TGCTAAAGTCCACGGCTCAT-3’. 




4.2.6 Western blot analysis and antibodies 
Cell protein lysates were harvested from 4WT or 4cKO primary osteoclasts using 
modified RIPA buffer (50 mM Tris ph 7.4, 150 mM NaCl, 1% IGEPAL, 0.25% sodium 
deoxycholate, I mM EDTA) containing Halt Protease & Phosphatase Inhibitor Cocktail 
(Thermo Scientific). Lysates were cleared by centrifugation at 12,000 x g at 4°C. Proteins 
were resolved by SDS-PAGE, transferred to PVDF membrane (Millipore), blocked, and 
blotted in primary antibody overnight at 4°C. Next day, blots were incubated with 
horseradish peroxidase conjugated secondary antibody (G.E. Healthcare) for 1 hour at 
room temperature. Antibody binding was detected using western blotting detection kit 
(WesternBrightTM Quantum, Advansta). Images were acquired using Chemitouch 
(BioRad) and cropped in Adobe Photoshop. The sources of the antibodies are follows: 
rabbit anti-HDAC4 (H9536) was from Sigma Aldrich, rabbit anti-Src (36D10) and 
phospho-Src (Y416) antibodies; rabbit anti-MEK1/2 (D1A5) and phospho-MEK1/2 
(S217/221) 41G9 antibodies; rabbit anti-p44/42 MAPK (ERK 1/2) and phospho-p44/42 
MAPK (T202/Y204) antibodies; rabbit anti-p38 and phospho-p38 (T180/182) antibodies; 
rabbit anti-Akt pan (C67E7) and phospho-Akt (S473) (193H12); rabbit anti-Pyk2 and 
phospho-Pyk2 (Y402) antibodies were obtained from Cell signaling (Beverly, MA). All 
densitometry data was generated using the Image Lab Software (Bio Rad) following the 
manufacturer’s instructions for normalizing data to a housekeeping protein. 
 
4.2.7 Tartrate Resistant Acid Phosphatase (TRAP) staining 
 For TRAP staining of 4WT or 4cKO osteoclast cultures, cells were washed with 1X 
PBS, fixed with 4% paraformaldehyde for 20 minutes and then incubated with pre-warmed 
TRAP staining solution (0.1M Acetate buffer, 0.3M Sodium Tartrate, 10mg/ml Naphthol 
AS-MX phosphate, Triton X-100, water, and Fast Red Violet LB salt) (BD Biosciences 
Technical Bulletin #445) at 37°C for 30 minutes. Color development was stopped by 
washing three times with 1X PBS. Stained cells were then imaged and photographed with 




4.2.8 Demineralization assays  
  60 
 
 
For demineralization assay, BMMs from 4WT or 4cKO 4-week-old male mice were 
plated at a density of 1x105 cells/well on calcium phosphate-coated plates (Osteo Assay 
Surface plates, Corning) and cultured with 1% CMG 14-12 culture supernatant containing 
1.2 µg/mL M-CSF and 10 ng/mL RANKL for 5 days. Medium was then removed from 
wells, 10% bleach solution was added to wells and incubated for 20 minutes at room 
temperature. After incubation period, bleach solution was aspirated and the wells were 
washed two times with water. The wells were then allowed to air dry completely at room 
temperature for 5 hours. Demineralized area was visualized using light (darkfield) 
microscopy, and images were taken for quantification. Visual enumeration of 
demineralization areas was done using NIH Image J software.  
 
4.2.9 Cell adhesion assay 
Untreated tissue culture 12-well plate were coated with 5ug/ml of vitronectin and 
incubated overnight at 4°C. Prior to use the plate was pre-warmed at room temperature for 
1 hour. Day 2 pre-osteoclasts that were plated on a 12-well plate at a density of 2 x 105 
cells/well were scraped and transferred one well to one well of the vitronectin coated plate. 
The plates were then incubated for 15 or 30 minutes at 37 oC in 5% CO2. After incubation 
time periods, cells were washed twice with 1xPBS, fixed with paraformaldehyde (PFA), 
and TRAP stained. Cells were then observed and captured with light microscopy and the 
measurements were analyzed using NIH Image J software. 
 
4.2.10 avb3 integrin-mediated signaling and western blot for p-Src and p-ERK 1/2 
(p-44/42) MAPK  
Untreated tissue culture plate was coated with 5ug/ml of vitronectin and incubated 
overnight at 4°C. Plate was then placed at room temperature for 1 hour to warm up. 4WT 
and 4cKO day 2 pre-osteoclasts were serum and cytokine starved for 4 hours. The pre-
osteoclasts were then lifted and re-plated onto wells coated with 5ug/ml of vitronectin (A) 
or left in suspension (S) for 30 minutes, followed by western blot for phospho-ERK1/2 and 
phospho-Src. 
 
4.2.11 M-CSF signaling and western blot for p-ERK 1/2 
BMMs from of 4-week-old 4WT or 4cKO were cultured with 1% CMG 14-12 culture 
supernatant containing M-CSF until day 1 of osteoclast differentiation. Cells were then 
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serum and cytokine starved for 4 hours. The adherent osteoclasts were then stimulated with 
M-CSF for 0, 5,15, 30 or 60 minutes prior to cell lysis. Western blot analysis was performed 
using anti-44/42 MAPK (ERK 1/2) and anti-phospho-p44/p42 MAPK (ERK1/2) 
antibodies. 
 
4.2.12 Cell migration assays 
Pre-osteoclast migration assays used transwell migration kit (Corning, NY, USA). 
4WT or 4cKO pre-osteoclasts were plated at a density of 2 x 105 cells/well on a 12-well 
plate and allowed to grow until day 2 of osteoclast differentiation. Cells were then scraped, 
combined and counted. 1 x 105 cells/well in 1% CMG 14-12 culture supernatant containing 
M-CSF in osteoclast media were plated in upper chamber. In the lower chamber, 700ul of 
osteoclast media was added with no cytokine. The transwell plate was incubated at 37°C 
for 2 hours. After 2 hours, 1% CMG 14-12 culture supernatant containing M-CSF was 
added to the lower chamber, and cells were allowed to migrate overnight. The cells in the 
lower chamber were fixed using 4% paraformaldehyde for 20 minutes. The fixed cells were 
then stained with TRAP. Light microscopy was used to visualized and take images of 
TRAP cells for quantification. Image analysis was done using NIH Image J software.  
 
4.2.13 Microcomputed Tomography (µCT) Analysis 
Mouse femora were dissected out, defleshed, and frozen in PBS.  Before scanning, 
frozen femora were equilibrated to room temperature and scanned in PBS with a 1 mm 
aluminum filter using the XT H 225 micro-computed tomography machine (Nikon 
Metrology Inc., Brighton, MI, USA) at an isotropic voxel size of 7.4 µm.  Samples were 
scanned at 120 kV, 61 µA, 720 projections, 2 frames per projection, and an integration time 
of 708 milliseconds.  CT Pro 3D (Nikon metrology, Inc., Brighton, MI, USA) was used to 
make 3D reconstruction volumes for each scan.  VGStudio MAX 3.2 (Volume Graphics 
GmbH, Heidelberg, Germany) was used to convert 3D reconstruction volumes to bitmap 
datasets.  Morphometric analyses were performed using SkyScan CT-Analyser 
(CTAn)(Bruker micro-CT, Belgium) following Bruker’s instructions and reported 
guidelines for the field3.  The region of interest for trabecular bone analysis in the distal 
metaphysis started 1 mm proximal to the growth plate and extended 2 mm proximally 
towards the diaphysis.  The region for cortical bone analysis was a 0.5 mm region at the 
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mid-diaphysis.  Automated contouring was used to determine the region of interest 
boundaries for both trabecular and cortical bone with manual editing as needed.  Global 
thresholding was used to segment bone from surrounding tissue for both 3D trabecular and 
2D cortical analyses.  One threshold value was used for all cortical analyses, and a different 
threshold value was used for all trabecular analyses.  CT-Volume (Bruker micro-CT, 
Belgium) was used to create all 3D models from bitmaps corresponding to cortical and 
trabecular regions analyzed; however, only a 1 mm region of the most distal trabecular 
region was used to create a model.   
 
4.2.14 In vivo TRAP staining 
3-month-old male mice were sacrificed by CO2 inhalation, and their femurs were 
isolated and fixed in an aqueous buffered zinc formalin (Z-FIX) (Anatech ltd, Battle Creek, 
MI) overnight, followed by decalcification in 10% EDTA, pH7.4, for 14 days, paraffin 
embedded, sectioned and stained for TRAP. Osteoclast parameters were measured and 
expressed in units following guidelines established by the America Society for Bone and 
Mineral Research histomorphometry nomenclature committee and analyzed using NIH 
Image J. 
 
4.2.15 Subcellular protein fraction Assay 
Cell membrane and cytosolic fractions were prepared using Mem-PER Plus Membrane 
Protein Extraction Kit from Pierce (89842). Briefly, we used 4WT and 4cKO osteoclasts 
were plated at a density of 5 x 106cells/dish on two 10cm dishes and allowed to grow until 
day 2 of osteoclast differentiation. Media was then removed, and 1X PBS was added and 
cells were then scraped off the surface. The harvested cell suspensions were centrifuged at 
300 xg for 5 minutes. The cell pellets were then washed with 3 mL a Cell Wash Solution 
and centrifuged at 300 xg for 5 minutes. Supernatant was removed and the cell pellet was 
resuspended in 1.5mL of Cell Wash Solution, transferred to a clear tube and centrifuged at 
300 xg for 5 minutes. After centrifugation, supernatant was discarded. To the cell pellet, 
0.75mL of Permeabilization Buffer containing protease and phosphatase inhibitors was 
added, vortex briefly and incubated at 10 minutes at 4°C with constant mixing. After 
incubation, the permeabilized cells were centrifuged at 16,000 xg  for 15 minutes at 4°C. 
The supernatant which contains cytosolic proteins was carefully removed and transferred 
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into a new tube. To the remaining cell pellet, 0.5 mL of Solubilization Buffer containing 
protease and phosphatase inhibitors was added and the cell pellet was resuspended by 
pipetting up and down. The tube was then incubated at 4°C for 30 minutes with constant 
mixing. The tube was then centrifuged at 16,000 xg for 15 minutes at 4°C. The supernatant 
containing solubilized membrane and membrane-associated proteins was transferred to a 
new tube. Western blotting analysis was then performed. 
    
4.2.16 Statistical analysis 
All experiments were completed in triplicate and performed independently three times. 
The quantitative data are represented as mean ± standard deviation (S.D.). Statistical 
significances were determined using Student’s t-test with p values ≤0.05 considered 
significant as determined by Prism. 
 
4.3 Results 
4.3.1 Hdac4 conditional knockout (4cKO) male mice exhibit increase bone mass at 
3-month of age 
To investigate the role of Hdac4 in regulating osteoclast differentiation and activity, 
we generated osteoclast-specific Hdac4 cKO (4cKO) mice by mating Hdac4fl/fl (4WT) 
mice with cFms-Cre transgenic mice, in which the Cre recombinase gene is inserted into 
c-Fms locus and expressed in osteoclasts (227). 4cKO mice were born alive and did not 
exhibit any abnormal phenotype. Immunoblot confirmed cFms-Cre-mediated deletion of 
HDAC4 throughout osteoclastogenesis (Figure 20A). Microcomputed tomography (micro-
CT) analysis of the distal femur revealed an increase in bone mass phenotype in the 4cKO 
male mice at 3-month of age compared to 4WT. Bone volume/tissue volume (BV/TV) and 
trabecular number were significantly increased. Trabecular separation (Tb.Sp) and 
trabecular thickness (Tb.Th) were not significant different between 4WT and 4cKO; 
however, trabecular separation did trend towards a decrease (Figure 20 B-F). There was no 
significant difference in 4cKO female BV/TV as compared to 4WT littermates at 3-month 
of age (data not shown). However, when the 4cKO male mice were aged to 6-month, micro-
CT analysis revealed that the increased bone mass phenotype that was seen at 3-month of 
age had resolved itself. There was no significant difference in BV/TV, Tb.N , Tb.Sp , and 
Tb.Th  between 4cKO and 4WTmice (Figure 21). In additional, there were no changes and 
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differences in cortical parameters of 4cKO and 4WT mice at 3- and 6-months of age (data 
not shown). These data suggest that HDAC4 plays an important role in regulating bone 
homeostasis in an age-dependent manner. 
 
 
Figure 20. HDAC4 conditional knockout (4cKO) male mice exhibit increase bone 
mass at 3-months of age. (A) Expression of HDAC4 in osteoclasts from 4WT mice and 
4cKO mice was analyzed by Western blotting. b-Actin was used as a loading control. (B) 
Representative micro-CT images of the distal femur in a 4WT mouse (left) and 4cKO 
mouse (right) at 3-month of age. (C–F) Graphs show quantitative data from the micro-CT 
analyses. BV/TV, bone volume per total volume; Tb.N, trabecular number; Tb.Th, 
trabecular thickness; Tb.Sp, trabecular separation. Data are represented as the mean ± SD 
(*P < 0.05; n =10 male mice in each group). P-values are based on Student’s t-test. P < 
0.05, is considered significant. NS, not significant. 







Figure 21. Micro-CT analysis revealed that 4cKO male mice resolves the increase 
bone mass phenotype (osteopetrotic) at 6-month of age. Graphs show quantitative data 
 
 
4.3.2 Deletion of HDAC4 in osteoclast does not affect in vitro osteoclast 
differentiation  
To assess the role of HDAC4 in the osteoclast differentiation process, we cultured 4WT 
and 4cKO BMMs with M-CSF and RANKL. RANKL-induced osteoclast differentiation 
was evaluated by tartrate resistant acid phosphatase (TRAP) staining at day 2, 3 and 4, and 
mRNA expression levels of osteoclast differentiation markers genes (c-Fos, Nfatc1and Dc-
stamp). After 2-day exposure to cytokines, 4WT and 4cKO BMMs cultures had many 
TRAP-expressing mononuclear osteoclasts (Figure 22A). By day 3 and 4, both BMMs 
cultures had differentiated into TRAP positive multinuclear osteoclasts. There was no 
significant difference in the number of TRAP+ multinuclear osteoclasts in 4WT and 4cKO 
BMMs cultures (Figure 22B); however, the 4cKO osteoclasts, had a trend towards 
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increased size at day 3 compared to their 4WT counterparts. The mRNA expression of 
osteoclast differentiation marker genes (c-Fos, Nfatc1and Dc-stamp) did not differ between 
4cKO and 4WT osteoclasts; even though, the mRNA expression levels of marker genes in 
4cKO osteoclasts showed an increase (Figure 23). The serum levels of TRAP5b, an in-vivo 
marker of TRAP activity, was not significantly different between 4cKO and 4WT mice at 
3-month (Figure 24A) or 6-month of age (Figure 24 B).  TRAP stained bone sections of 3-
month old 4cKO and 4WT male mice revealed that 4cKO male mice exhibited a significant 
increase in the osteoclast surface/bone surface (Oc.S/BS) but not in osteoclast number/bone 
surface (Oc.N/BS, not shown) (Figure 24C). This data suggests that osteoclast 
differentiation is enhanced in-vivo in the 4cKO mice compared to their 4WT littermates.  
 





Figure 22. Enhanced in vivo differentiation of 4cKO osteoclasts. (A) BMMs from 4WT 
and 4cKO mice were cultured in the presence of M-CSF and RANKL for 2, 3 or 4 days, 
followed by staining for TRAP+ cells. (B) Graphs show quantitative data for number and 
size of TRAP+ multinucleated cells generated from 4WT and 4cKO BMMs. Only cells 
containing more than 3 nuclei were counted as osteoclasts and quantified. Data are 
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represented as the mean ± SD. Data shown are representative of three independent 
experiments. (C) TRAP expression of decalcified bone sections of the femur from 3-month 
old 4WT male mice (left) or 4cKO male mice (right) was assessed by TRAP staining and 
the following parameter, Oc.N/BS, number of osteoclasts per bone surface and Oc.S/BS, 
osteoclast surface per bone surface was measured. Representative TRAP-stained images 
are shown. Black boxes indicate the region of magnification. Data are represented as the 
mean ± SD (***p < 0.001, n = 4 male mice in each group). P-values are based on Student’s 





Figure 23. Genetic deletion of Hdac4 results in no change in the expression of 
osteoclast differentiation markers in vitro. Analysis of the osteoclastogenic marker 
genes c-Fos, Nfatc1and Dc-stamp, was performed at day 0–4 from 4WT or 4cKO 
osteoclasts by qPCR. Data shown are representative of three independent experiments. p < 
0.05, is considered significant 
 
 





Figure 24. Hdac4 deletion does not affect TRAP activity in vivo. Blood plasma serum 
of 3-month (A) and 6-month (B) old 4WT and 4cKO male mice were analyzed for TRAP 
form 5b (TRACP 5b), a marker for TRAP activity. N = 10 male mice in each group. Data 




4.3.3 Bone resorption is decreased in 4cKO male mice 
Since the increased bone mass phenotype of 4cKO male mice could not be explained 
by the increased in vivo osteoclast differentiation we next analyzed the activity of the 
osteoclasts from the 4cKO mice. We first generated TRAP-expressing multinuclear 
osteoclasts on calcium phosphate plates. After 5 days in M-CSF and RANKL, the 
demineralized area was visualized using light microscope (Figure 25A). The 4cKO male 
mice exhibited significant decrease in percent demineralized area and average number of 
demineralized areas, but not in average size of demineralized areas (Figure 25B). The 
serum levels of C-terminal cross-linking telopeptide of type 1 collagen (CTX), a bone 
resorption in-vivo marker, were significantly decreased in 4cKO mice compared with 4WT 
mice (Figure 25C) at 3-month of age. There was no significant change in genes necessary 
for osteoclast activity (Acp5, Ctsk and Mmp9) (Figure 26). We found that resorptive 
capacity of 4cKO osteoclasts was not significantly different from 4WT at 6-month of age 
as measured by serum CTX but there was a trend towards decrease in the 4cKO mice 
(Figure 27). The serum levels of PINP, an in-vivo marker for bone formation, were not 
significantly different between 4cKO and 4WT mice at 3-month and 6-month of age, 
despite a trend towards increased PINP levels in 4cKO mice (Figure 28 A/B). These 
findings suggest that the increase bone mass phenotype of 4cKO mice at 3-month of age is 
a result of a decrease in bone resorbing activity of osteoclasts. 






Figure 25. HDAC4 aids the bone-resorbing activity of osteoclasts. (A) Osteoclasts from 
4WT and 4cKO mice were cultured on calcium phosphatase surface for 5 days, and the 
demineralized areas were visualized by light microscope and quantified using NIH Image 
J software. Representative images of demineralized area are shown. (B)  Graphs shows 
percent demineralized area, average size and average number quantification. Data are 
represented as the mean ± SD (****p < 0.0001; *p < 0.05). Data shown are representative 
of three independent experiments. (C) Serum concentration of CTX, an in-vivo marker of 
bone resorption, in 4WT mice and 4cKO mice was assessed by ELISA. Data are 
represented as the mean ± SD (*p < 0.05, n = 10 male mice in each group). P-values are 









Figure 26. Hdac4 deletion in osteoclasts does not alter expression of osteoclast 
activity marker genes. Analysis of the osteoclast activity marker genes Acp5, Ctsk and 
Mmp9 was performed at day 0–4 from 4WT or 4cKO osteoclast by qPCR. Data shown 





Figure 27. Bone resorption was trending toward decrease in 4cKO male mice at 6-
month of age. Blood plasma serum of 6-month old 4WT and 4cKO mice was analyzed 
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for CTX, a marker for global bone resorption. N = 10 male mice in each group. Data 




Figure 28. Deletion of Hdac4 mice cause a trend towards increase bone formation in 
vivo. Blood plasma serum of 3-month (A) and 6-month (B) old 4WT and 4cKO male 
mice was analyzed for PINP, a marker for bone formation. N = 10 male mice in each 





4.3.4 Reduced ERK and AKT activation in 4cKO osteoclasts 
Since we did not measure any changes in gene expression in the 4cKO osteoclasts, we 
next analyzed intracellular signaling pathways to determine if signaling pathways were 
altered to account for the change in osteoclast activity. As assessed by immunoblotting, the 
phosphorylation of MAPKs, in particular extracellular signal-related kinase 1/2 (ERK1/2), 
was significantly decreased at day 0 and 1 in 4cKO osteoclasts as compared with 4WT 
osteoclasts, while the phosphorylation of p38 was only significantly increased at day 1. In 
contrast, the phosphorylation of JNK was unchanged by Hdac4 deletion (Figure 29A, B). 
These results suggest that expression of HDAC4 is necessary for activation of ERK1/2 
MAPK signaling in osteoclast precursors. 
Since, PI3-K/AKT pathway has been shown to regulate osteoclast development (228), 
we also examined the phosphorylation of AKT in the cultured osteoclasts. As shown in 
Figure 29A and B, we found that the levels of AKT phosphorylation were also significantly 
reduced in 4cKO osteoclasts at day 0 and 1 compared to 4WT osteoclasts, suggesting that 
the functional abnormality observed in 4cKO osteoclasts are also AKT dependent. 
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Together, these results show that HDAC4 expression is required for activation of ERK and 
AKT signaling. 
We next asked whether M-CSF or RANKL activation was impaired in its ability to 
activate ERK1/2 signaling since both cytokines have been demonstrated to activate MAPK 
signaling in osteoclasts (229). We generated osteoclasts from 4cKO and 4WT mice by 
culturing BMMs in M-CSF till day 1. The cells were then cytokine starved, stimulated with 
M-CSF for 0, 5, 15, and 30 minutes, lysed and extracted protein for western blot. We 
assessed total and phosphorylated levels of ERK1/2. As seen in Figure 29C, following M-
CSF stimulation, the magnitude and duration of ERK1/2 phosphorylation was dampened 
in 4cKO osteoclasts compared to 4WT osteoclasts. This reduced M-CSF induced activation 
of ERK1/2 suggests a requirement for HDAC4 in the regulation of ERK1/2 by M-CSF.  
There was no difference observed in the ability of RANKL to activate ERK1/2 in the 4WT 
or 4cKO osteoclasts. 
 





Figure 29. HDAC4 positively regulates the activity of ERK1/2 and AKT. (A) 4WT and 
4cKO BMMs were cultured in M-CSF and RANKL for indicated time. The whole-cell 
lysates from 4WT and 4cKO osteoclasts were then subjected to Western blot using 
antibodies against phospho-ERK 1/2, phospho-JNK, phospho-p38, and phospho-AKT. 
Total-ERK 1/2, total-JNK, total-p38 and total-AKT served as a loading control. (B) Graphs 
shows quantifications of the Western blots. Data are represented as the mean ± SD (*P < 
0.05). Data quantified are representative of three independent experiments. P-values are 
based on Student’s t-test. p < 0.05, is considered significant. (C) Pre-osteoclasts were 
stimulated with M-CSF for 0,5,15,30 minutes, followed by western blot for phospho-ERK 
1/2. b-actin served as a loading control. 
 
In canonical MAPK signaling, ERK1/2 activation is dependent on MEK1/2 (230). 
Because 4cKO osteoclasts have reduced ERK1/2 activation, we asked whether upstream 
regulator of ERK1/2 signaling, MEK1/2 is also affected. We cultured BMMs cells 
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isolated from 4cKO and 4WT mice in M-CSF and RANKL. Generated osteoclasts were 
then collected, lysed and protein extracted for western blot. As shown in Fig. 5A, the 
phosphorylation of MEK1/2 was unchanged by Hdac4 deletion, suggesting that the 
reduced ERK1/2 phosphorylation seen in 4cKO osteoclasts was not due to significant 
change in MEK1/2 activity. Thus, changes in MEK 1/2 activation was not responsible for 
ERK1/2 changes we observed in 4cKO osteoclasts.  
 
 
Figure 30. Hdac4 deletion in osteoclasts does not alter MEK1/2 activation. 4WT and 
4cKO BMMs were cultured with M-CSF and RANKL up to 4 days. MEK1/2 
phosphorylation was determined by immunoblot. Total-MEK 1/2 served as a loading 




4.3.5 Impaired avb3 Integrin Signaling Activation in 4cKO Osteoclasts 
Resorption by osteoclasts requires migration across the bone surface and the ability to 
bind to the bone surface through avb3 engagement with RGD containing proteins in the 
bone matrix (11, 12, 231).  Mice that are null for ERK1/2 expression in osteoclasts have 
reduced migration and adhesion (232).  Since the 4cKO osteoclasts had reduced ERK1/2 
activation, we asked whether deletion of Hdac4 affects avb3 integrin-mediated adhesion 
and signaling. We differentiated 4WT and 4cKO BMMs cells till day 2, then re-plated the 
preosteoclasts on vitronectin (VTN), the avb3 ligand, and incubated the cells for 15 and 
30-minute period. As seen in Figure 31A, the number of adherent 4cKO osteoclasts was 
decreased significantly after 15 and 30 minutes compared to 4WT osteoclasts. This data 
suggests that HDAC4 is necessary for avb3 integrin-mediated adhesion. We next asked 
whether HDAC4 is also required for activations of upstream regulators of integrin-
mediated signaling. We cultured 4WTand 4cKO BMMs in M-CSF and RANKL. After 2 
days, we cytokine-starved and preosteoclasts were lifted and re-plated on the avb3 ligand, 
vitronectin (VTN, (A), or maintained in suspension (S) for 30-minutes. After 30-minute 
incubation, cells were lysed, and Src and ERK1/2 activation, as manifested by 
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phosphorylation, was assessed by immunoblot. As shown in Figure 32B, Src and ERK1/2 
activation are decreased in 4cKO, supporting our hypothesis that HDAC4 is required for 
integrin-mediated signaling. 
Because adhesion was affected in 4cKO osteoclasts, we next examined whether 
deletion of Hdac4 affected migration of preosteoclasts using transwell migration assay in 
response to M-CSF.  As shown by Figure 31C, 4cKO pre-osteoclasts migrated at lower 
numbers compared to 4WT pre-osteoclasts in response to M-CSF. Defective adhesion and 
migration of 4cKO preosteoclasts suggests a requirement for HDAC4 in the activation of 
avb3 integrin, which may underline the reduced bone resorption activity detected in 4cKO 




Figure 31. Defective avb3-dependent signaling in 4cKO osteoclasts. (A) M-SCF 
mediated pre-osteoclast adhesion to avb3. 4WT or 4cKO BMMs were cultured with M-
CSF and RANKL for 2 days to generate pre-osteoclasts. The cells were lifted and re-plated 
onto vitronectin-coated wells for 15 or 30 minutes, followed by TRAP staining. Data are 
represented as the mean ± SD (*p < 0.05). Data shown are representative of three 
independent experiments. (B)  4WT or 4cKO pre-osteoclasts were cytokine/serum starved, 
re-stimulated, lifted and re-plated onto vitronectin-coated wells for 30 minutes (A) or left 
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in suspension (S), followed by western blot for phospho-Src and phospho-ERK1/2. Total-
Src and total-ERK 1/2 served as a loading control. (C) Transwell migration of day 2 pre-
osteoclasts in response to M-CSF. Data are represented as the mean ± SD (**p < 0.01). 
Data shown are representative of three independent experiments. P-values are based on 
Student’s t-test. 
 
4.3.6 Pyk2 phosphorylation is reduced in 4cKO osteoclasts 
It has been previously shown that activation of avb3 integrin causes phosphorylation 
of Pyk2Y402, a calcium-dependent tyrosine kinase that is a FAK family member which then 
activates c-Src by binding to its SH2 domain in osteoclasts (233). Additionally, we have 
shown in this Chapter that Src phosphorylation is decreased in 4cKO osteoclasts after 
adhesion (Figure 31B), suggesting that HDAC4 is required for integrin-mediated signaling 
in osteoclasts. Because activation of Src by avb3 requires phosphorylation of Pyk2 (233), 
we evaluated whether HDAC4 is required for activation of Pyk2 in osteoclasts. To examine 
this, we analyzed phosphorylation of Pyk2 in 4WT and 4cKO differentiating osteoclasts. 
We found that Pyk2 phosphorylation was decreased in cells derived from 4cKO osteoclasts 
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Figure 32. Pyk2 phosphorylation is decreased in 4cKO osteoclasts. Expression levels 
of Pyk2 protein during osteoclastogenesis using 4WT and 4cKO BMMs in culture with M-
CSF plus RANKL from 0 to 4 days. Graph shows quantitative data of western blots. Data 
are represented as the mean ± SD (*p < 0.05). Data shown are representative of three 
independent experiments. 
 
4.3.7 Src phosphorylation is decreased in plasma membrane fraction of 4cKO 
osteoclasts 
The Src family of protein kinases are nonreceptor tyrosine kinases which associates 
with cell membrane to regulates different cellular events such as differentiation, adhesion 
and migration (234).  It has been reported that Src-membrane association-dissociation is 
regulated by CREB binding protein (CBP)-mediated acetylation (235). Since we observed 
reduced adhesion, migration and Src phosphorylation in 4cKO osteoclasts, we asked 
whether HDAC4 regulates Src-membrane association-dissociation. To delineate whether 
Src-cell membrane association changes in osteoclasts, we fractionated Src from two cell 
compartments: plasma membrane and cytoplasm using 4WT and 4cKO osteoclasts. Src 
phosphorylation was detected in the cytoplasmic fractions of both 4WT and 4cKO 
osteoclasts. While Src from plasma membrane fraction of 4WT osteoclasts had detectable 
phosphorylation, Src from plasma membrane fraction of 4cKO osteoclasts had 
undetectable phosphorylation (Figure 33). Our data suggests that HDAC4 regulates Src 
phosphorylation in the membrane of osteoclasts.  This data agrees with previous data from 
Figure 31 suggesting that integrin activation of Src which would take place at the plasma 
membrane is impaired in HDAC4 null osteoclasts.  Lastly this data suggests that loss of 
HDAC4 expression does not appear to affect total Src expression as there was no difference 
in total Src expression between 4WT and 4cKO osteoclasts (middle panel, Fig 33).  




Figure 33. Src phosphorylation is decreased in plasma membrane fraction of 4cKO 
osteoclasts. Src recovered from plasma membrane (M) and cytoplasmic (C) fractions 




Osteoclast dysfunction has been implicated in several bone disorders. Osteoclast 
hyperactivity is associated with diseases such as osteoporosis and cancer metastasis to 
bone; whereas osteoclast deficiency leads to diseases such as osteopetrosis (19, 236). We 
have begun to understand the mechanisms that regulate osteoclast differentiation and 
function; however, there is still a lot that is unknown. Recently, class IIa HDACs which 
include HDAC4, 5, 7 and 9 have been reported to be regulators of osteoclastogenesis.  Our 
lab reported that HDAC7 regulates osteoclast differentiation by inhibiting MITF’s 
activation of osteoclast genes (39, 140), Jin et al. reported  that HDAC7 negatively 
regulates osteoclastogenesis through suppressing Nfatc1 expression and preventing down-
regulation of b-catenin and cyclin D1 (40).  HDAC9  inhibits osteoclastogeneisis through 
suppression of PPARg/RANKL signaling (41). Our present study surprisingly 
demonstrates that HDAC4 positively regulates the bone resorption activity of osteoclasts 
in vitro and in vivo by impairing activation of c-Src and ERK1/2 through a mechanism 
involving αvβ3-integrin and M-CSF mediated signaling. Together these studies suggest 
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that class IIa HDACs are not redundant in their regulation of osteoclastogenesis. 
Consequently, deletion of HDAC4 in osteoclasts leads to an increase bone mass phenotype 
due to dysfunctional osteoclasts.   
Male mice null for HDAC4 in osteoclasts exhibited significantly decreased bone 
resorption and increased bone mass at 3-months of age. This finding suggests that unlike 
HDAC7 and -9 which negatively regulate osteoclast differentiation and activity (39-41), 
HDAC4 positively regulates osteoclast activity.  HDAC4’s role in regulating osteoclast 
differentiation are not as clear.  In our previous study, osteoclasts infected with an shRNAs 
against HDAC4 showed larger osteoclasts compared to control infected cells.  However, 
in our current study we did not see a significant difference in size or number of TRAP 
positive cells in vitro but we did measure an increase in size in TRAP positive cells in vivo.  
It is not clear whether our results with the Hdac4 shRNAs were due to off target effects 
against other class IIa HDACs during osteoclast differentiation.  An alternative explanation 
for the difference results could be to the timing of loss of HDAC4 expression during 
osteoclast differentiation.   
Based on the skeletal phenotype of Hdac4fl/fl;C-fms Cre mice HDAC4’s main role in 
osteoclasts involves regulating activity, as opposed to differentiation. Given the in vivo 
osteoclast defects in 4cKO mice, we examined the capacity of osteoclast precursors to 
differentiate in response to the osteoclastogenic cytokines RANKL and M-CSF, as well as 
the resorptive capacity of the osteoclasts, in vitro.  Expression of early osteoclast 
differentiation marker genes such as c-Fos, Nfatc-1 and Dc-stamp and late marker genes 
such as Acp5, Ctsk and Mmp9 were not significantly different in 4cKO osteoclasts 
compared to 4WT osteoclasts. This data suggests that HDAC4 does not regulate osteoclasts 
through regulation of these genes. Despite the ability of the mutant cells to fuse and become 
TRAP positive multinucleated cells, 4cKO osteoclasts had markedly diminished capacity 
to resorb bone. The finding of suppressed osteoclast function in the face of elevated 
osteoclast number in vivo is reminiscent of b3 integrin-deficient mice, whose bone mass is 
enhanced (12, 29). 
In an attempt to elucidate the mechanisms by which HDAC4 enhances the bone-
resorbing activity of osteoclasts, we demonstrated that the activity of ERK1/2 was 
significantly decreased in 4cKO osteoclasts. Previous studies have established the role of 
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ERK1/2 in osteoclasts.  He et al. reported that ERK1/2 positively regulates osteoclast 
function (232), providing grounds for our proposal that the decreased bone-resorbing 
activity of 4cKO osteoclasts, at least in part, is caused by the decreased in activity of 
ERK1/2. Although multiple studies have reported in the antiapoptotic effects of ERK1/2 
in osteoclasts (237, 238), we did not find a decrease or increase in survival of 4cKO 
osteoclasts (data not shown). This difference may be explained by the duration of ERK1/2 
phosphorylation and its subcellular localization. Chen et al. reported that both duration of 
ERK1/2 activity and localization of ERK1/2 are important for the proper function of 
ERK1/2 (239). Further studies are needed to determine the mechanisms by which HDAC4 
regulates ERK1/2 activation. 
In osteoclasts, differentiation and function involve activations of many signaling 
pathways such as ERK1/2 by M-CSF, through its cell surface receptor c-FMS and the αvβ3 
integrin (12, 24, 231, 240, 241). Given the in vitro reduction of ERK1/2 phosphorylation 
in 4cKO osteoclasts, we asked whether ERK1/2 activation in response to M-CSF is 
impaired. We find that ERK 1/2 activation after M-CSF stimulation is HDAC4 dependent. 
The importance of ERK 1/2 signaling pathway in regulating osteoclast differentiation and 
function has been shown with Erk1-/- and Erk2-/- mice, which reported that ERK1 
positively regulates osteoclast function (232). The fact that 4cKO osteoclasts have 
defective M-CSF induced activation of ERK 1/2 suggests a requirement for HDAC4 in the 
regulation of ERK1/2, which may partially underlie the defects in bone resorptive activity 
in 4cKO osteoclasts in vitro. 
Bone resorption by osteoclasts involve the binding of osteoclasts to bone via avb3 
integrin. The avb3 integrin is highly expressed in osteoclasts and mediates the ability of 
the cell to polarize, spread, migrate and degrade bone (11, 12). b3 integrin-deficient mice 
are osteopetrotic as a result of failure of their osteoclasts to spread (12). To determine if 
HDAC4 is required for osteoclast attachment, we analyzed avb3 – and M-CSF-mediated 
adhesion in 4WT and 4cKO preosteoclasts. The finding that fewer 4cKO preosteoclasts 
adhered to vitronectin coated plates during stimulation with M-CSF indicates a defect in 
the ability of osteoclasts to bind through interactions between avb3 integrin and its ligand 
vitronectin to initiate bone resorption. To confirm the role of HDAC4 during osteoclast 
attachment, we analyzed avb3-dependent activation of two kinases, namely c-Src and 
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ERK1/2, in 4WT and 4cKO preosteoclasts. We find that both c-Src and ERK 1/2 signals 
were reduced in 4cKO pre-osteoclasts, suggesting that HDAC4 is necessary for avb3- 
integrin-mediated signaling in osteoclasts during attachment. Because, 4cKO 
preosteoclasts do not adhere very well and activate avb3-dependent kinases (c-Src and 
ERK 1/2), we asked whether migratory capacity of the preosteoclasts is affected, using 
transwell migration in response to M-CSF. We find that 4cKO preosteoclasts migrated at 
a lower number in response to M-CSF. Thus, our results suggest preosteoclast migration 
across the bone might be blocked in cells lacking HDAC4, suggesting that HDAC4 is 
required for osteoclast migration in vitro. The finding of suppressed osteoclast function, in 
the face of impaired adhesion and migration is reminiscent of Erk1 knockout mice, who 
have an enhanced bone mass (232). 
Acetylation as a regulatory mechanism of enzymatic activity has been highly conserved 
in evolution. HDACs have been shown to modify histone and non-histone protein to 
regulate protein function (31, 183). A recent study using cancer cells reported that CREB 
binding protein (CBP), an acetyltransferase, regulates c-Src-cell membrane association and 
dissociation, hence its function (235). Our data suggest that HDAC4 may be deacetylating 
c-Src since we found that 4cKO osteoclasts have impaired c-Src activation. Sunjay et al. 
reported that when avb3 integrin is activated it results in phosphorylation of Pyk2, which 
then activates c-Src (233). Given the reduced c-Src activation we observed in 4cKO 
osteoclasts (Chapter 4, Figure 31B), we examined whether HDAC4 is required for 
activation of Pyk2 in osteoclasts. We observed diminished Pyk2 phosphorylation in 4cKO 
osteoclast, suggesting Pyk2 activation in osteoclasts may require HDAC4.  Therefore, the 
reduced bone resorption activity in 4cKO osteoclasts may be a result of avb3-Pyk2-c-Src 
being unable to be activated.  
Our studies do not rule of the possibility that Src activity may affect Pyk2 
phosphorylation directly through mechanism involving Src phosphorylation rather than 
acetylation. Previously, it has been shown that Src-Pyk2 interaction requires Src SH2 
domain, and that the domain is important in Src phosphorylation of Pyk2 (242). 
Furthermore, it has been reported that Src retains a basal activity in cells via an auto-
inhibitory mechanism, whereby a tyrosine phosphate Y526 or Y527 in the carboxyl 
terminal tail is phosphorylated allowing for interaction with Src homology 2 (SH2) domain 
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preventing catalytic activity (235). Src activation is initiated when the carboxyl terminal 
tyrosine phosphate is removed, causing a conformation change and subsequently, 
autophosphorylation (243). The fact that both Src and Pyk2 phosphorylation are abrogated 
in 4cKO osteoclast could suggest that Src is catalytically inactive, which in turn prevents 
interaction with Pyk2. This abolished interaction between Src and Pyk2 might impact Pyk2 
activation during osteoclastogensis.  This would seem to suggest that Src activation occurs 
separately from HDAC4 complex assembly and can exert its effects on Pyk2 directly. This 
provides yet an additional explanation of the importance of Src activation. Future studies 
are needed to precisely determine how Src-Pyk2 mechanism works in 4cKO osteoclasts. 
Among the various properties known to be important to Src, dynamic association with 
plasma membrane is one of them (235, 244). Given we observed reduced adhesion, 
migration and Src phosphorylation in 4cKO osteoclasts (Figure 31), we asked whether Src 
membrane association was affected using cytoplasmic and plasma membrane fractions. We 
found that Src phosphorylation was detected in both cytoplasmic fractions of 4WT and 
4cKO osteoclasts, but it was undetectable in the plasma fraction of 4cKO osteoclasts 
(Figure 33), suggesting that HDAC4 regulates Src phosphorylation in the membrane of 
osteoclasts. Furthermore, our data suggest that loss of HDAC4 expression in osteoclasts 
does not alter total Src expression as we did not detect changes in total Src between 4WT 
and 4cKO osteoclasts. In summary this data agrees with our previous data from Figure 31 
suggesting that integrin activation of Src which would take place at the plasma membrane 
is impaired in HDAC4 null osteoclasts. 
A limitation of this study is that deacetylation of Src was assessed only in cell lysates 
of osteoclasts. Further studies are needed to determine if c-Src acetylation status dictates 
cellular location. In addition, we did not elucidate which sites in c-Src unique domain and 
catalytic domain are the potential HDAC4 deacetylation sites in osteoclasts.  
In conclusion, our study identified HDAC4 as the significant regulator of osteoclast 
bone resorption both in vivo and in vitro. The characterization of 4cKO mice, molecular 
and cellular assays lends further support for the importance of the HDAC4 in osteoclasts. 
Collectively my data suggests that expression of HDAC4 regulates Pyk2 and Src 
phosphorylation in osteoclasts.  We hypothesize that the changes in Pyk2 and Src results 
in changes in adhesion and migration and ultimately resorption.  Several questions that 
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remain to be answered are 1) similar to cancer cells is deacetylation of Src necessary for 
activation of Src at the membrane, 2) is HDAC4 deacetylating Src which allows Src to be 
phosphorylated at the membrane, 3) can only deacetylated Src associate with integrins to 
allow for phosphorylation and 4) is ERK1/2 phosphorylation regulated by Src, M-CSF 
and/or RANKL signaling? (Fig 34) 
 
 
Figure 34. Mechanism of HDAC4 regulation of osteoclast function. Illustration of a 
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Chapter 5. RNA-Sequence based detection of differentially 
expressed genes in 4cKO osteoclasts 
 
Chapter summary 
The results of chapter 4 demonstrated that mice model lacking HDAC4 in osteoclasts 
had increased bone mass phenotype (osteopetrosis) resulting in decreased osteoclast-bone 
resorption with no effect on osteoclast differentiation. Moreover, the expression of the 
osteoclast differentiation markers genes from 4cKO osteoclasts did not differ from 4WT 
osteoclasts. It has been reported that in muscle cells, class IIa family members, HDAC4, 5 
and 7 are evolutionary conserved and can compensate for each other to regulate gene 
expression. Given this, the aim of this study was to investigate global changes in gene 




Of the class IIa HDACs, HDAC 4, 5 and 7 are more evolutionarily conserved and share 
approximately 57% similarity (31). During various stages of muscle differentiation, it has 
been shown that HDAC 4, 5 and 7 complement each other to regulate gene expression in 
response to specific signals (31, 226). However, it is not known whether the same process 
occurs in osteoclast. Since suppression of a single HDAC, either HDAC7 or 9 will enhance 
osteoclast formation, this data suggested that the class IIa HDACs are not functionally 
redundant (42, 140). Also, these results suggest that each HDAC provides a carefully 
regulated set of changes in gene expression to regulate osteoclast differentiation and 
activity. 
 
5.2 Experimental Procedure 
5.2.1 Primary Osteoclast Culture 
Cultures of murine osteoclast differentiation was performed as previously described 
(42). Briefly, bone marrow cells were flushed from the femora and tibiae of 4WT or 4cKO 
4-week-old male mice. Harvested cells were incubated in culture dishes overnight in 
phenol red-free alpha-MEM (Gibco) containing 5% fetal bone serum (Atlanta Biologicals), 
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25 units/mL penicillin/streptomycin (Invitrogen), 400 mM L-Glutamine (Invitrogen) in the 
presence of 1% CMG 14-12 culture supernatant containing M-CSF.  CMG14-12 cells were 
obtained from Dr. Sunao Takeshita (Nagoya City University, Nagoya, Japan). Non-
adherent cells were counted, plated in tissue culture plates, and cultured for 2 days with 
1% CMG culture supernatant containing M-CSF. After 2 days of culture, the cells are 
considered to be bone marrow-derived macrophages (BMMs). The BMMs were cultured 
for additional 2 days in phenol red-free alpha-MEM containing 5% fetal bone serum, 25 
units/mL penicillin/streptomycin, 1% CMG 14-12 culture supernatant containing M-CSF 
and 10 ng/mL RANKL (R&D Systems) to obtain osteoclasts.   
 
5.2.2 RNA-Sequence.  
4WT and 4cKO BMMs were differentiated into osteoclasts and harvested on day 2 
using RNeasy Plus Mini Kit (QIAGEN, Germantown, MD, USA). 50bp FastQ paired-end 
reads were trimmed via Trimmomatic (v 0.33). For each sample, quality control on raw 
data sequence was performed using FastQC. Read mapping was performed using Hisat2 
(v2.0.2) and mouse genome was used a reference. Gene quantification was achieved using 
Cuffquant for FPKM values and Feature Counts for raw read counts. Pathway analysis was 
performed using DAVID. 
 
5.3 Results 
To determine global changes in gene expression in 4cKO osteoclasts, I performed 
RNA-Sequence experiment using 4WT and 4cKO osteoclasts on day 2 of osteoclast 
differentiation.  A total of 745 mRNA genes were differentially expressed when 
considering exclusively a significance threshold of P-value ≤ 0.05. When we performed a 
more stringent analysis (P-value ≤ 0.01), 715 genes were differentially expressed (Table 2 
showing representative genes).  
We used DAVID analysis to identify pathways to which differentially expressed genes 
belong to as well as to explore the existence of signaling networks connecting differentially 
expressed genes. This information should be interpreted with caution because, in general, 
pathways were represented by a small number of genes and statistical significance was not 
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very high. As shown in Table 3, we found 14 regulatory networks related to variety of 
functions. 
Feature ID EDGE test: cfms vs HDAC4, tagwise 
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Table 2: Representative list of differentially expressed genes in HDAC4 osteoclasts. P 
value < 0.01. 
 
Pathway Genes Within Pathway 
Rap1 signaling pathway Adcy6, Angpt1, Cdh1, Csf1, Epha2, Fgf12, 
Fpr1, Hgf, Igf1, Itga2b, Itgb2l, Kdr, Kit, 
Pdgfc, Pdgfrb, Rapgef3, Rasgrp2, Thbs1, 
Vegfa 
Oocyte Meiosis Adcy6, Bub1, Cdc20, Cdk1, Cpeb1, Igf1, 
Mad2l1, Pgr 
p53 Ccnb1, Ccnb2, Ccnd2, Cdk1, Chek1, 
Gadd45a, Igf1, Serpine1, Sfn, Thbs1 
Cell Adhesion Cd22, Cd274, Cd4, Cdh1, H2-Aa, H2-Eb1, 
H2-Ob, H2-T24, Itgb2l, Nrcam, Pecam1, 
Sdc2, Sdc3, Sell, Selp, Siglec1, Vcam1, 
Vcan 
Cell Cycle Bub1, Ccnb1, Ccnb2, Ccnd2, Cdc20, 
Cdc25c, Cdk1, Chek1, Gadd45a, Mad2l1, 
Sfn, Tgfb2, Tgfb3 
PI3K/Akt Angpt1, Ccnd2, Colla2, Col1a1, Col1a2, 
Col3a1, Col5a2, Col6a1, Col6a2, Col6a3, 
Csf1, Csf3r Epha2, Fgf12, Fn1, Hgf, Igf1, 
Il7r, Itga2b, Kdr, Kit, Lamb1, Myb, Pdgfc, 
Pdgfrb, Sgk1, Thbs1, Thbs2, Tnc 
Hippo Afp, Birc5, Ccnd2, Cdh1, Ctgf, Fzd6, 
Itgb2l, Serpine1, Tgfb2, Tgfb3, Wnt6 
HIF1 Angpt1, Eno1b, Eno2, Igf1, Nos2, 
Serpine1, Timp1, Trf, Vegfa 
Hemopoietic Anpep, Cd22, Cd33, Cd36, Cd4, Cd7, 
Csf1, Csf3r, Fcgr1, Flt3, Gp1ba, Gp1bb, 
Gp5, Gp9, H2-Eb1, Il1b, Il1r1, Il7r, Itga2b, 
Kit, Siglech 
FoxO  Ccnb1, Ccnb2, Ccnd2, Gadd45a Igf1, Il7r, 
Irs2, Klf2, Plk2 Sgk1, Tgfb2, Tgfb3, 
Tnfsf10 
Focal Adhesion Cav1, Ccnd2, Col11a2, Col1a1, Col1a2, 
Col3a1, Col5a2, Col6a1, Col6a2, Col6a3, 
Fn1, Hgf, Igf1, Itga2b, Kdr, Lamb1, Myl9, 
Mylk, Parva, Pdgfc, Pdgfrb, Thbs1, Thbs2, 
Tnc, Vegfa 
CMP PGK Adcy6, Atp1a3, Ednrb, Gucy1a3, 
Gucy1b3, Irs2, Mrvi1, Myl9, Mylk, Pde3a, 
Prkg1, Trpc6 
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Cytokine cytokine interaction Cd3, Ccl4, Ccl5, Ccr2, Ccr5, Ccr7, Ccr9, 
Csf1, Csf3r, Cxcl9, Cxcr2, Flt3, Hgf, Il1b, 
Il1r1, Il7r, Kdr, Kit, Mpl, Pdgfc, Pdgfrb, 
Ppbp Tgfb2, Tgfb3, Tnfrsf18, Tnfsf10 
 





Hdac4 is highly expressed during early stages of osteoclastogenesis (chapter 3). Mice 
lacking HDAC4 in osteoclasts have increase bone mass phenotype and decrease bone 
resorption with no effect on osteoclast differentiation (chapter 4). Moreover, analysis of 
gene expression of osteoclast differentiation markers showed that gene marker expression 
did not differ from 4WT and 4cKO osteoclasts (chapter 4). Hence, this study aimed to 
investigate global gene changes in 4cKO osteoclasts in vitro using RNA-sequence. In this 
study, we confirmed that deletion of HDAC4 in osteoclasts does not affect the expression 
of osteoclasts marker genes since they did not appear in our list of differentially regulated 
genes.  We do show that deletion of HDAC4 in osteoclasts affected genes that participate 
in many regulatory pathways in osteoclasts which suggests that HDAC4 may be involved 
in the regulation of gene expression important in other phases of osteoclast life cycle. 
However, it should be noted that our RNA-sequence data focused only on day 2 of 
differentiation, maybe if we looked at different day of differentiation we might have 
identified more differentially expressed genes or even osteoclast marker genes that HDAC4 
targets, hence, have a more global picture of HDAC4 biological role(s) and activities. We 
need to critically consider these non-histone targets of HDAC4, which contains many 
important regulatory proteins. Future studies of these targets will expand our knowledge 
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Chapter 6: Conclusions and Future Directions 
6.1 Conclusions 
Since their development, HDAC inhibitors (HDIs) have been accepted as promising 
drugs for the treatment of several diseases such as cancers (221, 245) and epilepsy (246). 
The majority of research into these drugs have involved broad spectrum acting HDIs which 
are not only non-HDAC class specific but also are non-member specific. It should be noted 
that broad spectrum HDIs are more effective in hematologic cancers than in solid cancers 
(247), suggesting that these HDIs may also be effective in other hematopoietic cell types 
such as osteoclasts to affect bone resorption and bone mass.  
It has been reported in several human studies that long term use of broad HDI such as 
valproate causes decrease in bone mineral density (BMD) (157, 159). In vitro studies using 
broad spectrum HDIs such as trichostatin A (TSA) and sodium butyrate (NaB) have shown 
to promote osteoblast differentiation while suppressing osteoclast differentiation, 
suggesting bone protective effect (141, 248). The reason for this observation is that 
individual class members have been shown to play opposite roles during bone remodeling. 
For example, it has been observed that osteoclastogenesis is inhibited by HDAC7 (40, 140), 
while enhanced by HDAC3 (140). Of note, to date most of the studies of HDAC’s 
regulation of bone have been conducted using in vitro cultures and broad-spectrum HDIs. 
These approaches may distort the specific HDACs functions as a result of multitarget 
inhibition, pharmacologic effects, and thus making it impossible to determine the specific 
physiological role of each HDACs in skeletal maintenance.  
The particular focus of this research involved identify the in vivo role of HDAC4 in 
osteoclast differentiation and function. The hypothesis that defined this body of work is 
Hdac4 regulates osteoclast differentiation and function through its interactions with key 
osteoclast proteins. This hypothesis was confirmed by the results of the study. 
The skeleton is a metabolically active and regenerative organ. Dynamic and response 
nature of bone during bone remodeling process requires temporal changes in gene 
expression within the cells (osteoblasts, osteoclasts and osteocytes) required for 
maintenance of skeletal mass (as reviewed in (6)). Regulation of gene expression is in part 
accomplished by histone deacetylases which are intracellular enzymes that induce 
chromatin condensation and transcriptional repression. Key roles of HDACs in 
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chondrocytes and osteoblast differentiation and functions have been shown through in vivo 
and in vitro models, but in comparison little is known about the roles of HDACs in 
osteoclasts. Recent research observations suggest that clinically usage of broad-spectrum 
HDI to treat diseases such as epilepsy and cancer, may affect the bone cell population 
responsible for bone mass. The aim of Chapter 2 (96) was to highlight the progress that has 
been made in understanding how individual HDACs and their targets contribute to 
osteoclast biology and skeletal maintenance. Even though some aspects of the functions of 
individual HDACs in osteoclasts have been elucidated, a more comprehensive in vivo data 
are required to deduce potential therapeutic benefits. Conditionally knockout mouse 
models can provide knowledge about specific targets and help define the roles of each 
HDACs in osteoclasts.   
In order to understand the roles of individual HDACs in osteoclastogenesis, the gene 
expression patterns and the effects of suppressing individual class II (HDAC4, 5, 6, 9 and 
10) and class IV (HDAC11) throughout osteoclast formation was assessed in vitro (Chapter 
3 (42)). mRNA and protein expression of HDACs in both classes were found to be 
differentially expressed during osteoclast differentiation. Furthermore, suppression of class 
II and IV HDACs resulted in accelerated osteoclast differentiation. Recent in vivo and in 
vitro studies have also revealed that both HDAC7 and HDAC9 suppress osteoclast 
differentiation (39-41, 140). These findings and our results suggest that several HDACs 
regulate osteoclastogenesis and further studies are needed to determine the specific roles 
each HDAC plays in this process. Studies using conditional knockout mouse models will 
be important in elucidating which HDACs are physiologically important regulators of 
osteoclastogenesis and bone resorption. These attempts will eventually facilitate the 
development of class/member-specific HDI which not only will give therapeutic benefits 
but also minimize bone loss side effects. In designing these HDI, it is important to keep in 
mind the species of the cells studied as there may be differences in human and mice models. 
Overall the results obtained using a shRNA assay demonstrates the importance of 
HDACs in osteoclast regulation. The in vivo role of many HDACs, their intercellular 
mechanism (s), and targets involved in osteoclast differentiation and function are still 
unknown.   
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A key finding of the in vitro study described in Chapter 3 (42) was that suppression of 
HDAC4 accelerated osteoclast differentiation. Importantly, mRNA expression of key 
osteoclast genes including c-Fos, Nfatc1, Dc-stamp and Cathepsin K, which are important 
for differentiation were found to be upregulated. This suggested that HDC4 has a role in 
the regulation of osteoclast formation and activity. In regards to other aspects of bone 
development, HDAC4 has been shown to be critical in chondrocyte and osteoblast 
differentiation by interacting with RUNX2, a master transcription factor of osteoblasts and 
inhibiting its function (43). In vivo, HDAC4 null mice have been shown to have severe 
bone malformations due to chondrocyte hypertropy and do not survive weaning age (43). 
To date, there had been no reports on the in vivo role of HDAC4 in osteoclast formation 
and activity.  
Based on the promising in vitro effects of HDC4 suppression (Chapter 3), studies were 
carried out to assess the in vivo role of HDC4 in osteoclasts (Chapter 4). It was 
hypothesized that mice null for HDAC4 expression in osteoclasts would have enhanced 
osteoclast formation, resulting in an osteopenic phenotype. Interestingly, micro CT (µCT 
) analysis revealed that 4cKO mice exhibited an increase bone mass phenotype 
(osteopetrosis). This increase bone mass was due to increased bone volume/tissue volume 
ratio (BV/TV) and trabecular number (Tb.N). This observation was surprisingly since it 
has been shown that other class IIa HDACs, HDAC7 and HDAC9 have osteopenic 
phenotype. This finding suggested that there is no redundancy of individual HDACs 
required for osteoclast differentiation and function. Additionally, 4cKO osteoclasts had 
decreased bone resorption both in vivo and in vitro with no effect on osteoclast 
differentiation. These results were not consistent with the in vitro shRNA findings (Chapter 
3) which showed that suppression of HDAC4 increased demineralization activity (bone 
resorption) and suppressed osteoclast differentiation. The discrepancy in the results could 
be due to the fact that the HDAC4 inhibition is dependent upon the stage of development 
and the timing of shRNA treatment, although further investigations are needed.  
In an attempt to elucidate the mechanism by which HDAC4 increases the bone-
resorbing activity of osteoclasts, we demonstrated that the activity of MAPK, in particular 
ERK 1/2, was decreased in 4cKO osteoclasts. Many previous studies have reported the role 
of ERK 1/2 in osteoclasts. A recent study reported that ERK1 positively regulates 
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osteoclast function (232), suggesting that the decreased bone-resorbing activity of 4cKO 
osteoclasts is, at least in part, caused by the decreased activity of ERK 1/2. We speculated 
that the decreased in bone-resorbing activity observed in 4cKO osteoclasts was caused by 
the defects in osteoclasts adhesion and migration. As we anticipate, 4cKO pre-osteoclasts 
migrated at a lower number in response to M-CSF and fewer of them adhered to vitronectin 
during stimulation with M-CSF. This suggested that the decreased bone resorption activity 
in 4cKO osteoclasts may be caused by the reduction of both adhesion and migration. 
Prompted by this observation, we assess the role of HDAC4 during osteoclast attachment 
by analyzing avb3-dependent activation of two kinases, namely c-Src and ERK 1/2, in 
4cKO osteoclasts.  The finding that both of these signals were reduced in 4cKO osteoclasts 
suggested that HDAC4 may regulate avb3 integrin activity, further studies are needed to 
delineate this.  
The study described in Chapter 4 is the first to demonstrate the in vivo role of HDAC4 
in osteoclastic bone resorption. The results from this mouse model suggest that HDAC4 
plays a separate and pivotal role in osteoclast function, and has the potential to be used for 
the development of member-specific HDAC inhibitor to directly target bone mass increase 
disorders which activities of osteoclasts are decreased. 
Given the close similarity in shared sequence between class IIa HDACs, HDAC4, 5, 
and 7, global changes in gene expression in 4cKO osteoclasts was examined using RNA-
sequence in Chapter 5. RNA-sequence data showed 4cKO osteoclasts had 745 
differentially expressed genes which participated in various regulatory pathways including 
cell adhesion in osteoclasts. This was consistent with the observation that HDAC4 is 
involved in osteoclast adhesion in vitro (Chapter 4). Overall RNA-sequence results suggest 
that HDAC4 biological activities in osteoclasts is vast. In-depth investigation of the RNA-
sequence data will reveal novel mechanism(s) by which HDAC4 is involved and this will 
give further understanding of the overall effects on osteoclasts.  
 
In summary, this thesis confirms that HDAC4 positively regulates the bone-resorbing 
function of osteoclasts through its interactions with key osteoclast proteins. Using both in 
vitro and in vivo strategies, I have identified HDC4 as an important and physiological 
relevant positive regulator of osteoclastic bone resorption. The results of the studies 
  94 
 
 
described in this thesis shed light onto the mechanism of HDAC4 in regulating osteoclastic 
bone resorption as summarized in Figure 33. ERK1/2 and c-Src were identified as key 
osteoclasts proteins that are affected with loss of HDAC4 expression. Further studies of 
targets of HDC4 are required to fully understand the mechanisms of transcriptional 
regulation of osteoclast function. Knowledge from the targets of HDAC4 regulation will 
improve our understanding of HDAC4 biological activity. Future investigations may also 
give insight for development of highly selective pharmacologic drugs which are HDAC4 
based for treatment of diseases. This is the first in vivo study that reports critical function 
of HDAC4 in osteoclast bone resorption. 
 
6.2. Future Directions 
Overall the studies described in this thesis show that HDAC4 play a key role in 
osteoclast function. An interesting finding was that deletion of Hdac4 in osteoclasts results 
in an increase bone mass phenotype (osteopetrosis) in mice. This result highlighted that 
class IIa HDACs regulate targets in a non-redundant manner since two other class IIa 
members HDAC7 and HDAC9 have opposite phenotypes. Studies of the HDACs 
regulation of osteoclasts are complicated by the lack of more comprehensive in vivo data. 
This data can help with understanding of specific role(s) of each HDACs members in bone 
remodeling. For example, some important observations can be made from the studies 
described in this thesis. Both in vivo and in vitro, deletion of Hdac4 in osteoclasts affected 
osteoclast bone resorption. Deletion of Hdac4 did not affect osteoclast size and number in 
vitro but did measure larger osteoclasts in vivo. 
 
A number of key future directions can be identified by the work presented in this thesis: 
• More studies are necessary to assess HDAC4 other important substrates such as 
non-histone targets during osteoclastogenesis to determine if they play a role in 
HDAC4 biological activity and function in osteoclasts. 
• Appropriate acetylation assays need to be developed/utilized to determine which 
c-Src protein domain is a potential HDAC4 acetylation site 
• It would be interesting to determine if the deacetylase activity is dispensable to 
HDAC4 phenotype in osteoclasts 
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• Studies are needed to investigate the role of HDAC4 in adult skeleton and aging 
to determine if deletion of Hdac4 affect young and adult skeleton differently 
• It would be interesting to determine whether RANKL signaling regulates 
phosphorylation of HDAC4 in osteoclasts 
• It is important to determine the effects of deleting Hdac4 in osteoclasts on other 
bone remodeling cells such as osteoblasts and osteocytes. 
• There is a need to determine HDAC4’s unique as well as redundant role(s) in 
bone development 
 
The results of this thesis have demonstrated the significant function of HDAC4 in 
regulating osteoclast bone resorption. Even though our knowledge of HDACs roles in 
osteoclastogenesis and bone resorption is limited, the data presented here, and work of 
others, demonstrates that regulation of osteoclasts by HDACs is important for bone 
remodeling, hence skeletal maintenance. This level of understanding will result in the 
development of therapy that are class/member specific HDI. This may also open an 














  96 
 
 
Bibliography:   
1. Hadjidakis DJ, Androulakis, II. Bone remodeling. Ann N Y Acad Sci. 
2006;1092:385-96. Epub 2007/02/20. doi: 10.1196/annals.1365.035. PubMed PMID: 
17308163. 
2. Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic 
drug effects. Bonekey Rep. 2013;2:447. Epub 2014/02/07. doi: 
10.1038/bonekey.2013.181. PubMed PMID: 24501681; PMCID: PMC3909232. 
3. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and 
implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 
2000;21(2):115-37. Epub 2000/04/27. doi: 10.1210/edrv.21.2.0395. PubMed PMID: 
10782361. 
4. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal 
framework for signal traffic in adult human bone. J Cell Biochem. 1994;55(3):273-86. 
Epub 1994/07/01. doi: 10.1002/jcb.240550303. PubMed PMID: 7962158. 
5. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local 
communication on and within bone controls bone remodeling. Bone. 2009;44(6):1026-
33. Epub 2009/04/07. doi: 10.1016/j.bone.2009.03.671. PubMed PMID: 19345750. 
6. McGee-Lawrence ME, Westendorf JJ. Histone deacetylases in skeletal 
development and bone mass maintenance. Gene. 2011;474(1-2):1-11. Epub 2010/12/28. 
doi: 10.1016/j.gene.2010.12.003. PubMed PMID: 21185361; PMCID: PMC3046313. 
7. Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. 
Annu Rev Cell Dev Biol. 2009;25:629-48. Epub 2009/07/07. doi: 
10.1146/annurev.cellbio.042308.113308. PubMed PMID: 19575648. 
8. Neve A, Corrado A, Cantatore FP. Osteocytes: central conductors of bone biology 
in normal and pathological conditions. Acta Physiol (Oxf). 2012;204(3):317-30. Epub 
2011/11/22. doi: 10.1111/j.1748-1716.2011.02385.x. PubMed PMID: 22099166. 
9. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol. 
2008;3:457-84. Epub 2007/11/28. doi: 10.1146/annurev.pathmechdis.3.121806.151431. 
PubMed PMID: 18039135. 
10. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-8. 
doi: 8789 [pii]. 
11. Nakamura I, Duong LT, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 
integrins in osteoclast function. J Bone Miner Metab. 2007;25(6):337-44. Epub 
2007/10/31. doi: 10.1007/s00774-007-0773-9. PubMed PMID: 17968485. 
12. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, 
Ross FP, Hynes RO, Teitelbaum SL. Mice lacking beta3 integrins are osteosclerotic 
because of dysfunctional osteoclasts. J Clin Invest. 2000;105(4):433-40. Epub 
2000/02/23. doi: 10.1172/JCI8905. PubMed PMID: 10683372; PMCID: PMC289172. 
13. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a 
polarized vacuolar proton pump. Science. 1989;245(4920):855-7. Epub 1989/08/25. 
doi: 10.1126/science.2528207. PubMed PMID: 2528207. 
14. Teti A, Blair HC, Teitelbaum SL, Kahn AJ, Koziol C, Konsek J, Zambonin-Zallone 
A, Schlesinger PH. Cytoplasmic pH regulation and chloride/bicarbonate exchange in 
avian osteoclasts. J Clin Invest. 1989;83(1):227-33. Epub 1989/01/01. doi: 
10.1172/JCI113863. PubMed PMID: 2910910; PMCID: PMC303666. 
15. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake 
F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I. Cathepsin K knockout mice 
develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J 
Bone Miner Res. 1999;14(10):1654-63. Epub 1999/09/22. doi: 
10.1359/jbmr.1999.14.10.1654. PubMed PMID: 10491212. 
  97 
 
 
16. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing 
osteoclasts. Science. 1997;276(5310):266-9. Epub 1997/04/11. doi: 
10.1126/science.276.5310.266. PubMed PMID: 9092478. 
17. Ross FP, Christiano AM. Nothing but skin and bone. J Clin Invest. 
2006;116(5):1140-9. Epub 2006/05/04. doi: 10.1172/JCI28605. PubMed PMID: 
16670754; PMCID: PMC1451223. 
18. Henriksen K, Karsdal MA, Martin TJ. Osteoclast-derived coupling factors in bone 
remodeling. Calcif Tissue Int. 2014;94(1):88-97. Epub 2013/05/24. doi: 
10.1007/s00223-013-9741-7. PubMed PMID: 23700149. 
19. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. 
Nature. 2003;423(6937):337-42. doi: 10.1038/nature01658. PubMed PMID: 12748652. 
20. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, 
Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, 
Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and 
lymph node development. Genes Dev. 1999;13(18):2412-24. Epub 1999/09/29. doi: 
10.1101/gad.13.18.2412. PubMed PMID: 10500098; PMCID: PMC317030. 
21. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, 
Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, 
Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, 
lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-
23. Epub 1999/02/09. doi: 10.1038/16852. PubMed PMID: 9950424. 
22. Cheng X, Kinosaki M, Murali R, Greene MI. The TNF receptor superfamily: role 
in immune inflammation and bone formation. Immunol Res. 2003;27(2-3):287-94. 
Epub 2003/07/15. doi: 10.1385/IR:27:2-3:287. PubMed PMID: 12857975. 
23. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, Jr., Ahmed-Ansari A, Sell KW, 
Pollard JW, Stanley ER. Total absence of colony-stimulating factor 1 in the macrophage-
deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87(12):4828-32. 
Epub 1990/06/01. doi: 10.1073/pnas.87.12.4828. PubMed PMID: 2191302; PMCID: 
PMC54211. 
24. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, 
Stanley ER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene 
results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive 
progenitor cell frequencies, and reproductive defects. Blood. 2002;99(1):111-20. Epub 
2002/01/05. doi: 10.1182/blood.v99.1.111. PubMed PMID: 11756160. 
25. Sherr CJ, Matsushime H, Roussel MF. Regulation of CYL/cyclin D genes by 
colony-stimulating factor 1. Ciba Found Symp. 1992;170:209-19; discussion 19-26. Epub 
1992/01/01. PubMed PMID: 1483347. 
26. Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, Yeung YG. Biology 
and action of colony--stimulating factor-1. Mol Reprod Dev. 1997;46(1):4-10. Epub 
1997/01/01. doi: 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V. 
PubMed PMID: 8981357. 
27. Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: 
partners in osteoclast biology. Immunol Rev. 2005;208:88-105. Epub 2005/11/30. doi: 
10.1111/j.0105-2896.2005.00331.x. PubMed PMID: 16313343. 
28. Ross FP. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann N 
Y Acad Sci. 2006;1068:110-6. Epub 2006/07/13. doi: 10.1196/annals.1346.014. PubMed 
PMID: 16831911. 
29. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. c-Fms and the 
alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest. 
2003;111(5):749-58. Epub 2003/03/06. doi: 10.1172/JCI16924. PubMed PMID: 
12618529; PMCID: PMC151897. 
  98 
 
 
30. Zou W, Reeve JL, Liu Y, Teitelbaum SL, Ross FP. DAP12 couples c-Fms 
activation to the osteoclast cytoskeleton by recruitment of Syk. Mol Cell. 
2008;31(3):422-31. Epub 2008/08/12. doi: 10.1016/j.molcel.2008.06.023. PubMed 
PMID: 18691974; PMCID: PMC2584874. 
31. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone 
deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 
2003;370(Pt 3):737-49. doi: 10.1042/BJ20021321. PubMed PMID: 12429021; PMCID: 
PMC1223209. 
32. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone 
deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell 
Res. 2007;17(3):195-211. Epub 2007/02/28. doi: 10.1038/sj.cr.7310149. PubMed PMID: 
17325692. 
33. Vaquero A, Sternglanz R, Reinberg D. NAD+-dependent deacetylation of H4 
lysine 16 by class III HDACs. Oncogene. 2007;26(37):5505-20. Epub 2007/08/19. doi: 
10.1038/sj.onc.1210617. PubMed PMID: 17694090. 
34. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and 
yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3):206-18. Epub 2008/02/23. 
doi: 10.1038/nrm2346. PubMed PMID: 18292778; PMCID: PMC2667380. 
35. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv 
Cancer Res. 2004;91:137-68. doi: 10.1016/S0065-230X(04)91004-4. PubMed PMID: 
15327890. 
36. Bradley EW, Carpio LR, van Wijnen AJ, McGee-Lawrence ME, Westendorf JJ. 
Histone Deacetylases in Bone Development and Skeletal Disorders. Physiol Rev. 
2015;95(4):1359-81. doi: 10.1152/physrev.00004.2015. PubMed PMID: 26378079; 
PMCID: PMC4600951. 
37. Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: conducting 
development and differentiation. Int J Dev Biol. 2009;53(2-3):291-301. Epub 
2009/05/05. doi: 10.1387/ijdb.082698mm. PubMed PMID: 19412888. 
38. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced 
expression of class II histone deacetylase genes is associated with poor prognosis in lung 
cancer patients. Int J Cancer. 2004;112(1):26-32. Epub 2004/08/12. doi: 
10.1002/ijc.20395. PubMed PMID: 15305372. 
39. Stemig M, Astelford K, Emery A, Cho JJ, Allen B, Huang TH, Gopalakrishnan R, 
Mansky KC, Jensen ED. Deletion of histone deacetylase 7 in osteoclasts decreases bone 
mass in mice by interactions with MITF. PLoS One. 2015;10(4):e0123843. doi: 
10.1371/journal.pone.0123843. PubMed PMID: 25875108; PMCID: PMC4398560. 
40. Jin Z, Wei W, Dechow PC, Wan Y. HDAC7 inhibits osteoclastogenesis by 
reversing RANKL-triggered beta-catenin switch. Mol Endocrinol. 2013;27(2):325-35. 
doi: 10.1210/me.2012-1302. PubMed PMID: 23204328; PMCID: PMC3683803. 
41. Jin Z, Wei W, Huynh H, Wan Y. HDAC9 Inhibits Osteoclastogenesis via Mutual 
Suppression of PPARgamma/RANKL Signaling. Mol Endocrinol. 2015;29(5):730-8. doi: 
10.1210/me.2014-1365. PubMed PMID: 25793404; PMCID: PMC4415206. 
42. Blixt NC, Faulkner BK, Astleford K, Lelich R, Schering J, Spencer E, 
Gopalakrishnan R, Jensen ED, Mansky KC. Class II and IV HDACs function as inhibitors 
of osteoclast differentiation. PLoS One. 2017;12(9):e0185441. Epub 2017/09/28. doi: 
10.1371/journal.pone.0185441. PubMed PMID: 28953929; PMCID: PMC5617211. 
43. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, 
Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 
controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004;119(4):555-66. Epub 
2004/11/13. doi: 10.1016/j.cell.2004.10.024. PubMed PMID: 15537544. 
  99 
 
 
44. Haberland M, Montgomery RL, Olson EN. The many roles of histone 
deacetylases in development and physiology: implications for disease and therapy. Nat 
Rev Genet. 2009;10(1):32-42. doi: 10.1038/nrg2485. PubMed PMID: 19065135; PMCID: 
PMC3215088. 
45. Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th'ng J, Han 
J, Yang XJ. HDAC4, a human histone deacetylase related to yeast HDA1, is a 
transcriptional corepressor. Mol Cell Biol. 1999;19(11):7816-27. Epub 1999/10/19. doi: 
10.1128/mcb.19.11.7816. PubMed PMID: 10523670; PMCID: PMC84849. 
46. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone 
remodeling. J Biol Chem. 2010;285(33):25103-8. Epub 2010/05/27. doi: 
10.1074/jbc.R109.041087. PubMed PMID: 20501658; PMCID: PMC2919071. 
47. Khosla S, Westendorf JJ, Modder UI. Concise review: Insights from normal bone 
remodeling and stem cell-based therapies for bone repair. Stem Cells. 2010;28(12):2124-
8. Epub 2010/10/21. doi: 10.1002/stem.546. PubMed PMID: 20960512; PMCID: 
PMC3125598. 
48. Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. Bone remodelling 
at a glance. J Cell Sci. 2011;124(Pt 7):991-8. Epub 2011/03/16. doi: 10.1242/jcs.063032. 
PubMed PMID: 21402872. 
49. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 
2011;6:121-45. Epub 2010/10/13. doi: 10.1146/annurev-pathol-011110-130203. PubMed 
PMID: 20936937; PMCID: PMC3571087. 
50. Bi H, Chen X, Gao S, Yu X, Xiao J, Zhang B, Liu X, Dai M. Key Triggers of 
Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review. 
Front Med (Lausanne). 2017;4:234. Epub 2018/01/13. doi: 10.3389/fmed.2017.00234. 
PubMed PMID: 29326938; PMCID: PMC5742334. 
51. Novack DV, Mbalaviele G. Osteoclasts-Key Players in Skeletal Health and 
Disease. Microbiol Spectr. 2016;4(3). doi: 10.1128/microbiolspec.MCHD-0011-2015. 
PubMed PMID: 27337470; PMCID: PMC4920143. 
52. Mellis DJ, Itzstein C, Helfrich MH, Crockett JC. The skeleton: a multi-functional 
complex organ: the role of key signalling pathways in osteoclast differentiation and in 
bone resorption. J Endocrinol. 2011;211(2):131-43. doi: 10.1530/JOE-11-0212. PubMed 
PMID: 21903860. 
53. Wade PA. Transcriptional control at regulatory checkpoints by histone 
deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 
2001;10(7):693-8. Epub 2001/03/21. PubMed PMID: 11257101. 
54. Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular 
Diseases. Chonnam Med J. 2016;52(1):1-11. Epub 2016/02/13. doi: 
10.4068/cmj.2016.52.1.1. PubMed PMID: 26865995; PMCID: PMC4742605. 
55. Ikeda K, Takeshita S. The role of osteoclast differentiation and function in 
skeletal homeostasis. J Biochem. 2016;159(1):1-8. Epub 2015/11/06. doi: 
10.1093/jb/mvv112. PubMed PMID: 26538571; PMCID: PMC4882648. 
56. Feng X, Teitelbaum SL. Osteoclasts: New Insights. Bone Res. 2013;1(1):11-26. 
Epub 2013/03/01. doi: 10.4248/BR201301003. PubMed PMID: 26273491; PMCID: 
PMC4472093. 
57. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-
embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-41. doi: 
10.1038/nm.2448. PubMed PMID: 21909103; PMCID: PMC3192296. 
58. Vaananen HK, Laitala-Leinonen T. Osteoclast lineage and function. Arch 
Biochem Biophys. 2008;473(2):132-8. doi: 10.1016/j.abb.2008.03.037. PubMed PMID: 
18424258. 
  100 
 
 
59. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor 
PU.1 in the development of multiple hematopoietic lineages. Science. 
1994;265(5178):1573-7. Epub 1994/09/09. PubMed PMID: 8079170. 
60. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, 
Teitelbaum SL. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. 
Nature. 1997;386(6620):81-4. Epub 1997/03/06. doi: 10.1038/386081a0. PubMed 
PMID: 9052784. 
61. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, 
Hisatake K, Nogi Y. Essential role of p38 mitogen-activated protein kinase in cathepsin K 
gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J 
Biol Chem. 2004;279(44):45969-79. Epub 2004/08/12. doi: 10.1074/jbc.M408795200. 
PubMed PMID: 15304486. 
62. DeKoter RP, Walsh JC, Singh H. PU.1 regulates both cytokine-dependent 
proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J. 
1998;17(15):4456-68. Epub 1998/08/04. doi: 10.1093/emboj/17.15.4456. PubMed 
PMID: 9687512; PMCID: PMC1170777. 
63. Kwon OH, Lee CK, Lee YI, Paik SG, Lee HJ. The hematopoietic transcription 
factor PU.1 regulates RANK gene expression in myeloid progenitors. Biochem Biophys 
Res Commun. 2005;335(2):437-46. Epub 2005/08/09. doi: 
10.1016/j.bbrc.2005.07.092. PubMed PMID: 16083856. 
64. So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, Choi Y, Kim N. 
Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte 
receptor osteoclast-associated receptor gene expression. J Biol Chem. 
2003;278(26):24209-16. Epub 2003/04/16. doi: 10.1074/jbc.M302940200. PubMed 
PMID: 12695521. 
65. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of 
nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor 
osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 
during osteoclastogenesis. J Biol Chem. 2005;280(38):32905-13. Epub 2005/07/28. 
doi: 10.1074/jbc.M505820200. PubMed PMID: 16046394. 
66. Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, 
Jenkins NA, Arnheiter H. Mutations at the mouse microphthalmia locus are associated 
with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 
1993;74(2):395-404. Epub 1993/07/30. PubMed PMID: 8343963. 
67. Hughes MJ, Lingrel JB, Krakowsky JM, Anderson KP. A helix-loop-helix 
transcription factor-like gene is located at the mi locus. J Biol Chem. 
1993;268(28):20687-90. Epub 1993/10/05. PubMed PMID: 8407885. 
68. Mansky KC, Sankar U, Han J, Ostrowski MC. Microphthalmia transcription 
factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa 
B ligand signaling. J Biol Chem. 2002;277(13):11077-83. doi: 10.1074/jbc.M111696200. 
PubMed PMID: 11792706. 
69. Marks SC, Jr., Walker DG. The hematogenous origin of osteoclasts: experimental 
evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige 
mouse donors. Am J Anat. 1981;161(1):1-10. Epub 1981/05/01. doi: 
10.1002/aja.1001610102. PubMed PMID: 6264778. 
70. Glowacki J, Cox KA, Wilcon S. Impaired osteoclast differentiation in 
subcutaneous implants of bone particles in osteopetrotic mutants. Bone Miner. 
1989;5(3):271-8. Epub 1989/03/01. PubMed PMID: 2655776. 
71. Ishii J, Kitazawa R, Mori K, McHugh KP, Morii E, Kondo T, Kitazawa S. 
Lipopolysaccharide suppresses RANK gene expression in macrophages by down-
  101 
 
 
regulating PU.1 and MITF. J Cell Biochem. 2008;105(3):896-904. Epub 2008/09/02. 
doi: 10.1002/jcb.21886. PubMed PMID: 18759249. 
72. Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, Hume DA, 
Ostrowski MC. The microphthalmia transcription factor regulates expression of the 
tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J 
Bone Miner Res. 2000;15(3):451-60. Epub 2000/04/06. doi: 
10.1359/jbmr.2000.15.3.451. PubMed PMID: 10750559. 
73. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE. 
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the 
microphthalmia transcription factor family. Proc Natl Acad Sci U S A. 2001;98(10):5798-
803. Epub 2001/05/02. doi: 10.1073/pnas.091479298. PubMed PMID: 11331755; 
PMCID: PMC33293. 
74. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and 
regulation. Biochem J. 2002;365(Pt 3):561-75. Epub 2002/05/15. doi: 
10.1042/BJ20020508. PubMed PMID: 12006103; PMCID: PMC1222736. 
75. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription 
activation function of C/EBPalpha is required for induction of granulocytic 
differentiation. Blood. 2003;102(4):1267-75. Epub 2003/04/19. doi: 10.1182/blood-
2003-02-0477. PubMed PMID: 12702500. 
76. Chen W, Zhu G, Hao L, Wu M, Ci H, Li YP. C/EBPalpha regulates osteoclast 
lineage commitment. Proc Natl Acad Sci U S A. 2013;110(18):7294-9. Epub 2013/04/13. 
doi: 10.1073/pnas.1211383110. PubMed PMID: 23580622; PMCID: PMC3645589. 
77. Jules J, Li YP, Chen W. C/EBPalpha and PU.1 exhibit different responses to 
RANK signaling for osteoclastogenesis. Bone. 2018;107:104-14. Epub 2017/10/17. doi: 
10.1016/j.bone.2017.05.009. PubMed PMID: 29032174; PMCID: PMC6240464. 
78. Chen W, Zhu G, Tang J, Zhou HD, Li YP. C/ebpalpha controls osteoclast terminal 
differentiation, activation, function, and postnatal bone homeostasis through direct 
regulation of Nfatc1. J Pathol. 2018;244(3):271-82. Epub 2017/10/31. doi: 
10.1002/path.5001. PubMed PMID: 29083488; PMCID: PMC6240466. 
79. Chen W, Zhu G, Jules J, Nguyen D, Li YP. Monocyte-Specific Knockout of 
C/ebpalpha Results in Osteopetrosis Phenotype, Blocks Bone Loss in Ovariectomized 
Mice, and Reveals an Important Function of C/ebpalpha in Osteoclast Differentiation 
and Function. J Bone Miner Res. 2018;33(4):691-703. Epub 2017/11/18. doi: 
10.1002/jbmr.3342. PubMed PMID: 29149533; PMCID: PMC6240465. 
80. Jules J, Chen W, Feng X, Li YP. CCAAT/Enhancer-binding Protein alpha 
(C/EBPalpha) Is Important for Osteoclast Differentiation and Activity. J Biol Chem. 
2016;291(31):16390-403. Epub 2016/04/30. doi: 10.1074/jbc.M115.674598. PubMed 
PMID: 27129246; PMCID: PMC4965585. 
81. Pon JR, Marra MA. MEF2 transcription factors: developmental regulators and 
emerging cancer genes. Oncotarget. 2016;7(3):2297-312. doi: 10.18632/oncotarget.6223. 
PubMed PMID: 26506234; PMCID: PMC4823036. 
82. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental 
programs. Development. 2007;134(23):4131-40. Epub 2007/10/26. doi: 
10.1242/dev.008367. PubMed PMID: 17959722. 
83. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell 
division, differentiation and death. Trends Biochem Sci. 2002;27(1):40-7. Epub 
2002/02/14. PubMed PMID: 11796223. 
84. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. 
Bone and haematopoietic defects in mice lacking c-fos. Nature. 1992;360(6406):741-5. 
Epub 1992/12/24. doi: 10.1038/360741a0. PubMed PMID: 1465144. 
  102 
 
 
85. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe 
M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and 
activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in 
terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901. Epub 2002/12/14. 
PubMed PMID: 12479813. 
86. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, 
Wagner EF. c-Fos: a key regulator of osteoclast-macrophage lineage determination and 
bone remodeling. Science. 1994;266(5184):443-8. PubMed PMID: 7939685. 
87. Soysa NS, Alles N. NF-kappaB functions in osteoclasts. Biochem Biophys Res 
Commun. 2009;378(1):1-5. Epub 2008/11/11. doi: 10.1016/j.bbrc.2008.10.146. PubMed 
PMID: 18992710. 
88. Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-kappaB-Mediated Regulation of 
Osteoclastogenesis. Endocrinol Metab (Seoul). 2015;30(1):35-44. Epub 2015/04/02. doi: 
10.3803/EnM.2015.30.1.35. PubMed PMID: 25827455; PMCID: PMC4384681. 
89. Novack DV. Role of NF-kappaB in the skeleton. Cell Res. 2011;21(1):169-82. Epub 
2010/11/17. doi: 10.1038/cr.2010.159. PubMed PMID: 21079651; PMCID: PMC3193402. 
90. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner 
EF, Noda M, Matsuo K, Xing L, Boyce BF. NF-kappaB p50 and p52 regulate receptor 
activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast 
precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 
2007;282(25):18245-53. Epub 2007/05/09. doi: 10.1074/jbc.M610701200. PubMed 
PMID: 17485464. 
91. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation 
and function. Annu Rev Immunol. 1997;15:707-47. Epub 1997/01/01. doi: 
10.1146/annurev.immunol.15.1.707. PubMed PMID: 9143705. 
92. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano 
H, Aburatani H, Ishikawa H, Wagner EF. Nuclear factor of activated T-cells (NFAT) 
rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 
2004;279(25):26475-80. Epub 2004/04/10. doi: 10.1074/jbc.M313973200. PubMed 
PMID: 15073183. 
93. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N. Regulatory mechanism of 
NFATc1 in RANKL-induced osteoclast activation. FEBS Lett. 2009;583(14):2435-40. 
Epub 2009/07/07. doi: 10.1016/j.febslet.2009.06.047. PubMed PMID: 19576893. 
94. Kim JH, Kim K, Jin HM, Song I, Youn BU, Lee SH, Choi Y, Kim N. Negative 
feedback control of osteoclast formation through ubiquitin-mediated down-regulation of 
NFATc1. J Biol Chem. 2010;285(8):5224-31. doi: 10.1074/jbc.M109.042812. PubMed 
PMID: 20037154; PMCID: PMC2820750. 
95. Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, Ostrowski MC. MITF 
and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast 
differentiation. J Biol Chem. 2007;282(21):15921-9. doi: 10.1074/jbc.M609723200. 
PubMed PMID: 17403683. 
96. Faulkner B, Astleford K, Mansky KC. Regulation of Osteoclast Differentiation and 
Skeletal Maintenance by Histone Deacetylases. Molecules. 2019;24(7). Epub 
2019/04/10. doi: 10.3390/molecules24071355. PubMed PMID: 30959867; PMCID: 
PMC6479495. 
97. Bertos NR, Wang AH, Yang XJ. Class II histone deacetylases: structure, function, 
and regulation. Biochem Cell Biol. 2001;79(3):243-52. PubMed PMID: 11467738. 
98. Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: regulating the 
regulators. Oncogene. 2007;26(37):5450-67. doi: 10.1038/sj.onc.1210613. PubMed 
PMID: 17694086. 
  103 
 
 
99. Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases 
(HDACs)-Sirtuins. Transl Oncogenomics. 2008;3:53-65. Epub 2008/01/01. PubMed 
PMID: 21566744; PMCID: PMC3022360. 
100. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization 
of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 
2002;277(28):25748-55. doi: 10.1074/jbc.M111871200. PubMed PMID: 11948178. 
101. Singh N, Gupta M, Trivedi CM, Singh MK, Li L, Epstein JA. Murine craniofacial 
development requires Hdac3-mediated repression of Msx gene expression. Dev Biol. 
2013;377(2):333-44. Epub 2013/03/20. doi: 10.1016/j.ydbio.2013.03.008. PubMed 
PMID: 23506836; PMCID: PMC3652235. 
102. Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of 
skull morphogenesis by histone deacetylase 8. Genes Dev. 2009;23(14):1625-30. Epub 
2009/07/17. doi: 10.1101/gad.1809209. PubMed PMID: 19605684; PMCID: 
PMC2714711. 
103. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, 
Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of 
histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 
2002;21(11):2672-81. Epub 2002/05/29. doi: 10.1093/emboj/21.11.2672. PubMed 
PMID: 12032080; PMCID: PMC126040. 
104. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 
maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 
2006;126(2):321-34. Epub 2006/07/29. doi: 10.1016/j.cell.2006.05.040. PubMed 
PMID: 16873063. 
105. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW. 
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA 
damage control. Mol Cell. 2008;30(1):61-72. Epub 2008/04/15. doi: 
10.1016/j.molcel.2008.02.030. PubMed PMID: 18406327; PMCID: PMC2373760. 
106. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, 
Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber PJ, Epstein JA. Hdac2 
regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med. 
2007;13(3):324-31. Epub 2007/02/27. doi: 10.1038/nm1552. PubMed PMID: 17322895. 
107. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone 
deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and 
play redundant roles in heart development. Mol Cell Biol. 2004;24(19):8467-76. doi: 
10.1128/MCB.24.19.8467-8476.2004. PubMed PMID: 15367668; PMCID: PMC516756. 
108. Razidlo DF, Whitney TJ, Casper ME, McGee-Lawrence ME, Stensgard BA, Li X, 
Secreto FJ, Knutson SK, Hiebert SW, Westendorf JJ. Histone deacetylase 3 depletion in 
osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS 
One. 2010;5(7):e11492. Epub 2010/07/16. doi: 10.1371/journal.pone.0011492. PubMed 
PMID: 20628553; PMCID: PMC2901996. 
109. Bradley EW, McGee-Lawrence ME, Westendorf JJ. Hdac-mediated control of 
endochondral and intramembranous ossification. Crit Rev Eukaryot Gene Expr. 
2011;21(2):101-13. Epub 2011/11/15. PubMed PMID: 22077150; PMCID: PMC3218555. 
110. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi JY, Yoshida 
M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC. Bone morphogenetic protein-2 stimulates 
Runx2 acetylation. J Biol Chem. 2006;281(24):16502-11. Epub 2006/04/15. doi: 
10.1074/jbc.M512494200. PubMed PMID: 16613856. 
111. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida 
M, Stein GS, Li X. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and 
represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22(22):7982-92. Epub 
2002/10/23. PubMed PMID: 12391164; PMCID: PMC134736. 
  104 
 
 
112. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts 
with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J 
Biol Chem. 2004;279(40):41998-2007. Epub 2004/08/05. doi: 
10.1074/jbc.M403702200. PubMed PMID: 15292260. 
113. Westendorf JJ. Transcriptional co-repressors of Runx2. J Cell Biochem. 
2006;98(1):54-64. Epub 2006/01/28. doi: 10.1002/jcb.20805. PubMed PMID: 
16440320. 
114. Obri A, Makinistoglu MP, Zhang H, Karsenty G. HDAC4 integrates PTH and 
sympathetic signaling in osteoblasts. J Cell Biol. 2014;205(6):771-80. doi: 
10.1083/jcb.201403138. PubMed PMID: 24934156; PMCID: PMC4068141. 
115. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ. Histone 
deacetylase 7 associates with Runx2 and represses its activity during osteoblast 
maturation in a deacetylation-independent manner. J Bone Miner Res. 2008;23(3):361-
72. Epub 2007/11/14. doi: 10.1359/jbmr.071104. PubMed PMID: 17997710; PMCID: 
PMC2669158. 
116. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB. Histone deacetylase 1-
mediated histone modification regulates osteoblast differentiation. Mol Endocrinol. 
2006;20(10):2432-43. Epub 2006/05/27. doi: 10.1210/me.2006-0061. PubMed PMID: 
16728531. 
117. Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P, Nagano K, Baron R, 
Brooks D, Bouxsein M, Pajevic PD, Kronenberg HM. HDAC5 controls MEF2C-driven 
sclerostin expression in osteocytes. J Bone Miner Res. 2015;30(3):400-11. doi: 
10.1002/jbmr.2381. PubMed PMID: 25271055; PMCID: PMC4342334. 
118. Baertschi S, Baur N, Lueders-Lefevre V, Voshol J, Keller H. Class I and IIa 
histone deacetylases have opposite effects on sclerostin gene regulation. J Biol Chem. 
2014;289(36):24995-5009. Epub 2014/07/12. doi: 10.1074/jbc.M114.564997. PubMed 
PMID: 25012661; PMCID: PMC4155667. 
119. Huynh NC, Everts V, Ampornaramveth RS. Histone deacetylases and their roles 
in mineralized tissue regeneration. Bone Rep. 2017;7:33-40. Epub 2017/09/01. doi: 
10.1016/j.bonr.2017.08.001. PubMed PMID: 28856178; PMCID: PMC5565747. 
120. Harakalova M, van den Boogaard MJ, Sinke R, van Lieshout S, van Tuil MC, 
Duran K, Renkens I, Terhal PA, de Kovel C, Nijman IJ, van Haelst M, Knoers NV, van 
Haaften G, Kloosterman W, Hennekam RC, Cuppen E, Ploos van Amstel HK. X-exome 
sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual 
disability, truncal obesity, gynaecomastia, hypogonadism and unusual face. J Med 
Genet. 2012;49(8):539-43. Epub 2012/08/15. doi: 10.1136/jmedgenet-2012-100921. 
PubMed PMID: 22889856. 
121. Kaiser FJ, Ansari M, Braunholz D, Concepcion Gil-Rodriguez M, Decroos C, 
Wilde JJ, Fincher CT, Kaur M, Bando M, Amor DJ, Atwal PS, Bahlo M, Bowman CM, 
Bradley JJ, Brunner HG, Clark D, Del Campo M, Di Donato N, Diakumis P, Dubbs H, 
Dyment DA, Eckhold J, Ernst S, Ferreira JC, Francey LJ, Gehlken U, Guillen-Navarro E, 
Gyftodimou Y, Hall BD, Hennekam R, Hudgins L, Hullings M, Hunter JM, Yntema H, 
Innes AM, Kline AD, Krumina Z, Lee H, Leppig K, Lynch SA, Mallozzi MB, Mannini L, 
McKee S, Mehta SG, Micule I, Care4Rare Canada C, Mohammed S, Moran E, Mortier 
GR, Moser JA, Noon SE, Nozaki N, Nunes L, Pappas JG, Penney LS, Perez-Aytes A, 
Petersen MB, Puisac B, Revencu N, Roeder E, Saitta S, Scheuerle AE, Schindeler KL, Siu 
VM, Stark Z, Strom SP, Thiese H, Vater I, Willems P, Williamson K, Wilson LC, 
University of Washington Center for Mendelian G, Hakonarson H, Quintero-Rivera F, 
Wierzba J, Musio A, Gillessen-Kaesbach G, Ramos FJ, Jackson LG, Shirahige K, Pie J, 
Christianson DW, Krantz ID, Fitzpatrick DR, Deardorff MA. Loss-of-function HDAC8 
mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, 
  105 
 
 
ocular hypertelorism, large fontanelle and X-linked inheritance. Hum Mol Genet. 
2014;23(11):2888-900. Epub 2014/01/10. doi: 10.1093/hmg/ddu002. PubMed PMID: 
24403048; PMCID: PMC4014191. 
122. Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, Saitoh K, 
Komata M, Katou Y, Clark D, Cole KE, De Baere E, Decroos C, Di Donato N, Ernst S, 
Francey LJ, Gyftodimou Y, Hirashima K, Hullings M, Ishikawa Y, Jaulin C, Kaur M, 
Kiyono T, Lombardi PM, Magnaghi-Jaulin L, Mortier GR, Nozaki N, Petersen MB, 
Seimiya H, Siu VM, Suzuki Y, Takagaki K, Wilde JJ, Willems PJ, Prigent C, Gillessen-
Kaesbach G, Christianson DW, Kaiser FJ, Jackson LG, Hirota T, Krantz ID, Shirahige K. 
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. 
Nature. 2012;489(7415):313-7. Epub 2012/08/14. doi: 10.1038/nature11316. PubMed 
PMID: 22885700; PMCID: PMC3443318. 
123. Tassano E, Mirabelli-Badenier M, Veneselli E, Puliti A, Lerone M, Vaccari CM, 
Morana G, Porta S, Gimelli G, Cuoco C. Clinical and molecular characterization of a 
patient with interstitial 6q21q22.1 deletion. Mol Cytogenet. 2015;8:31. Epub 
2015/06/09. doi: 10.1186/s13039-015-0134-7. PubMed PMID: 26052347; PMCID: 
PMC4457201. 
124. Villavicencio-Lorini P, Klopocki E, Trimborn M, Koll R, Mundlos S, Horn D. 
Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an 
inherited interstitial 2q37.3 microdeletion including HDAC4. Eur J Hum Genet. 
2013;21(7):743-8. Epub 2012/11/29. doi: 10.1038/ejhg.2012.240. PubMed PMID: 
23188045; PMCID: PMC3722943. 
125. Williams SR, Aldred MA, Der Kaloustian VM, Halal F, Gowans G, McLeod DR, 
Zondag S, Toriello HV, Magenis RE, Elsea SH. Haploinsufficiency of HDAC4 causes 
brachydactyly mental retardation syndrome, with brachydactyly type E, developmental 
delays, and behavioral problems. Am J Hum Genet. 2010;87(2):219-28. Epub 
2010/08/10. doi: 10.1016/j.ajhg.2010.07.011. PubMed PMID: 20691407; PMCID: 
PMC2917703. 
126. Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, 
Luo XH. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice 
and contributes to primary osteoporosis in humans. J Clin Invest. 2009;119(12):3666-77. 
Epub 2009/11/19. doi: 10.1172/JCI39832. PubMed PMID: 19920351; PMCID: 
PMC2786801. 
127. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards 
JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, 
Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, 
Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, 
Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, 
Stefansson K, Ioannidis JP, Uitterlinden AG, Genetic Factors for Osteoporosis C. Twenty 
bone-mineral-density loci identified by large-scale meta-analysis of genome-wide 
association studies. Nat Genet. 2009;41(11):1199-206. Epub 2009/10/06. doi: 
10.1038/ng.446. PubMed PMID: 19801982; PMCID: PMC2783489. 
128. Simon D, Laloo B, Barillot M, Barnetche T, Blanchard C, Rooryck C, Marche M, 
Burgelin I, Coupry I, Chassaing N, Gilbert-Dussardier B, Lacombe D, Grosset C, Arveiler 
B. A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional 
regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked 
chondrodysplasia. Hum Mol Genet. 2010;19(10):2015-27. Epub 2010/02/26. doi: 
10.1093/hmg/ddq083. PubMed PMID: 20181727. 
129. Hong S, Derfoul A, Pereira-Mouries L, Hall DJ. A novel domain in histone 
deacetylase 1 and 2 mediates repression of cartilage-specific genes in human 
  106 
 
 
chondrocytes. FASEB J. 2009;23(10):3539-52. Epub 2009/06/30. doi: 10.1096/fj.09-
133215. PubMed PMID: 19561124; PMCID: PMC2747680. 
130. Higashiyama R, Miyaki S, Yamashita S, Yoshitaka T, Lindman G, Ito Y, Sasho T, 
Takahashi K, Lotz M, Asahara H. Correlation between MMP-13 and HDAC7 expression 
in human knee osteoarthritis. Mod Rheumatol. 2010;20(1):11-7. Epub 2009/09/29. doi: 
10.1007/s10165-009-0224-7. PubMed PMID: 19784544; PMCID: PMC2818344. 
131. Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation of cartilage-specific 
gene expression in human chondrocytes by SirT1 and nicotinamide 
phosphoribosyltransferase. J Biol Chem. 2008;283(52):36300-10. Epub 2008/10/30. 
doi: 10.1074/jbc.M803196200. PubMed PMID: 18957417; PMCID: PMC2605985. 
132. Abed E, Couchourel D, Delalandre A, Duval N, Pelletier JP, Martel-Pelletier J, 
Lajeunesse D. Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead 
to abnormal sclerostin expression which decreases Wnt/beta-catenin activity. Bone. 
2014;59:28-36. Epub 2013/11/05. doi: 10.1016/j.bone.2013.10.020. PubMed PMID: 
24184155. 
133. Gabay O, Zaal KJ, Sanchez C, Dvir-Ginzberg M, Gagarina V, Song Y, He XH, 
McBurney MW. Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone 
Spine. 2013;80(6):613-20. Epub 2013/04/17. doi: 10.1016/j.jbspin.2013.01.001. PubMed 
PMID: 23587642; PMCID: PMC4288855. 
134. Lee HA, Song MJ, Seok YM, Kang SH, Kim SY, Kim I. Histone Deacetylase 3 and 
4 Complex Stimulates the Transcriptional Activity of the Mineralocorticoid Receptor. 
PLoS One. 2015;10(8):e0136801. Epub 2015/08/26. doi: 10.1371/journal.pone.0136801. 
PubMed PMID: 26305553; PMCID: PMC4549324. 
135. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and 
transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S 
A. 2000;97(14):7835-40. Epub 2000/06/28. doi: 10.1073/pnas.140199597. PubMed 
PMID: 10869435; PMCID: PMC16631. 
136. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human 
HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem. 
2001;276(38):35826-35. Epub 2001/07/24. doi: 10.1074/jbc.M104935200. PubMed 
PMID: 11466315. 
137. Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, Kim N. Protein inhibitor of 
activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and 
osteoclast-associated receptor. J Immunol. 2007;178(9):5588-94. Epub 2007/04/20. 
PubMed PMID: 17442941. 
138. Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, Ostrowski MC. Eos, MITF, 
and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid 
progenitors. Mol Cell Biol. 2007;27(11):4018-27. doi: 10.1128/MCB.01839-06. 
139. Dou C, Li N, Ding N, Liu C, Yang X, Kang F, Cao Z, Quan H, Hou T, Xu J, Dong S. 
HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis. Am J Physiol Cell 
Physiol. 2016;310(10):C780-7. Epub 2016/03/11. doi: 10.1152/ajpcell.00351.2015. 
PubMed PMID: 26962001. 
140. Pham L, Kaiser B, Romsa A, Schwarz T, Gopalakrishnan R, Jensen ED, Mansky 
KC. HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem. 
2011;286(14):12056-65. doi: 10.1074/jbc.M110.216853. PubMed PMID: 21324898; 
PMCID: PMC3069409. 
141. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two 
histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress 
differentiation into osteoclasts but not into macrophages. Blood. 2003;101(9):3451-9. 
Epub 2003/01/04. doi: 10.1182/blood-2002-08-2622. PubMed PMID: 12511413. 
  107 
 
 
142. Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH. Trichostatin A 
inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by 
RANKL. Eur J Pharmacol. 2009;623(1-3):22-9. Epub 2009/09/22. doi: 
10.1016/j.ejphar.2009.09.025. PubMed PMID: 19766111. 
143. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human 
histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A. 1999;96(9):4868-
73. Epub 1999/04/29. PubMed PMID: 10220385; PMCID: PMC21783. 
144. Chawla S, Vanhoutte P, Arnold FJ, Huang CL, Bading H. Neuronal activity-
dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J Neurochem. 
2003;85(1):151-9. PubMed PMID: 12641737. 
145. Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T. HDAC4 
deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 
1999;18(18):5099-107. Epub 1999/09/16. doi: 10.1093/emboj/18.18.5099. PubMed 
PMID: 10487761; PMCID: PMC1171580. 
146. Kim JH, Kim K, Youn BU, Jin HM, Kim JY, Moon JB, Ko A, Seo SB, Lee KY, Kim 
N. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases 
during osteoclast differentiation. Biochem J. 2011;436(2):253-62. doi: 
10.1042/BJ20110062. PubMed PMID: 21413932. 
147. Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S, Ory S, Jurdic P. A novel 
Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule 
acetylation in osteoclasts. J Cell Sci. 2005;118(Pt 13):2901-11. doi: 10.1242/jcs.02425. 
PubMed PMID: 15976449. 
148. Zilberman Y, Ballestrem C, Carramusa L, Mazitschek R, Khochbin S, Bershadsky 
A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. 
J Cell Sci. 2009;122(Pt 19):3531-41. doi: 10.1242/jcs.046813. PubMed PMID: 19737819. 
149. Kao HY, Lee CH, Komarov A, Han CC, Evans RM. Isolation and characterization 
of mammalian HDAC10, a novel histone deacetylase. J Biol Chem. 2002;277(1):187-93. 
Epub 2001/10/26. doi: 10.1074/jbc.M108931200. PubMed PMID: 11677242. 
150. Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, 
aging, and calorie restriction. Genes Dev. 2006;20(21):2913-21. Epub 2006/11/03. doi: 
10.1101/gad.1467506. PubMed PMID: 17079682. 
151. Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida 
M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 
2015;29(10):1498-509. Epub 2015/08/20. doi: 10.1210/me.2015-1133. PubMed PMID: 
26287518; PMCID: PMC4588729. 
152. Huh JE, Shin JH, Jang ES, Park SJ, Park DR, Ko R, Seo DH, Kim HS, Lee SH, 
Choi Y, Kim HS, Lee SY. Sirtuin 3 (SIRT3) maintains bone homeostasis by regulating 
AMPK-PGC-1beta axis in mice. Sci Rep. 2016;6:22511. Epub 2016/03/02. doi: 
10.1038/srep22511. PubMed PMID: 26928655; PMCID: PMC4772385. 
153. Lee HS, Ka SO, Lee SM, Lee SI, Park JW, Park BH. Overexpression of sirtuin 6 
suppresses inflammatory responses and bone destruction in mice with collagen-induced 
arthritis. Arthritis Rheum. 2013;65(7):1776-85. Epub 2013/04/05. doi: 
10.1002/art.37963. PubMed PMID: 23553536. 
154. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase 
enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713. Epub 2014/04/03. doi: 
10.1101/cshperspect.a018713. PubMed PMID: 24691964; PMCID: PMC3970420. 
155. Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR. Histone 
deacetylases (HDAC) in physiological and pathological bone remodelling. Bone. 
2017;95:162-74. Epub 2016/12/04. doi: 10.1016/j.bone.2016.11.028. PubMed PMID: 
27913271. 
  108 
 
 
156. Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, 
Bodensteiner JB. Effect of carbamazepine and valproate on bone mineral density. J 
Pediatr. 1995;127(2):256-62. Epub 1995/08/01. PubMed PMID: 7636651. 
157. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of 
valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 
2004;50(1):93-7. Epub 2004/04/15. doi: 10.1016/j.phrs.2003.11.011. PubMed PMID: 
15082034. 
158. Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. 
Seizure. 2007;16(1):22-34. Epub 2006/11/18. doi: 10.1016/j.seizure.2006.10.001. 
PubMed PMID: 17110134. 
159. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of 
antiepileptic drugs. Epilepsia. 2004;45(11):1330-7. Epub 2004/10/29. doi: 
10.1111/j.0013-9580.2004.18804.x. PubMed PMID: 15509233. 
160. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K. 
Decreased bone mass and increased bone turnover with valproate therapy in adults with 
epilepsy. Neurology. 2001;57(3):445-9. Epub 2001/08/15. PubMed PMID: 11502911. 
161. Oner N, Kaya M, Karasalihoglu S, Karaca H, Celtik C, Tutunculer F. Bone mineral 
metabolism changes in epileptic children receiving valproic acid. J Paediatr Child 
Health. 2004;40(8):470-3. Epub 2004/07/22. doi: 10.1111/j.1440-1754.2004.00431.x. 
PubMed PMID: 15265190. 
162. Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of 
bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 
2007;10(2):291-5. Epub 2007/01/17. doi: 10.1016/j.yebeh.2006.11.007. PubMed PMID: 
17224308. 
163. Rieger-Wettengl G, Tutlewski B, Stabrey A, Rauch F, Herkenrath P, Schauseil-
Zipf U, Schoenau E. Analysis of the musculoskeletal system in children and adolescents 
receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics. 
2001;108(6):E107. Epub 2001/12/04. PubMed PMID: 11731634. 
164. Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, 
Tsukahara Y, Miura M, Mayumi M. Bone mineral status in ambulatory pediatric patients 
on long-term anti-epileptic drug therapy. Pediatr Int. 2002;44(3):247-53. Epub 
2002/05/02. PubMed PMID: 11982890. 
165. van der Laan JW, de Boer T, Bruinvels J. Di-n-propylacetate and GABA 
degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and 
indirect inhibition of GABA-transaminase. J Neurochem. 1979;32(6):1769-80. Epub 
1979/06/01. PubMed PMID: 376783. 
166. Loscher W. Valproate induced changes in GABA metabolism at the subcellular 
level. Biochem Pharmacol. 1981;30(11):1364-6. Epub 1981/06/01. PubMed PMID: 
6791653. 
167. Cantley MD, Bartold PM, Marino V, Fairlie DP, Le GT, Lucke AJ, Haynes DR. 
Histone deacetylase inhibitors and periodontal bone loss. J Periodontal Res. 
2011;46(6):697-703. Epub 2011/07/13. doi: 10.1111/j.1600-0765.2011.01392.x. PubMed 
PMID: 21745207. 
168. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone 
deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis 
of rheumatoid arthritis. Mol Ther. 2003;8(5):707-17. Epub 2003/11/06. PubMed PMID: 
14599803. 
169. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, 
Baron R, Rawadi G, Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase 
(HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 
  109 
 
 
2007;150(7):862-72. Epub 2007/02/28. doi: 10.1038/sj.bjp.0707165. PubMed PMID: 
17325656; PMCID: PMC2013883. 
170. Lohman RJ, Iyer A, Fairlie TJ, Cotterell A, Gupta P, Reid RC, Vesey DA, Sweet 
MJ, Fairlie DP. Differential Anti-inflammatory Activity of HDAC Inhibitors in Human 
Macrophages and Rat Arthritis. J Pharmacol Exp Ther. 2016;356(2):387-96. Epub 
2015/12/15. doi: 10.1124/jpet.115.229328. PubMed PMID: 26660228. 
171. Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R. 
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, 
diminishes proliferation and causes apoptosis in multiple myeloma cells. Br J Haematol. 
2012;156(5):633-42. Epub 2012/01/04. doi: 10.1111/j.1365-2141.2011.08983.x. PubMed 
PMID: 22211565. 
172. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van 
Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, 
Bradner J, Anderson KC, Jones SS, Raje N. Preclinical activity, pharmacodynamic, and 
pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination 
with bortezomib in multiple myeloma. Blood. 2012;119(11):2579-89. Epub 2012/01/21. 
doi: 10.1182/blood-2011-10-387365. PubMed PMID: 22262760; PMCID: PMC3337713. 
173. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De 
Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. Bortezomib alone or in 
combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma 
bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69(13):5307-
11. Epub 2009/06/18. doi: 10.1158/0008-5472.CAN-08-4472. PubMed PMID: 
19531653. 
174. Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, Leo E, 
Bargou RC. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-
26481585. Br J Haematol. 2010;149(4):529-36. Epub 2010/03/25. doi: 10.1111/j.1365-
2141.2010.08126.x. PubMed PMID: 20331455. 
175. Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011;42(6):551-5. 
Epub 2011/04/15. doi: 10.1016/j.injury.2011.03.031. PubMed PMID: 21489527; PMCID: 
PMC3105171. 
176. Lee SU, Kwak HB, Pi SH, You HK, Byeon SR, Ying Y, Luesch H, Hong J, Kim SH. 
In Vitro and In Vivo Osteogenic Activity of Largazole. ACS Med Chem Lett. 
2011;2(3):248-51. Epub 2011/06/15. doi: 10.1021/ml1002794. PubMed PMID: 
21666868; PMCID: PMC3109915. 
177. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation 
of osteoclast differentiation and function by the new members of the tumor necrosis 
factor receptor and ligand families. Endocr Rev. 1999;20(3):345-57. doi: 
10.1210/edrv.20.3.0367. PubMed PMID: 10368775. 
178. Asagiri M, Takayanagi H. The molecular understanding of osteoclast 
differentiation. Bone. 2007;40(2):251-64. doi: 10.1016/j.bone.2006.09.023. PubMed 
PMID: 17098490. 
179. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and 
function. Nat Rev Genet. 2003;4(8):638-49. doi: 10.1038/nrg1122. PubMed PMID: 
12897775. 
180. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a 
transcriptional target of c-Fos during osteoclast differentiation. Nat Genet. 
2000;24(2):184-7. doi: 10.1038/72855. PubMed PMID: 10655067. 
181. Jenuwein T, Allis CD. Translating the histone code. Science. 
2001;293(5532):1074-80. doi: 10.1126/science.1063127. PubMed PMID: 11498575. 
182. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, 
Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular 
  110 
 
 
functions. Science. 2009;325(5942):834-40. doi: 10.1126/science.1175371. PubMed 
PMID: 19608861. 
183. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-
histone proteins. Gene. 2005;363:15-23. Epub 2005/11/18. doi: 
10.1016/j.gene.2005.09.010. PubMed PMID: 16289629. 
184. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin 
E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein 
complex containing HDAC3 and SMRT/N-CoR. Mol Cell. 2002;9(1):45-57. PubMed 
PMID: 11804585. 
185. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, 
Bottomley MJ, Lo Surdo P, Carfi A, Koch U, De Francesco R, Steinkuhler C, Gallinari P. 
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc 
Natl Acad Sci U S A. 2007;104(44):17335-40. doi: 10.1073/pnas.0706487104. PubMed 
PMID: 17956988; PMCID: PMC2077257. 
186. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases 
adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone 
Miner Res. 2006;21(7):993-1002. doi: 10.1359/jbmr.060415. PubMed PMID: 16813520. 
187. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. 
Annu Rev Biochem. 2006;75:435-65. doi: 10.1146/annurev.biochem.74.082803.133500. 
PubMed PMID: 16756498. 
188. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, 
regulation, and clinical implication. Mol Cell Biol. 2005;25(8):2873-84. doi: 
10.1128/MCB.25.8.2873-2884.2005. PubMed PMID: 15798178; PMCID: PMC1069616. 
189. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ, Holding 
CA, Haynes DR. Inhibitors of histone deacetylases in class I and class II suppress human 
osteoclasts in vitro. J Cell Physiol. 2011;226(12):3233-41. doi: 10.1002/jcp.22684. 
PubMed PMID: 21344383. 
190. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, 
Kohashi O, Kukita A. Inhibition of histone deacetylase suppresses osteoclastogenesis and 
bone destruction by inducing IFN-beta production. J Immunol. 2005;175(9):5809-16. 
PubMed PMID: 16237073. 
191. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new 
osteoclast progenitor with macrophage phenotypes being able to differentiate into 
mature osteoclasts. J Bone Miner Res. 2000;15(8):1477-88. doi: 
10.1359/jbmr.2000.15.8.1477. PubMed PMID: 10934646. 
192. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang 
XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature. 
2002;417(6887):455-8. doi: 10.1038/417455a. PubMed PMID: 12024216. 
193. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, 
Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M. In vivo 
destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 
2002;21(24):6820-31. PubMed PMID: 12486003; PMCID: PMC139102. 
194. Purev E, Neff L, Horne WC, Baron R. c-Cbl and Cbl-b act redundantly to protect 
osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing 
microtubules and podosomes. Mol Biol Cell. 2009;20(18):4021-30. doi: 
10.1091/mbc.E09-03-0248. PubMed PMID: 19641021; PMCID: PMC2743621. 
195. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, Trogani N, Widmer 
R, Atadja P, Cohen D. Isolation and characterization of a novel class II histone 
deacetylase, HDAC10. J Biol Chem. 2002;277(8):6656-66. doi: 
10.1074/jbc.M108055200. PubMed PMID: 11739383. 
  111 
 
 
196. Guardiola AR, Yao TP. Molecular cloning and characterization of a novel histone 
deacetylase HDAC10. J Biol Chem. 2002;277(5):3350-6. doi: 10.1074/jbc.M109861200. 
PubMed PMID: 11726666. 
197. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA. Nuclear 
receptor corepressors partner with class II histone deacetylases in a Sin3-independent 
repression pathway. Genes Dev. 2000;14(1):45-54. PubMed PMID: 10640275; PMCID: 
PMC316335. 
198. Morrison BE, D'Mello SR. Polydactyly in mice lacking HDAC9/HDRP. Exp Biol 
Med (Maywood). 2008;233(8):980-8. doi: 10.3181/0802-RM-48. PubMed PMID: 
18480421; PMCID: PMC2656257. 
199. Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello 
SR. Neuroprotection by histone deacetylase-related protein. Mol Cell Biol. 
2006;26(9):3550-64. doi: 10.1128/MCB.26.9.3550-3564.2006. PubMed PMID: 
16611996; PMCID: PMC1447420. 
200. Zhang CL, McKinsey TA, Chang SR, Antos CL, Hill JA, Olson EN. Class II histone 
deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 
2002;110(4):479-88. doi: Doi 10.1016/S0092-8674(02)00861-9. PubMed PMID: 
WOS:000177653200009. 
201. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via 
up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-
STAMP). Mol Endocrinol. 2008;22(1):176-85. doi: 10.1210/me.2007-0237. PubMed 
PMID: 17885208; PMCID: PMC2725751. 
202. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, 
Mak TW, Serfling E, Takayanagi H. Autoamplification of NFATc1 expression determines 
its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261-9. doi: 
10.1084/jem.20051150. PubMed PMID: 16275763; PMCID: PMC2213228. 
203. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, 
Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone 
deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. 
Nat Immunol. 2009;10(1):92-100. doi: 10.1038/ni.1673. PubMed PMID: 19011628; 
PMCID: PMC3925685. 
204. Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, 
Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. 
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) 
on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol. 
2014;60(1):44-53. doi: 10.1016/j.molimm.2014.02.019. PubMed PMID: 24747960; 
PMCID: PMC4020151. 
205. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide 
mapping of HATs and HDACs reveals distinct functions in active and inactive genes. 
Cell. 2009;138(5):1019-31. doi: 10.1016/j.cell.2009.06.049. PubMed PMID: 19698979; 
PMCID: PMC2750862. 
206. Liu Y, Peng L, Seto E, Huang S, Qiu Y. Modulation of histone deacetylase 6 
(HDAC6) nuclear import and tubulin deacetylase activity through acetylation. J Biol 
Chem. 2012;287(34):29168-74. doi: 10.1074/jbc.M112.371120. PubMed PMID: 
22778253; PMCID: PMC3436516. 
207. Li L, Yang XJ. Tubulin acetylation: responsible enzymes, biological functions and 
human diseases. Cell Mol Life Sci. 2015;72(22):4237-55. doi: 10.1007/s00018-015-
2000-5. PubMed PMID: 26227334. 
208. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P. HDAC-6 
interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 
  112 
 
 
2003;22(5):1168-79. doi: 10.1093/emboj/cdg115. PubMed PMID: 12606581; PMCID: 
PMC150348. 
209. Akisaka T, Yoshida H, Takigawa T. Differential distribution of posttranslationally 
modified microtubules in osteoclasts. J Histochem Cytochem. 2011;59(6):630-8. doi: 
10.1369/0022155411405334. PubMed PMID: 21421796; PMCID: PMC3201188. 
210. Duplan MB, Zalli D, Stephens S, Zenger S, Neff L, Oelkers JM, Lai FPL, Horne W, 
Rottner K, Baron R. Microtubule Dynamic Instability Controls Podosome Patterning in 
Osteoclasts through EB1, Cortactin, and Src. Molecular and Cellular Biology. 
2014;34(1):16-29. doi: 10.1128/Mcb.00578-13. PubMed PMID: 
WOS:000330581600002. 
211. Asthana J, Kapoor S, Mohan R, Panda D. Inhibition of HDAC6 deacetylase 
activity increases its binding with microtubules and suppresses microtubule dynamic 
instability in MCF-7 cells. J Biol Chem. 2013;288(31):22516-26. doi: 
10.1074/jbc.M113.489328. PubMed PMID: 23798680; PMCID: PMC3829339. 
212. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, 
SIRT2, is an NAD(+)-dependent tubulin deacetylase. Molecular Cell. 2003;11(2):437-44. 
doi: Doi 10.1016/S1097-2765(03)00038-8. PubMed PMID: WOS:000181296800018. 
213. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13(7):791-
801. Epub 2007/07/10. doi: 10.1038/nm1593. PubMed PMID: 17618270. 
214. Takeda S, Elefteriou F, Karsenty G. Common endocrine control of body weight, 
reproduction, and bone mass. Annu Rev Nutr. 2003;23:403-11. Epub 2003/05/06. doi: 
10.1146/annurev.nutr.23.011702.073312. PubMed PMID: 12730321. 
215. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, 
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli 
A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and 
activation. Cell. 1998;93(2):165-76. Epub 1998/05/06. PubMed PMID: 9568710. 
216. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, 
Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa 
N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for 
osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to 
TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-602. Epub 1998/05/09. 
PubMed PMID: 9520411; PMCID: PMC19881. 
217. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol. 
2004;14(14):R546-51. Epub 2004/07/23. doi: 10.1016/j.cub.2004.07.007. PubMed 
PMID: 15268870. 
218. Di Giorgio E, Brancolini C. Regulation of class IIa HDAC activities: it is not only 
matter of subcellular localization. Epigenomics. 2016;8(2):251-69. Epub 2016/01/23. 
doi: 10.2217/epi.15.106. PubMed PMID: 26791815. 
219. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase 
inhibitors. Nat Rev Drug Discov. 2006;5(9):769-84. Epub 2006/09/07. doi: 
10.1038/nrd2133. PubMed PMID: 16955068. 
220. Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, Lee ZH. MS-275, a benzamide 
histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos 
expression and suppresses bone loss in mice. Eur J Pharmacol. 2012;691(1-3):69-76. 
Epub 2012/08/01. doi: 10.1016/j.ejphar.2012.07.034. PubMed PMID: 22846626. 
221. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of 
cancer. Nat Rev Drug Discov. 2002;1(4):287-99. Epub 2002/07/18. doi: 
10.1038/nrd772. PubMed PMID: 12120280. 
  113 
 
 
222. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase 
inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7(10):854-
68. Epub 2008/10/02. doi: 10.1038/nrd2681. PubMed PMID: 18827828. 
223. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, Shelton JM, 
Richardson JA, Bassel-Duby R, Olson EN. MEF2C transcription factor controls 
chondrocyte hypertrophy and bone development. Dev Cell. 2007;12(3):377-89. Epub 
2007/03/06. doi: 10.1016/j.devcel.2007.02.004. PubMed PMID: 17336904. 
224. Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myogenesis by 
association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell. 
2000;6(2):233-44. Epub 2000/09/13. PubMed PMID: 10983972. 
225. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a 
histone deacetylase regulates muscle differentiation. Nature. 2000;408(6808):106-11. 
Epub 2000/11/18. doi: 10.1038/35040593. PubMed PMID: 11081517; PMCID: 
PMC4459600. 
226. Miska EA, Langley E, Wolf D, Karlsson C, Pines J, Kouzarides T. Differential 
localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res. 
2001;29(16):3439-47. Epub 2001/08/16. doi: 10.1093/nar/29.16.3439. PubMed PMID: 
11504882; PMCID: PMC55849. 
227. Li J, Chen K, Zhu L, Pollard JW. Conditional deletion of the colony stimulating 
factor-1 receptor (c-fms proto-oncogene) in mice. Genesis. 2006;44(7):328-35. Epub 
2006/07/11. doi: 10.1002/dvg.20219. PubMed PMID: 16823860. 
228. Munugalavadla V, Borneo J, Ingram DA, Kapur R. p85alpha subunit of class IA 
PI-3 kinase is crucial for macrophage growth and migration. Blood. 2005;106(1):103-9. 
Epub 2005/03/17. doi: 10.1182/blood-2004-10-4041. PubMed PMID: 15769893; 
PMCID: PMC1895121. 
229. Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med 
J. 2016;52(1):12-7. Epub 2016/02/13. doi: 10.4068/cmj.2016.52.1.12. PubMed PMID: 
26865996; PMCID: PMC4742606. 
230. Chung E, Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological 
hematopoiesis and leukemia development. Immunol Res. 2011;49(1-3):248-68. Epub 
2010/12/21. doi: 10.1007/s12026-010-8187-5. PubMed PMID: 21170740. 
231. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue 
Res. 2001;305(3):285-98. Epub 2001/09/27. PubMed PMID: 11572082. 
232. He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, Yuan J, Yang X, Li X, Jiang L, 
Chen S, Yang FC. Erk1 positively regulates osteoclast differentiation and bone resorptive 
activity. PLoS One. 2011;6(9):e24780. Epub 2011/10/01. doi: 
10.1371/journal.pone.0024780. PubMed PMID: 21961044; PMCID: PMC3178550. 
233. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, 
Gailit J, Bowtell D, Horne WC, Baron R. Cbl associates with Pyk2 and Src to regulate Src 
kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast 
motility. J Cell Biol. 2001;152(1):181-95. Epub 2001/01/10. doi: 10.1083/jcb.152.1.181. 
PubMed PMID: 11149930; PMCID: PMC2193648. 
234. Daoud G, Rassart E, Masse A, Lafond J. Src family kinases play multiple roles in 
differentiation of trophoblasts from human term placenta. J Physiol. 2006;571(Pt 
3):537-53. Epub 2006/01/18. doi: 10.1113/jphysiol.2005.102285. PubMed PMID: 
16410281; PMCID: PMC1805791. 
235. Huang C, Zhang Z, Chen L, Lee HW, Ayrapetov MK, Zhao TC, Hao Y, Gao J, Yang 
C, Mehta GU, Zhuang Z, Zhang X, Hu G, Chin YE. Acetylation within the N- and C-
Terminal Domains of Src Regulates Distinct Roles of STAT3-Mediated Tumorigenesis. 
Cancer Res. 2018;78(11):2825-38. Epub 2018/03/14. doi: 10.1158/0008-5472.CAN-17-
2314. PubMed PMID: 29531159. 
  114 
 
 
236. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 
2004;351(27):2839-49. Epub 2004/12/31. doi: 10.1056/NEJMra040952. PubMed 
PMID: 15625335. 
237. Nakamura H, Hirata A, Tsuji T, Yamamoto T. Role of osteoclast extracellular 
signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone 
Miner Res. 2003;18(7):1198-205. Epub 2003/07/12. doi: 10.1359/jbmr.2003.18.7.1198. 
PubMed PMID: 12854829. 
238. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, 
Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S. Reciprocal role of ERK 
and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol. 
2000;148(2):333-42. Epub 2000/01/29. doi: 10.1083/jcb.148.2.333. PubMed PMID: 
10648566; PMCID: PMC2174281. 
239. Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, Kousteni S, Bellido T, 
Manolagas SC. Transient versus sustained phosphorylation and nuclear accumulation of 
ERKs underlie anti-versus pro-apoptotic effects of estrogens. J Biol Chem. 
2005;280(6):4632-8. Epub 2004/11/24. doi: 10.1074/jbc.M411530200. PubMed PMID: 
15557324. 
240. Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, Sebti SM, Woodley DT, 
Imamoto A, Li W. Colony-stimulating factor-1 receptor utilizes multiple signaling 
pathways to induce cyclin D2 expression. Mol Biol Cell. 2000;11(11):3835-48. Epub 
2000/11/10. doi: 10.1091/mbc.11.11.3835. PubMed PMID: 11071910; PMCID: 
PMC15040. 
241. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 
requirement for sustained mitogen-activated protein kinase activity during angiogenesis. 
J Cell Biol. 1998;140(5):1255-63. Epub 1998/04/18. doi: 10.1083/jcb.140.5.1255. 
PubMed PMID: 9490736; PMCID: PMC2132684. 
242. Zhao M, Finlay D, Zharkikh I, Vuori K. Novel Role of Src in Priming Pyk2 
Phosphorylation. PLoS One. 2016;11(2):e0149231. Epub 2016/02/13. doi: 
10.1371/journal.pone.0149231. PubMed PMID: 26866924; PMCID: PMC4750869. 
243. Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. 
Biochem Biophys Res Commun. 2005;331(1):1-14. Epub 2005/04/23. doi: 
10.1016/j.bbrc.2005.03.012. PubMed PMID: 15845350. 
244. Liebl EC, Martin GS. Intracellular targeting of pp60src expression: localization of 
v-src to adhesion plaques is sufficient to transform chicken embryo fibroblasts. 
Oncogene. 1992;7(12):2417-28. Epub 1992/12/01. PubMed PMID: 1334249. 
245. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, 
Chumakov A, Imai Y, Koeffler HP. Histone deacetylase inhibitor, suberoylanilide 
hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human 
pancreatic cancer cells. Int J Cancer. 2007;121(3):656-65. Epub 2007/04/10. doi: 
10.1002/ijc.22558. PubMed PMID: 17417771. 
246. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, 
Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell 
SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, 
Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR, 
group SS. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for 
generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. 
Lancet. 2007;369(9566):1016-26. Epub 2007/03/27. doi: 10.1016/S0140-
6736(07)60461-9. PubMed PMID: 17382828; PMCID: PMC2039891. 
247. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-
Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon 
V, Marks P, Kelly WK. Clinical experience with intravenous and oral formulations of the 
  115 
 
 
novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with 
advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166-73. Epub 
2005/12/07. doi: 10.1200/JCO.2005.01.9679. PubMed PMID: 16330674. 
248. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast 
maturation. J Bone Miner Res. 2005;20(12):2254-63. Epub 2005/11/19. doi: 
10.1359/JBMR.050813. PubMed PMID: 16294278. 
 
   
 
 
